[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fgTkLLTqwzmBJ8w93_seCkSfWTuz4FJsxKrIL4cKpLkM":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":38,"phaseBuckets":88,"rows":95},"Chinese University of Hong Kong",[4],1400,false,436,92,1075302,80,1155,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Stroke",43,{"name":18,"count":19},"Prostate Cancer",35,{"name":21,"count":22},"Depression",28,{"name":24,"count":25},"Colorectal Cancer",21,{"name":27,"count":28},"Hypertension",20,{"name":30,"count":31},"Obstructive Sleep Apnea",19,{"name":33,"count":34},"Hepatocellular Carcinoma",17,{"name":36,"count":37},"Autism Spectrum Disorder",15,[39,44,49,54,59,64,69,74,79,84],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT06728371","Intravenous Methadone for Sternotomy Pain Control in Cardiac Surgery","2024-12-01","Methadone",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT05264896","Perioperative FLOT vs Adjuvant XELOX for CA Stomach","2024-12-31","5-FU, Leucovorin, Oxaliplatin, Docetaxel",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT03734809","NEO-SPACE Trial: Pembrolizumab and Chemoradiation in Nasopharyngeal Cancer","2025-01-25","Pembrolizumab",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT05209035","Evaluation of Trazodone in OSA-MCI","2025-05-02","Trazodone",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT04611243","Lung Function, Exercise Capacity, and Serology Responses in Patients With COVID-19","2025-08-18","third dose vaccination with CoronaVac vaccine",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT06608017","Study of Yupingfeng Powder Treating Allergic Rhinitis (AR)","2025-08-31","Chinese Herbal Medicine granules",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT05503225","Colchicine Use in Intracranial Atherosclerotic Disease","2025-09-30","Colchicine 0.5 MG",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT05423834","Chronic Kidney Disease Progression in Chronic Hepatitis B Patients on Tenofovir Alafenamide (TAF) Versus Entecavir","2025-12-21","Tenofovir alafenamide",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT03322306","Establishment of Genetic Basis for Neurological Disease by Genetic Screening","2025-12-31","Genechip screening kit",{"nctId":85,"briefTitle":86,"date":82,"intervention":87},"NCT05532878","Pharmacokinetics of Apixaban in Peritoneal Dialysis","Apixaban",[89,90,91,92,93,94],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[96,137,174,240,278,296,321,339,357,384,413,431,454,477,503,528,554,572,599,626,652,678,704,739,761,783,807,825,849,873,894,912,936,962,1001,1045,1083,1128,1152,1178,1202,1230,1248,1273,1299,1323,1346,1364,1389,1416,1434,1458,1476,1500,1522,1548,1571,1589,1612,1636,1674,1707,1732,1750,1770,1796,1821,1848,1866,1884,1905,1933,1951,1969,1987,2012,2030,2055,2073,2096,2114,2155,2202,2228,2265,2303,2328,2352,2376,2402,2420,2444,2462,2486,2509,2531,2557,2581,2606,2633,2651,2677,2703,2728,2751,2777,2795,2821,2839,2863,2881,2904,2929,2953,2975,2998,3016,3041,3064,3087,3111,3136,3154,3177,3201,3226,3255,3291,3332,3358,3376,3400,3426,3451,3472,3490,3508,3532,3556,3580,3603,3627,3652,3670,3693,3718,3736,3759,3785,3803,3827,3851,3869,3892,3914,3932,3954,3981,3999,4017,4043,4061,4086,4109,4133,4157,4180,4202,4220,4238,4278,4321,4352,4387,4414,4439,4464,4489,4512,4537,4555,4579,4604,4625,4648,4671,4689,4713,4738,4762,4787,4812,4837,4861,4879,4904,4922,4947,4969,4995,5013,5031,5049,5067,5085,5109,5135,5158,5182,5200,5223,5247,5269,5294,5318,5341,5359,5382,5406,5429,5451,5477,5495,5518,5544,5570,5588,5634,5672,5702,5729,5751,5784,5813,5838,5862,5885,5910,5928,5953,5977,5995,6016,6041,6067,6091,6109,6131,6156,6174,6197,6222,6246,6271,6297,6321,6346,6364,6391,6409,6427,6445,6466,6491,6517,6535,6553,6579,6602,6626,6644,6662,6686,6712,6735,6758,6782,6804,6822],{"intervention":97,"totalTrials":98,"cells":99},"Prednisolone",2,{"EARLY_PHASE1":100,"PHASE1":103,"PHASE2":105,"PHASE3":107,"PHASE4":122,"NA":135},{"trials":101,"activeCount":102},[],0,{"trials":104,"activeCount":102},[],{"trials":106,"activeCount":102},[],{"trials":108,"activeCount":121,"soonestReadout":114},[109],{"nctId":110,"briefTitle":111,"status":112,"phases":113,"primaryCompletion":114,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":120},"NCT03902912","Effect of Prednisolone Treatment on Uterine Natural Killer Cells","RECRUITING",[92],"2027-04-30","2028-04-30","2019-07-30",84,[119],"Recurrent Miscarriage",[97],1,{"trials":123,"activeCount":121,"soonestReadout":129},[124],{"nctId":125,"briefTitle":126,"status":127,"phases":128,"primaryCompletion":129,"completion":129,"start":130,"enrollment":131,"conditions":132,"interventions":134},"NCT07252271","Very Low Dose Prednisolone on Newly Diagnosed Rheumatoid Arthritis","NOT_YET_RECRUITING",[93],"2028-06-30","2025-12-01",112,[133],"Rhematoid Arthritis",[97],{"trials":136,"activeCount":102},[],{"intervention":138,"totalTrials":98,"cells":139},"0.5% Levobupivacaine",{"EARLY_PHASE1":140,"PHASE1":142,"PHASE2":144,"PHASE3":146,"PHASE4":148,"NA":161},{"trials":141,"activeCount":102},[],{"trials":143,"activeCount":102},[],{"trials":145,"activeCount":102},[],{"trials":147,"activeCount":102},[],{"trials":149,"activeCount":121,"soonestReadout":154},[150],{"nctId":151,"briefTitle":152,"status":112,"phases":153,"primaryCompletion":154,"completion":154,"start":155,"enrollment":156,"conditions":157,"interventions":159},"NCT04397484","Prospective RCT Lidocaine & Levobupivacaine on Block Dynamics After Subparaneural Popliteal Sciatic Nerve Block",[93],"2026-09-30","2023-09-20",40,[158],"Musculoskeletal Diseases or Conditions",[138,160],"2% Xylocaine with adrenaline 1:200,000",{"trials":162,"activeCount":121,"soonestReadout":167},[163],{"nctId":164,"briefTitle":165,"status":112,"phases":166,"primaryCompletion":167,"completion":168,"start":169,"enrollment":170,"conditions":171,"interventions":172},"NCT04941664","Minimum Effective Local Anesthetic Volume for Ultrasound Guided Superior Trunk Block",[94],"2026-07-31","2026-08-31","2023-01-19",25,[158],[173],"0.5% levobupivacaine",{"intervention":175,"totalTrials":176,"cells":177},"Esomeprazole",4,{"EARLY_PHASE1":178,"PHASE1":180,"PHASE2":182,"PHASE3":184,"PHASE4":211,"NA":238},{"trials":179,"activeCount":102},[],{"trials":181,"activeCount":102},[],{"trials":183,"activeCount":102},[],{"trials":185,"activeCount":102},[186,200],{"nctId":187,"briefTitle":188,"status":189,"phases":190,"primaryCompletion":191,"completion":191,"start":192,"enrollment":193,"conditions":194,"interventions":196},"NCT03142620","Effect of Vitamin D on Drug Resistant Helicobacter Pylori (HP) Eradication Study","UNKNOWN",[92],"2017-12","2015-03",96,[195],"H. Pylori Infection",[175,197,198,199],"Amoxicillin-Potassium Clavulanate Combination","Clarithromycin","Vitamin D3",{"nctId":201,"briefTitle":202,"status":203,"phases":204,"primaryCompletion":205,"completion":205,"start":206,"enrollment":207,"conditions":208,"interventions":210},"NCT00164840","Symptomatic Gastroesophageal Reflux Disease: Double Blind Randomized Controlled Study of On-demand Therapy Versus Maintenance Therapy","COMPLETED",[92],"2008-11","2003-05",244,[209],"Gastroesophageal Reflux Disease",[175],{"trials":212,"activeCount":121,"soonestReadout":228},[213,224],{"nctId":214,"briefTitle":215,"status":203,"phases":216,"primaryCompletion":217,"completion":218,"start":219,"enrollment":220,"conditions":221,"interventions":223},"NCT00951431","Gastric Functions & Proton Pump Inhibitor( PPI) Study",[93],"2015-12-31","2016-02-19","2009-12-03",155,[222],"Functional Dyspepsia",[175],{"nctId":225,"briefTitle":226,"status":112,"phases":227,"primaryCompletion":228,"completion":229,"start":230,"enrollment":231,"conditions":232,"interventions":235},"NCT05582174","PPI Infusion Versus Oral Acid Pump Inhibitors for Bleeding Peptic Ulcers",[93],"2028-01-02","2028-07-03","2023-05-18",594,[233,234],"Upper GI Bleeding","Proton Pump Inhibitors",[236,237],"Vonoprazan","esomeprazole",{"trials":239,"activeCount":102},[],{"intervention":241,"totalTrials":98,"cells":242},"Misoprostol Oral",{"EARLY_PHASE1":243,"PHASE1":245,"PHASE2":247,"PHASE3":249,"PHASE4":263,"NA":276},{"trials":244,"activeCount":102},[],{"trials":246,"activeCount":102},[],{"trials":248,"activeCount":102},[],{"trials":250,"activeCount":102},[251],{"nctId":252,"briefTitle":253,"status":203,"phases":254,"primaryCompletion":255,"completion":256,"start":257,"enrollment":258,"conditions":259,"interventions":261},"NCT01998776","Evaluate Misoprostol for the Healing of Small Bowel Ulcers in Low-dose Aspirin Users Complicated by Small Bowel Bleeding",[91,92],"2018-01-22","2018-02","2013-04",82,[260],"Ulcer Hemorrhage",[262],"Misoprostol",{"trials":264,"activeCount":121,"soonestReadout":269},[265],{"nctId":266,"briefTitle":267,"status":112,"phases":268,"primaryCompletion":269,"completion":270,"start":271,"enrollment":272,"conditions":273,"interventions":275},"NCT03675672","Prevention of Recurrent Ulcer Bleeding in Patients With Idiopathic Gastroduodenal Ulcer",[93],"2026-12-31","2027-03-31","2018-06-21",154,[274],"Active Peptic Ulcer Disease\u002FGI Bleeding",[241],{"trials":277,"activeCount":102},[],{"intervention":160,"totalTrials":121,"cells":279},{"EARLY_PHASE1":280,"PHASE1":282,"PHASE2":284,"PHASE3":286,"PHASE4":288,"NA":294},{"trials":281,"activeCount":102},[],{"trials":283,"activeCount":102},[],{"trials":285,"activeCount":102},[],{"trials":287,"activeCount":102},[],{"trials":289,"activeCount":121,"soonestReadout":154},[290],{"nctId":151,"briefTitle":152,"status":112,"phases":291,"primaryCompletion":154,"completion":154,"start":155,"enrollment":156,"conditions":292,"interventions":293},[93],[158],[138,160],{"trials":295,"activeCount":102},[],{"intervention":297,"totalTrials":121,"cells":298},"Semaglutide 0.5 mg",{"EARLY_PHASE1":299,"PHASE1":301,"PHASE2":303,"PHASE3":305,"PHASE4":307,"NA":319},{"trials":300,"activeCount":102},[],{"trials":302,"activeCount":102},[],{"trials":304,"activeCount":102},[],{"trials":306,"activeCount":102},[],{"trials":308,"activeCount":121,"soonestReadout":313},[309],{"nctId":310,"briefTitle":311,"status":127,"phases":312,"primaryCompletion":313,"completion":313,"start":130,"enrollment":156,"conditions":314,"interventions":316},"NCT07251556","GLP-1 Receptor Agonists in Non-diabetic Patients With Psoriatic Arthritis",[93],"2027-01-01",[315],"Psoriasis Arthritis",[297,317,318],"Semaglutide 1.0 mg","Semaglutide 0.25 mg",{"trials":320,"activeCount":102},[],{"intervention":317,"totalTrials":121,"cells":322},{"EARLY_PHASE1":323,"PHASE1":325,"PHASE2":327,"PHASE3":329,"PHASE4":331,"NA":337},{"trials":324,"activeCount":102},[],{"trials":326,"activeCount":102},[],{"trials":328,"activeCount":102},[],{"trials":330,"activeCount":102},[],{"trials":332,"activeCount":121,"soonestReadout":313},[333],{"nctId":310,"briefTitle":311,"status":127,"phases":334,"primaryCompletion":313,"completion":313,"start":130,"enrollment":156,"conditions":335,"interventions":336},[93],[315],[297,317,318],{"trials":338,"activeCount":102},[],{"intervention":318,"totalTrials":121,"cells":340},{"EARLY_PHASE1":341,"PHASE1":343,"PHASE2":345,"PHASE3":347,"PHASE4":349,"NA":355},{"trials":342,"activeCount":102},[],{"trials":344,"activeCount":102},[],{"trials":346,"activeCount":102},[],{"trials":348,"activeCount":102},[],{"trials":350,"activeCount":121,"soonestReadout":313},[351],{"nctId":310,"briefTitle":311,"status":127,"phases":352,"primaryCompletion":313,"completion":313,"start":130,"enrollment":156,"conditions":353,"interventions":354},[93],[315],[297,317,318],{"trials":356,"activeCount":102},[],{"intervention":358,"totalTrials":121,"cells":359},"Amgevita 40Mg Solution for",{"EARLY_PHASE1":360,"PHASE1":362,"PHASE2":364,"PHASE3":366,"PHASE4":368,"NA":382},{"trials":361,"activeCount":102},[],{"trials":363,"activeCount":102},[],{"trials":365,"activeCount":102},[],{"trials":367,"activeCount":102},[],{"trials":369,"activeCount":121,"soonestReadout":374},[370],{"nctId":371,"briefTitle":372,"status":112,"phases":373,"primaryCompletion":374,"completion":375,"start":376,"enrollment":377,"conditions":378,"interventions":380},"NCT07486843","Preventing Structural Damage in Early Psoriatic Arthritis",[93],"2027-12-31","2028-12-31","2026-03-16",108,[379],"Psoriatic Arthritis (PsA)",[358,381],"Methotrexate",{"trials":383,"activeCount":102},[],{"intervention":385,"totalTrials":121,"cells":386},"DoxyODPrEP",{"EARLY_PHASE1":387,"PHASE1":389,"PHASE2":391,"PHASE3":393,"PHASE4":395,"NA":411},{"trials":388,"activeCount":102},[],{"trials":390,"activeCount":102},[],{"trials":392,"activeCount":102},[],{"trials":394,"activeCount":102},[],{"trials":396,"activeCount":121,"soonestReadout":374},[397],{"nctId":398,"briefTitle":399,"status":112,"phases":400,"primaryCompletion":374,"completion":401,"start":402,"enrollment":403,"conditions":404,"interventions":409},"NCT06188442","Superiority of On-demand PrEP Versus PEP on Using Doxycycline for Preventing STI in MSM",[93],"2028-12","2025-03-29",300,[405,406,407,408],"Sexually Transmitted Diseases, Bacterial","Syphilis","Gonorrhea","Chlamydia",[385,410],"DoxyPEP",{"trials":412,"activeCount":102},[],{"intervention":410,"totalTrials":121,"cells":414},{"EARLY_PHASE1":415,"PHASE1":417,"PHASE2":419,"PHASE3":421,"PHASE4":423,"NA":429},{"trials":416,"activeCount":102},[],{"trials":418,"activeCount":102},[],{"trials":420,"activeCount":102},[],{"trials":422,"activeCount":102},[],{"trials":424,"activeCount":121,"soonestReadout":374},[425],{"nctId":398,"briefTitle":399,"status":112,"phases":426,"primaryCompletion":374,"completion":401,"start":402,"enrollment":403,"conditions":427,"interventions":428},[93],[405,406,407,408],[385,410],{"trials":430,"activeCount":102},[],{"intervention":432,"totalTrials":121,"cells":433},"Finerenone",{"EARLY_PHASE1":434,"PHASE1":436,"PHASE2":438,"PHASE3":440,"PHASE4":442,"NA":452},{"trials":435,"activeCount":102},[],{"trials":437,"activeCount":102},[],{"trials":439,"activeCount":102},[],{"trials":441,"activeCount":102},[],{"trials":443,"activeCount":121,"soonestReadout":167},[444],{"nctId":445,"briefTitle":446,"status":112,"phases":447,"primaryCompletion":167,"completion":269,"start":448,"enrollment":258,"conditions":449,"interventions":451},"NCT06727409","Use of Clinical-trials and Simulation Models to Estimate Cost-effectiveness of Non-steroidal Mineralocorticoid Antagonists, RASi and SGLT2i as Triple Therapy With Type 2 Diabetes and Chronic Kidney Disease",[93],"2024-12-12",[450],"Patients With Type 2 Diabetes",[432],{"trials":453,"activeCount":102},[],{"intervention":58,"totalTrials":121,"cells":455},{"EARLY_PHASE1":456,"PHASE1":458,"PHASE2":460,"PHASE3":462,"PHASE4":464,"NA":475},{"trials":457,"activeCount":102},[],{"trials":459,"activeCount":102},[],{"trials":461,"activeCount":102},[],{"trials":463,"activeCount":102},[],{"trials":465,"activeCount":121,"soonestReadout":57},[466],{"nctId":55,"briefTitle":56,"status":467,"phases":468,"primaryCompletion":57,"completion":469,"start":470,"enrollment":471,"conditions":472,"interventions":474},"ACTIVE_NOT_RECRUITING",[93],"2026-02-28","2022-05-10",134,[473,30],"Mild Cognitive Impairment",[58],{"trials":476,"activeCount":102},[],{"intervention":478,"totalTrials":121,"cells":479},"Riociguat",{"EARLY_PHASE1":480,"PHASE1":482,"PHASE2":484,"PHASE3":486,"PHASE4":488,"NA":501},{"trials":481,"activeCount":102},[],{"trials":483,"activeCount":102},[],{"trials":485,"activeCount":102},[],{"trials":487,"activeCount":102},[],{"trials":489,"activeCount":121,"soonestReadout":494},[490],{"nctId":491,"briefTitle":492,"status":112,"phases":493,"primaryCompletion":494,"completion":495,"start":496,"enrollment":497,"conditions":498,"interventions":500},"NCT06715280","Switching of Sildenafil to Riociguat in CTEPH Patients",[93],"2026-07-22","2027-01-22","2024-07-25",30,[499],"Chronic Thromboembolic Pulmonary Hypertension",[478],{"trials":502,"activeCount":102},[],{"intervention":504,"totalTrials":121,"cells":505},"Hydrochlorothiazide 25mg once per day",{"EARLY_PHASE1":506,"PHASE1":508,"PHASE2":510,"PHASE3":512,"PHASE4":514,"NA":526},{"trials":507,"activeCount":102},[],{"trials":509,"activeCount":102},[],{"trials":511,"activeCount":102},[],{"trials":513,"activeCount":102},[],{"trials":515,"activeCount":121,"soonestReadout":269},[516],{"nctId":517,"briefTitle":518,"status":112,"phases":519,"primaryCompletion":269,"completion":520,"start":521,"enrollment":156,"conditions":522,"interventions":525},"NCT07271420","Blood Pressure Control With Thiazide Diuretics in Peritoneal Dialysis Patients",[93],"2027-06-30","2020-01-01",[27,523,524],"Peritoneal Dialysis","End Stage Kidney Disease (ESRD)",[504],{"trials":527,"activeCount":102},[],{"intervention":529,"totalTrials":121,"cells":530},"Baricitinib 4 MG",{"EARLY_PHASE1":531,"PHASE1":533,"PHASE2":535,"PHASE3":537,"PHASE4":539,"NA":552},{"trials":532,"activeCount":102},[],{"trials":534,"activeCount":102},[],{"trials":536,"activeCount":102},[],{"trials":538,"activeCount":102},[],{"trials":540,"activeCount":121,"soonestReadout":545},[541],{"nctId":542,"briefTitle":543,"status":112,"phases":544,"primaryCompletion":545,"completion":546,"start":547,"enrollment":548,"conditions":549,"interventions":551},"NCT05955066","Effect of JAK Inhibitor on Erosion Healing in RA",[93],"2026-02","2026-06","2023-12-01",60,[550],"Rheumatoid Arthritis",[529],{"trials":553,"activeCount":102},[],{"intervention":236,"totalTrials":121,"cells":555},{"EARLY_PHASE1":556,"PHASE1":558,"PHASE2":560,"PHASE3":562,"PHASE4":564,"NA":570},{"trials":557,"activeCount":102},[],{"trials":559,"activeCount":102},[],{"trials":561,"activeCount":102},[],{"trials":563,"activeCount":102},[],{"trials":565,"activeCount":121,"soonestReadout":228},[566],{"nctId":225,"briefTitle":226,"status":112,"phases":567,"primaryCompletion":228,"completion":229,"start":230,"enrollment":231,"conditions":568,"interventions":569},[93],[233,234],[236,237],{"trials":571,"activeCount":102},[],{"intervention":573,"totalTrials":121,"cells":574},"Carvedilol",{"EARLY_PHASE1":575,"PHASE1":577,"PHASE2":579,"PHASE3":581,"PHASE4":583,"NA":597},{"trials":576,"activeCount":102},[],{"trials":578,"activeCount":102},[],{"trials":580,"activeCount":102},[],{"trials":582,"activeCount":102},[],{"trials":584,"activeCount":121,"soonestReadout":589},[585],{"nctId":586,"briefTitle":587,"status":112,"phases":588,"primaryCompletion":589,"completion":589,"start":590,"enrollment":591,"conditions":592,"interventions":596},"NCT06449339","Non-selective Beta-blocker in Compensated Advanced Chronic Liver Disease",[93],"2031-07-30","2024-07-17",474,[593,594,595],"Portal Hypertension","Hepatic Decompensation","Advanced Chronic Liver Disease",[573],{"trials":598,"activeCount":102},[],{"intervention":600,"totalTrials":121,"cells":601},"RSV vaccination",{"EARLY_PHASE1":602,"PHASE1":604,"PHASE2":606,"PHASE3":608,"PHASE4":610,"NA":624},{"trials":603,"activeCount":102},[],{"trials":605,"activeCount":102},[],{"trials":607,"activeCount":102},[],{"trials":609,"activeCount":102},[],{"trials":611,"activeCount":121,"soonestReadout":616},[612],{"nctId":613,"briefTitle":614,"status":127,"phases":615,"primaryCompletion":616,"completion":617,"start":618,"enrollment":619,"conditions":620,"interventions":623},"NCT07508644","RSV Vaccination to Reduce Recurrent AECOPD",[93],"2030-06-30","2030-12-31","2027-07-01",320,[621,622],"COPD","RSV",[600],{"trials":625,"activeCount":102},[],{"intervention":627,"totalTrials":121,"cells":628},"Bisacodyl 5 mg",{"EARLY_PHASE1":629,"PHASE1":631,"PHASE2":633,"PHASE3":635,"PHASE4":637,"NA":650},{"trials":630,"activeCount":102},[],{"trials":632,"activeCount":102},[],{"trials":634,"activeCount":102},[],{"trials":636,"activeCount":102},[],{"trials":638,"activeCount":121,"soonestReadout":643},[639],{"nctId":640,"briefTitle":641,"status":127,"phases":642,"primaryCompletion":643,"completion":644,"start":645,"enrollment":646,"conditions":647,"interventions":649},"NCT07351357","Bisacodyl Oral for Lowering Dysfunction (of Tenckhoff Catheter)",[93],"2027-08-30","2027-09-30","2026-01-12",398,[648,523],"Renal Failure Chronic Requiring Dialysis",[627],{"trials":651,"activeCount":102},[],{"intervention":653,"totalTrials":121,"cells":654},"Dapagliflozin 10mg Tab",{"EARLY_PHASE1":655,"PHASE1":657,"PHASE2":659,"PHASE3":661,"PHASE4":663,"NA":676},{"trials":656,"activeCount":102},[],{"trials":658,"activeCount":102},[],{"trials":660,"activeCount":102},[],{"trials":662,"activeCount":102},[],{"trials":664,"activeCount":121,"soonestReadout":669},[665],{"nctId":666,"briefTitle":667,"status":112,"phases":668,"primaryCompletion":669,"completion":670,"start":671,"enrollment":672,"conditions":673,"interventions":675},"NCT06364930","SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus",[93],"2030-10-31","2031-03-30","2024-03-26",412,[674],"Chronic Hepatitis B",[653],{"trials":677,"activeCount":102},[],{"intervention":381,"totalTrials":98,"cells":679},{"EARLY_PHASE1":680,"PHASE1":682,"PHASE2":684,"PHASE3":686,"PHASE4":688,"NA":694},{"trials":681,"activeCount":102},[],{"trials":683,"activeCount":102},[],{"trials":685,"activeCount":102},[],{"trials":687,"activeCount":102},[],{"trials":689,"activeCount":121,"soonestReadout":374},[690],{"nctId":371,"briefTitle":372,"status":112,"phases":691,"primaryCompletion":374,"completion":375,"start":376,"enrollment":377,"conditions":692,"interventions":693},[93],[379],[358,381],{"trials":695,"activeCount":102},[696],{"nctId":697,"briefTitle":698,"status":203,"phases":699,"primaryCompletion":700,"completion":700,"start":205,"enrollment":156,"conditions":701,"interventions":702},"NCT00901550","The Chinese University of Hong Kong Early Arthritis Study",[94],"2011-10",[550],[381,703],"Infliximab",{"intervention":43,"totalTrials":98,"cells":705},{"EARLY_PHASE1":706,"PHASE1":708,"PHASE2":710,"PHASE3":712,"PHASE4":735,"NA":737},{"trials":707,"activeCount":102},[],{"trials":709,"activeCount":102},[],{"trials":711,"activeCount":102},[],{"trials":713,"activeCount":98,"soonestReadout":42},[714,729],{"nctId":715,"briefTitle":716,"status":467,"phases":717,"primaryCompletion":718,"completion":719,"start":720,"enrollment":721,"conditions":722,"interventions":727},"NCT05913284","Intravenous Methadone in Perioperative Acute and Chronic Management in Chinese Adult Cardiac Surgical Patients",[92],"2026-02-01","2026-04-01","2024-01-15",86,[723,724,725,726],"Pain, Postoperative","Pain, Acute","Pain, Chronic","Anesthesia",[43,728],"Morphine",{"nctId":40,"briefTitle":41,"status":112,"phases":730,"primaryCompletion":42,"completion":731,"start":732,"enrollment":721,"conditions":733,"interventions":734},[92],"2025-06-01","2024-03-01",[723],[43,728],{"trials":736,"activeCount":102},[],{"trials":738,"activeCount":102},[],{"intervention":728,"totalTrials":98,"cells":740},{"EARLY_PHASE1":741,"PHASE1":743,"PHASE2":745,"PHASE3":747,"PHASE4":757,"NA":759},{"trials":742,"activeCount":102},[],{"trials":744,"activeCount":102},[],{"trials":746,"activeCount":102},[],{"trials":748,"activeCount":98,"soonestReadout":42},[749,753],{"nctId":715,"briefTitle":716,"status":467,"phases":750,"primaryCompletion":718,"completion":719,"start":720,"enrollment":721,"conditions":751,"interventions":752},[92],[723,724,725,726],[43,728],{"nctId":40,"briefTitle":41,"status":112,"phases":754,"primaryCompletion":42,"completion":731,"start":732,"enrollment":721,"conditions":755,"interventions":756},[92],[723],[43,728],{"trials":758,"activeCount":102},[],{"trials":760,"activeCount":102},[],{"intervention":68,"totalTrials":121,"cells":762},{"EARLY_PHASE1":763,"PHASE1":765,"PHASE2":767,"PHASE3":769,"PHASE4":779,"NA":781},{"trials":764,"activeCount":102},[],{"trials":766,"activeCount":102},[],{"trials":768,"activeCount":102},[],{"trials":770,"activeCount":121,"soonestReadout":67},[771],{"nctId":65,"briefTitle":66,"status":127,"phases":772,"primaryCompletion":67,"completion":773,"start":774,"enrollment":775,"conditions":776,"interventions":778},[91,92],"2025-10-31","2024-10-01",140,[777],"Allergic Rhinitis",[68],{"trials":780,"activeCount":102},[],{"trials":782,"activeCount":102},[],{"intervention":784,"totalTrials":121,"cells":785},"talc powder",{"EARLY_PHASE1":786,"PHASE1":788,"PHASE2":790,"PHASE3":792,"PHASE4":803,"NA":805},{"trials":787,"activeCount":102},[],{"trials":789,"activeCount":102},[],{"trials":791,"activeCount":102},[],{"trials":793,"activeCount":121,"soonestReadout":798},[794],{"nctId":795,"briefTitle":796,"status":127,"phases":797,"primaryCompletion":798,"completion":798,"start":719,"enrollment":497,"conditions":799,"interventions":801},"NCT06883188","Stop Air Leak by Talc or Autologous Blood Patch Therapy",[91,92],"2029-03-31",[800],"Pneumothorax Spontaneous Secondary",[784,802],"patient's own venous blood",{"trials":804,"activeCount":102},[],{"trials":806,"activeCount":102},[],{"intervention":802,"totalTrials":121,"cells":808},{"EARLY_PHASE1":809,"PHASE1":811,"PHASE2":813,"PHASE3":815,"PHASE4":821,"NA":823},{"trials":810,"activeCount":102},[],{"trials":812,"activeCount":102},[],{"trials":814,"activeCount":102},[],{"trials":816,"activeCount":121,"soonestReadout":798},[817],{"nctId":795,"briefTitle":796,"status":127,"phases":818,"primaryCompletion":798,"completion":798,"start":719,"enrollment":497,"conditions":819,"interventions":820},[91,92],[800],[784,802],{"trials":822,"activeCount":102},[],{"trials":824,"activeCount":102},[],{"intervention":826,"totalTrials":121,"cells":827},"Antibiotics first",{"EARLY_PHASE1":828,"PHASE1":830,"PHASE2":832,"PHASE3":834,"PHASE4":845,"NA":847},{"trials":829,"activeCount":102},[],{"trials":831,"activeCount":102},[],{"trials":833,"activeCount":102},[],{"trials":835,"activeCount":121,"soonestReadout":374},[836],{"nctId":837,"briefTitle":838,"status":112,"phases":839,"primaryCompletion":374,"completion":374,"start":840,"enrollment":841,"conditions":842,"interventions":844},"NCT05893511","EUS-GBD vs Antibiotics for Patients at High Risk for Cholecystectomy",[92],"2023-04-26",110,[843],"Acute Cholecystitis",[826],{"trials":846,"activeCount":102},[],{"trials":848,"activeCount":102},[],{"intervention":850,"totalTrials":121,"cells":851},"Indomethacin",{"EARLY_PHASE1":852,"PHASE1":854,"PHASE2":856,"PHASE3":858,"PHASE4":869,"NA":871},{"trials":853,"activeCount":102},[],{"trials":855,"activeCount":102},[],{"trials":857,"activeCount":102},[],{"trials":859,"activeCount":121,"soonestReadout":269},[860],{"nctId":861,"briefTitle":862,"status":112,"phases":863,"primaryCompletion":269,"completion":269,"start":864,"enrollment":865,"conditions":866,"interventions":868},"NCT03713879","Comparative Effectiveness Between Indomethacin and Pancreatic Stenting in the Prevention of Post ERCP Pancreatitis",[92],"2019-03-21",1734,[867],"Post ERCP Pancreatitis",[850],{"trials":870,"activeCount":102},[],{"trials":872,"activeCount":102},[],{"intervention":48,"totalTrials":121,"cells":874},{"EARLY_PHASE1":875,"PHASE1":877,"PHASE2":879,"PHASE3":881,"PHASE4":890,"NA":892},{"trials":876,"activeCount":102},[],{"trials":878,"activeCount":102},[],{"trials":880,"activeCount":102},[],{"trials":882,"activeCount":121,"soonestReadout":47},[883],{"nctId":45,"briefTitle":46,"status":112,"phases":884,"primaryCompletion":47,"completion":374,"start":885,"enrollment":841,"conditions":886,"interventions":888},[92],"2022-03-21",[887],"Cancer of Stomach, Adenocarcinoma",[48,889],"XELOX",{"trials":891,"activeCount":102},[],{"trials":893,"activeCount":102},[],{"intervention":889,"totalTrials":121,"cells":895},{"EARLY_PHASE1":896,"PHASE1":898,"PHASE2":900,"PHASE3":902,"PHASE4":908,"NA":910},{"trials":897,"activeCount":102},[],{"trials":899,"activeCount":102},[],{"trials":901,"activeCount":102},[],{"trials":903,"activeCount":121,"soonestReadout":47},[904],{"nctId":45,"briefTitle":46,"status":112,"phases":905,"primaryCompletion":47,"completion":374,"start":885,"enrollment":841,"conditions":906,"interventions":907},[92],[887],[48,889],{"trials":909,"activeCount":102},[],{"trials":911,"activeCount":102},[],{"intervention":913,"totalTrials":121,"cells":914},"Tissue Plasminogen Activator",{"EARLY_PHASE1":915,"PHASE1":917,"PHASE2":919,"PHASE3":921,"PHASE4":932,"NA":934},{"trials":916,"activeCount":102},[],{"trials":918,"activeCount":102},[],{"trials":920,"activeCount":102},[],{"trials":922,"activeCount":121,"soonestReadout":927},[923],{"nctId":924,"briefTitle":925,"status":112,"phases":926,"primaryCompletion":927,"completion":129,"start":928,"enrollment":497,"conditions":929,"interventions":931},"NCT05766124","Trial of Reduced Alteplase Dose for Parapneumonic Effusion (TRAPPE)",[91,92],"2028-03-31","2024-11-01",[930],"Pleural Infection",[913],{"trials":933,"activeCount":102},[],{"trials":935,"activeCount":102},[],{"intervention":937,"totalTrials":121,"cells":938},"4CMenB vaccine",{"EARLY_PHASE1":939,"PHASE1":941,"PHASE2":943,"PHASE3":945,"PHASE4":958,"NA":960},{"trials":940,"activeCount":102},[],{"trials":942,"activeCount":102},[],{"trials":944,"activeCount":102},[],{"trials":946,"activeCount":121,"soonestReadout":951},[947],{"nctId":948,"briefTitle":949,"status":467,"phases":950,"primaryCompletion":951,"completion":952,"start":953,"enrollment":954,"conditions":955,"interventions":957},"NCT05766904","Efficacy Trial on Meningococcal B Vaccine for Preventing Gonorrhea Infections",[92],"2026-09","2026-12","2023-05-04",150,[407,956],"Sexually Transmitted Infection",[937],{"trials":959,"activeCount":102},[],{"trials":961,"activeCount":102},[],{"intervention":963,"totalTrials":98,"cells":964},"Aspirin 80mg",{"EARLY_PHASE1":965,"PHASE1":967,"PHASE2":969,"PHASE3":971,"PHASE4":985,"NA":987},{"trials":966,"activeCount":102},[],{"trials":968,"activeCount":102},[],{"trials":970,"activeCount":102},[],{"trials":972,"activeCount":121,"soonestReadout":617},[973],{"nctId":974,"briefTitle":975,"status":112,"phases":976,"primaryCompletion":617,"completion":977,"start":978,"enrollment":979,"conditions":980,"interventions":984},"NCT07052799","Aspirin Continuation or Interruption in Patients at Moderate Risk for Cardiovascular Events Undergoing Colonoscopy and\u002For Polypectomy",[92],"2031-12-31","2026-02-10",2514,[981,982,983],"Myocardial Infarction (MI)","Cardiovascular Events","Post Polypectomy Bleeding in Antiplatelet Patients",[963],{"trials":986,"activeCount":102},[],{"trials":988,"activeCount":102},[989],{"nctId":990,"briefTitle":991,"status":189,"phases":992,"primaryCompletion":993,"completion":994,"start":995,"enrollment":996,"conditions":997,"interventions":1000},"NCT03450317","Influence of Aspirin on Human Gut Microbiota Composition and Metabolome",[94],"2020-12-31","2021-12-31","2018-03-01",100,[998,999],"Aspirin","Microbiota",[963],{"intervention":53,"totalTrials":1002,"cells":1003},3,{"EARLY_PHASE1":1004,"PHASE1":1006,"PHASE2":1008,"PHASE3":1039,"PHASE4":1041,"NA":1043},{"trials":1005,"activeCount":102},[],{"trials":1007,"activeCount":102},[],{"trials":1009,"activeCount":98,"soonestReadout":52},[1010,1022,1028],{"nctId":1011,"briefTitle":1012,"status":112,"phases":1013,"primaryCompletion":1014,"completion":1015,"start":1016,"enrollment":1017,"conditions":1018,"interventions":1020},"NCT06055465","Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer",[91],"2028-12-30","2029-12-30","2024-02-28",37,[1019],"Lung Cancer",[1021,53],"Sacituzumab Govitecan",{"nctId":50,"briefTitle":51,"status":467,"phases":1023,"primaryCompletion":52,"completion":374,"start":1024,"enrollment":16,"conditions":1025,"interventions":1027},[91],"2019-05-03",[1026],"NPC",[53],{"nctId":1029,"briefTitle":1030,"status":203,"phases":1031,"primaryCompletion":1032,"completion":1032,"start":1033,"enrollment":1034,"conditions":1035,"interventions":1037},"NCT02875132","Pembrolizumab in Advanced\u002FMetastatic Acral Lentiginous Melanoma",[91],"2022-02-28","2017-02-15",9,[1036],"Acral Lentiginous Melanoma",[1038],"pembrolizumab",{"trials":1040,"activeCount":102},[],{"trials":1042,"activeCount":102},[],{"trials":1044,"activeCount":102},[],{"intervention":1046,"totalTrials":98,"cells":1047},"Empagliflozin 10 MG",{"EARLY_PHASE1":1048,"PHASE1":1050,"PHASE2":1052,"PHASE3":1067,"PHASE4":1079,"NA":1081},{"trials":1049,"activeCount":102},[],{"trials":1051,"activeCount":102},[],{"trials":1053,"activeCount":121,"soonestReadout":167},[1054],{"nctId":1055,"briefTitle":1056,"status":112,"phases":1057,"primaryCompletion":167,"completion":1058,"start":1059,"enrollment":1060,"conditions":1061,"interventions":1066},"NCT06483074","Empagliflozin on Residual Kidney Function in Incident Peritoneal Dialysis Patients",[91],"2026-10-31","2024-07-29",48,[1062,1063,1064,1065],"End Stage Renal Disease on Dialysis","Peritoneal Dialysis Complication","Sodium-glucose Cotransporter-2 Inhibitor","Residual Kidney Function",[1046],{"trials":1068,"activeCount":102},[1069],{"nctId":1070,"briefTitle":1071,"status":189,"phases":1072,"primaryCompletion":1016,"completion":1073,"start":1074,"enrollment":1075,"conditions":1076,"interventions":1078},"NCT05556044","Empagliflozin for New On-set Heart Failure Study Regardless of Ejection Fraction",[92],"2024-05-31","2022-09-27",200,[1077],"Acute Heart Failure",[1046],{"trials":1080,"activeCount":102},[],{"trials":1082,"activeCount":102},[],{"intervention":1084,"totalTrials":1002,"cells":1085},"Dorzagliatin",{"EARLY_PHASE1":1086,"PHASE1":1088,"PHASE2":1090,"PHASE3":1122,"PHASE4":1124,"NA":1126},{"trials":1087,"activeCount":102},[],{"trials":1089,"activeCount":102},[],{"trials":1091,"activeCount":121,"soonestReadout":269},[1092,1102,1111],{"nctId":1093,"briefTitle":1094,"status":203,"phases":1095,"primaryCompletion":1096,"completion":1096,"start":1097,"enrollment":1098,"conditions":1099,"interventions":1101},"NCT04531631","Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes",[91],"2022-02-15","2020-09-30",18,[1100],"Diabetes Mellitus, Type 2",[1084],{"nctId":1103,"briefTitle":1104,"status":189,"phases":1105,"primaryCompletion":1106,"completion":1106,"start":1107,"enrollment":28,"conditions":1108,"interventions":1110},"NCT05468229","Dorzagliatin and 1st Phase Insulin and Beta-cell Glucose Sensitivity in IGT and NGT",[90,91],"2023-04","2022-08",[1109],"Glucose Intolerance",[1084],{"nctId":1112,"briefTitle":1113,"status":112,"phases":1114,"primaryCompletion":269,"completion":269,"start":1115,"enrollment":1116,"conditions":1117,"interventions":1120},"NCT06976658","Glucokinase Activator in Monogenic Diabetes",[91],"2025-04-30",44,[1118,1119],"Diabetes Mellitus","Monogenic Diabetes",[1084,1121],"matched placebo",{"trials":1123,"activeCount":102},[],{"trials":1125,"activeCount":102},[],{"trials":1127,"activeCount":102},[],{"intervention":1129,"totalTrials":121,"cells":1130},"Fezolinetant",{"EARLY_PHASE1":1131,"PHASE1":1133,"PHASE2":1135,"PHASE3":1146,"PHASE4":1148,"NA":1150},{"trials":1132,"activeCount":102},[],{"trials":1134,"activeCount":102},[],{"trials":1136,"activeCount":121,"soonestReadout":374},[1137],{"nctId":1138,"briefTitle":1139,"status":127,"phases":1140,"primaryCompletion":374,"completion":927,"start":1141,"enrollment":1142,"conditions":1143,"interventions":1145},"NCT07568236","A Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT)",[91],"2026-07-01",54,[1144,18],"Vasomotor Symptoms",[1129],{"trials":1147,"activeCount":102},[],{"trials":1149,"activeCount":102},[],{"trials":1151,"activeCount":102},[],{"intervention":1153,"totalTrials":121,"cells":1154},"Modified Suan ZaoRen Tang-TianWang BuXin Dan",{"EARLY_PHASE1":1155,"PHASE1":1157,"PHASE2":1159,"PHASE3":1172,"PHASE4":1174,"NA":1176},{"trials":1156,"activeCount":102},[],{"trials":1158,"activeCount":102},[],{"trials":1160,"activeCount":121,"soonestReadout":1165},[1161],{"nctId":1162,"briefTitle":1163,"status":127,"phases":1164,"primaryCompletion":1165,"completion":1166,"start":1167,"enrollment":1168,"conditions":1169,"interventions":1171},"NCT06511011","Chinese Medicine in Treating Insomnia",[91],"2026-05","2026-08","2024-09",76,[1170],"Insomnia Chronic",[1153],{"trials":1173,"activeCount":102},[],{"trials":1175,"activeCount":102},[],{"trials":1177,"activeCount":102},[],{"intervention":1179,"totalTrials":121,"cells":1180},"Semaglutide, 0.5 mg\u002FmL",{"EARLY_PHASE1":1181,"PHASE1":1183,"PHASE2":1185,"PHASE3":1196,"PHASE4":1198,"NA":1200},{"trials":1182,"activeCount":102},[],{"trials":1184,"activeCount":102},[],{"trials":1186,"activeCount":121,"soonestReadout":1191},[1187],{"nctId":1188,"briefTitle":1189,"status":127,"phases":1190,"primaryCompletion":1191,"completion":375,"start":1192,"enrollment":1075,"conditions":1193,"interventions":1195},"NCT07613437","GLP-1 Receptor Agonist in Primary Intracerebral Hemorrhage: A Phase 2 Randomized Trial",[91],"2028-06-14","2026-06-15",[1194],"Intracerebral Hemorrhage",[1179],{"trials":1197,"activeCount":102},[],{"trials":1199,"activeCount":102},[],{"trials":1201,"activeCount":102},[],{"intervention":1203,"totalTrials":121,"cells":1204},"Fludrocortisone 100 mcg daily",{"EARLY_PHASE1":1205,"PHASE1":1207,"PHASE2":1209,"PHASE3":1224,"PHASE4":1226,"NA":1228},{"trials":1206,"activeCount":102},[],{"trials":1208,"activeCount":102},[],{"trials":1210,"activeCount":121,"soonestReadout":1215},[1211],{"nctId":1212,"briefTitle":1213,"status":112,"phases":1214,"primaryCompletion":1215,"completion":1215,"start":719,"enrollment":1216,"conditions":1217,"interventions":1223},"NCT07451886","Adjunctive Fludrocortisone in Septic Shock",[91],"2028-07-31",32,[1218,1219,1220,1221,1222],"Sepsis","Septic Shock","Sepsis - to Reduce Mortality in the Intensive Care Unit","Sepsis and Septic Shock","Sepsis at Intensive Care Unit",[1203],{"trials":1225,"activeCount":102},[],{"trials":1227,"activeCount":102},[],{"trials":1229,"activeCount":102},[],{"intervention":1021,"totalTrials":121,"cells":1231},{"EARLY_PHASE1":1232,"PHASE1":1234,"PHASE2":1236,"PHASE3":1242,"PHASE4":1244,"NA":1246},{"trials":1233,"activeCount":102},[],{"trials":1235,"activeCount":102},[],{"trials":1237,"activeCount":121,"soonestReadout":1014},[1238],{"nctId":1011,"briefTitle":1012,"status":112,"phases":1239,"primaryCompletion":1014,"completion":1015,"start":1016,"enrollment":1017,"conditions":1240,"interventions":1241},[91],[1019],[1021,53],{"trials":1243,"activeCount":102},[],{"trials":1245,"activeCount":102},[],{"trials":1247,"activeCount":102},[],{"intervention":1249,"totalTrials":121,"cells":1250},"Cisplatin and Doxorubicin",{"EARLY_PHASE1":1251,"PHASE1":1253,"PHASE2":1255,"PHASE3":1267,"PHASE4":1269,"NA":1271},{"trials":1252,"activeCount":102},[],{"trials":1254,"activeCount":102},[],{"trials":1256,"activeCount":121,"soonestReadout":1262},[1257],{"nctId":1258,"briefTitle":1259,"status":1260,"phases":1261,"primaryCompletion":1262,"completion":1262,"start":1263,"enrollment":497,"conditions":1264,"interventions":1266},"NCT07517419","PIPAC in Gastric Peritoneal Metastasis","ENROLLING_BY_INVITATION",[91],"2031-02-28","2021-10-11",[1265],"Gastric Cancer Peritoneal Metastases",[1249],{"trials":1268,"activeCount":102},[],{"trials":1270,"activeCount":102},[],{"trials":1272,"activeCount":102},[],{"intervention":1274,"totalTrials":121,"cells":1275},"Yunzhi Essence",{"EARLY_PHASE1":1276,"PHASE1":1278,"PHASE2":1280,"PHASE3":1293,"PHASE4":1295,"NA":1297},{"trials":1277,"activeCount":102},[],{"trials":1279,"activeCount":102},[],{"trials":1281,"activeCount":121,"soonestReadout":1286},[1282],{"nctId":1283,"briefTitle":1284,"status":127,"phases":1285,"primaryCompletion":1286,"completion":154,"start":1287,"enrollment":1288,"conditions":1289,"interventions":1292},"NCT05754801","Yunzhi Essence to Improve the Quality of Life of Patients With Advanced Stage of Cancer",[91],"2026-03-31","2023-04-01",172,[1290,1291],"Cancer","Palliative Care",[1274],{"trials":1294,"activeCount":102},[],{"trials":1296,"activeCount":102},[],{"trials":1298,"activeCount":102},[],{"intervention":1300,"totalTrials":121,"cells":1301},"NEPA",{"EARLY_PHASE1":1302,"PHASE1":1304,"PHASE2":1306,"PHASE3":1317,"PHASE4":1319,"NA":1321},{"trials":1303,"activeCount":102},[],{"trials":1305,"activeCount":102},[],{"trials":1307,"activeCount":121,"soonestReadout":374},[1308],{"nctId":1309,"briefTitle":1310,"status":467,"phases":1311,"primaryCompletion":374,"completion":375,"start":1312,"enrollment":1313,"conditions":1314,"interventions":1316},"NCT03386617","AKY15-HK-301_NEPA Study",[91],"2018-02-27",55,[1315],"Breast Cancer",[1300],{"trials":1318,"activeCount":102},[],{"trials":1320,"activeCount":102},[],{"trials":1322,"activeCount":102},[],{"intervention":1324,"totalTrials":121,"cells":1325},"Standard antiemetic regimen or Olanzapine antiemetic regimen",{"EARLY_PHASE1":1326,"PHASE1":1328,"PHASE2":1330,"PHASE3":1340,"PHASE4":1342,"NA":1344},{"trials":1327,"activeCount":102},[],{"trials":1329,"activeCount":102},[],{"trials":1331,"activeCount":121,"soonestReadout":1336},[1332],{"nctId":1333,"briefTitle":1334,"status":112,"phases":1335,"primaryCompletion":1336,"completion":229,"start":1286,"enrollment":1075,"conditions":1337,"interventions":1338},"NCT07455955","Personalized Antiemetic Regimen According to Patients' Pharmacogenetic Profile",[91],"2027-06-03",[1315],[1324,1339],"Standard antiemetic regimen",{"trials":1341,"activeCount":102},[],{"trials":1343,"activeCount":102},[],{"trials":1345,"activeCount":102},[],{"intervention":1339,"totalTrials":121,"cells":1347},{"EARLY_PHASE1":1348,"PHASE1":1350,"PHASE2":1352,"PHASE3":1358,"PHASE4":1360,"NA":1362},{"trials":1349,"activeCount":102},[],{"trials":1351,"activeCount":102},[],{"trials":1353,"activeCount":121,"soonestReadout":1336},[1354],{"nctId":1333,"briefTitle":1334,"status":112,"phases":1355,"primaryCompletion":1336,"completion":229,"start":1286,"enrollment":1075,"conditions":1356,"interventions":1357},[91],[1315],[1324,1339],{"trials":1359,"activeCount":102},[],{"trials":1361,"activeCount":102},[],{"trials":1363,"activeCount":102},[],{"intervention":1365,"totalTrials":121,"cells":1366},"Dachaihu Decoction combined Erzhiwan with variation",{"EARLY_PHASE1":1367,"PHASE1":1369,"PHASE2":1371,"PHASE3":1383,"PHASE4":1385,"NA":1387},{"trials":1368,"activeCount":102},[],{"trials":1370,"activeCount":102},[],{"trials":1372,"activeCount":121,"soonestReadout":952},[1373],{"nctId":1374,"briefTitle":1375,"status":127,"phases":1376,"primaryCompletion":952,"completion":1377,"start":1378,"enrollment":1379,"conditions":1380,"interventions":1382},"NCT06700408","RCT for the Chinese Medicine in Treating Hypercholesterolemia",[91],"2027-04","2025-01",70,[1381],"Hypercholesterolemia",[1365],{"trials":1384,"activeCount":102},[],{"trials":1386,"activeCount":102},[],{"trials":1388,"activeCount":102},[],{"intervention":1390,"totalTrials":121,"cells":1391},"JM-LD",{"EARLY_PHASE1":1392,"PHASE1":1394,"PHASE2":1396,"PHASE3":1410,"PHASE4":1412,"NA":1414},{"trials":1393,"activeCount":102},[],{"trials":1395,"activeCount":102},[],{"trials":1397,"activeCount":121,"soonestReadout":1402},[1398],{"nctId":1399,"briefTitle":1400,"status":127,"phases":1401,"primaryCompletion":1402,"completion":1403,"start":1404,"enrollment":1405,"conditions":1406,"interventions":1408},"NCT06978023","Novel Chinese Medicine Formula for Diabetes",[91],"2026-10","2027-02","2025-05",162,[1407],"Type 2 Diabetes",[1390,1409],"JM-HD",{"trials":1411,"activeCount":102},[],{"trials":1413,"activeCount":102},[],{"trials":1415,"activeCount":102},[],{"intervention":1409,"totalTrials":121,"cells":1417},{"EARLY_PHASE1":1418,"PHASE1":1420,"PHASE2":1422,"PHASE3":1428,"PHASE4":1430,"NA":1432},{"trials":1419,"activeCount":102},[],{"trials":1421,"activeCount":102},[],{"trials":1423,"activeCount":121,"soonestReadout":1402},[1424],{"nctId":1399,"briefTitle":1400,"status":127,"phases":1425,"primaryCompletion":1402,"completion":1403,"start":1404,"enrollment":1405,"conditions":1426,"interventions":1427},[91],[1407],[1390,1409],{"trials":1429,"activeCount":102},[],{"trials":1431,"activeCount":102},[],{"trials":1433,"activeCount":102},[],{"intervention":1435,"totalTrials":121,"cells":1436},"neoadjuvant FOLFOXIRI",{"EARLY_PHASE1":1437,"PHASE1":1439,"PHASE2":1441,"PHASE3":1452,"PHASE4":1454,"NA":1456},{"trials":1438,"activeCount":102},[],{"trials":1440,"activeCount":102},[],{"trials":1442,"activeCount":121,"soonestReadout":269},[1443],{"nctId":1444,"briefTitle":1445,"status":467,"phases":1446,"primaryCompletion":269,"completion":374,"start":1447,"enrollment":156,"conditions":1448,"interventions":1450},"NCT01941641","Colon Neoadjuvant FOLFOXIRI Study",[91],"2013-10-09",[1449],"Rectal Cancer",[1435,1451],"Capecitabine",{"trials":1453,"activeCount":102},[],{"trials":1455,"activeCount":102},[],{"trials":1457,"activeCount":102},[],{"intervention":1451,"totalTrials":121,"cells":1459},{"EARLY_PHASE1":1460,"PHASE1":1462,"PHASE2":1464,"PHASE3":1470,"PHASE4":1472,"NA":1474},{"trials":1461,"activeCount":102},[],{"trials":1463,"activeCount":102},[],{"trials":1465,"activeCount":121,"soonestReadout":269},[1466],{"nctId":1444,"briefTitle":1445,"status":467,"phases":1467,"primaryCompletion":269,"completion":374,"start":1447,"enrollment":156,"conditions":1468,"interventions":1469},[91],[1449],[1435,1451],{"trials":1471,"activeCount":102},[],{"trials":1473,"activeCount":102},[],{"trials":1475,"activeCount":102},[],{"intervention":1477,"totalTrials":121,"cells":1478},"Atezolizumab plus Bevacizumab",{"EARLY_PHASE1":1479,"PHASE1":1481,"PHASE2":1483,"PHASE3":1494,"PHASE4":1496,"NA":1498},{"trials":1480,"activeCount":102},[],{"trials":1482,"activeCount":102},[],{"trials":1484,"activeCount":121,"soonestReadout":1489},[1485],{"nctId":1486,"briefTitle":1487,"status":112,"phases":1488,"primaryCompletion":1489,"completion":1215,"start":1490,"enrollment":156,"conditions":1491,"interventions":1493},"NCT06823375","SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis",[91],"2027-07-31","2025-07-10",[1492],"HCC",[1477],{"trials":1495,"activeCount":102},[],{"trials":1497,"activeCount":102},[],{"trials":1499,"activeCount":102},[],{"intervention":73,"totalTrials":121,"cells":1501},{"EARLY_PHASE1":1502,"PHASE1":1504,"PHASE2":1506,"PHASE3":1516,"PHASE4":1518,"NA":1520},{"trials":1503,"activeCount":102},[],{"trials":1505,"activeCount":102},[],{"trials":1507,"activeCount":121,"soonestReadout":72},[1508],{"nctId":70,"briefTitle":71,"status":112,"phases":1509,"primaryCompletion":72,"completion":1510,"start":1511,"enrollment":1512,"conditions":1513,"interventions":1515},[91],"2026-05-31","2022-11-28",72,[1514],"ICAD - Intracranial Atherosclerotic Disease",[73],{"trials":1517,"activeCount":102},[],{"trials":1519,"activeCount":102},[],{"trials":1521,"activeCount":102},[],{"intervention":1523,"totalTrials":121,"cells":1524},"Osimertinib alone",{"EARLY_PHASE1":1525,"PHASE1":1527,"PHASE2":1529,"PHASE3":1542,"PHASE4":1544,"NA":1546},{"trials":1526,"activeCount":102},[],{"trials":1528,"activeCount":102},[],{"trials":1530,"activeCount":121,"soonestReadout":1535},[1531],{"nctId":1532,"briefTitle":1533,"status":112,"phases":1534,"primaryCompletion":1535,"completion":1536,"start":1537,"enrollment":1538,"conditions":1539,"interventions":1541},"NCT07379476","Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer",[91],"2029-03-03","2030-03-03","2026-02-11",64,[1540],"Lung Cancer (NSCLC)",[1523],{"trials":1543,"activeCount":102},[],{"trials":1545,"activeCount":102},[],{"trials":1547,"activeCount":102},[],{"intervention":1549,"totalTrials":121,"cells":1550},"Modified Qing-Zao-Jiu-Fei Decoction",{"EARLY_PHASE1":1551,"PHASE1":1553,"PHASE2":1555,"PHASE3":1565,"PHASE4":1567,"NA":1569},{"trials":1552,"activeCount":102},[],{"trials":1554,"activeCount":102},[],{"trials":1556,"activeCount":121,"soonestReadout":269},[1557],{"nctId":1558,"briefTitle":1559,"status":127,"phases":1560,"primaryCompletion":269,"completion":114,"start":1561,"enrollment":11,"conditions":1562,"interventions":1564},"NCT07178184","Evaluating the Efficacy and Safety of Modified Qing-Zao-Jiu-Fei Decoction on Pneumoconiosis Patients",[91],"2025-11-01",[1563],"Pneumoconiosis",[1549],{"trials":1566,"activeCount":102},[],{"trials":1568,"activeCount":102},[],{"trials":1570,"activeCount":102},[],{"intervention":1121,"totalTrials":121,"cells":1572},{"EARLY_PHASE1":1573,"PHASE1":1575,"PHASE2":1577,"PHASE3":1583,"PHASE4":1585,"NA":1587},{"trials":1574,"activeCount":102},[],{"trials":1576,"activeCount":102},[],{"trials":1578,"activeCount":121,"soonestReadout":269},[1579],{"nctId":1112,"briefTitle":1113,"status":112,"phases":1580,"primaryCompletion":269,"completion":269,"start":1115,"enrollment":1116,"conditions":1581,"interventions":1582},[91],[1118,1119],[1084,1121],{"trials":1584,"activeCount":102},[],{"trials":1586,"activeCount":102},[],{"trials":1588,"activeCount":102},[],{"intervention":1590,"totalTrials":121,"cells":1591},"Exenatide extended release",{"EARLY_PHASE1":1592,"PHASE1":1594,"PHASE2":1596,"PHASE3":1606,"PHASE4":1608,"NA":1610},{"trials":1593,"activeCount":102},[],{"trials":1595,"activeCount":102},[],{"trials":1597,"activeCount":121,"soonestReadout":1165},[1598],{"nctId":1599,"briefTitle":1600,"status":112,"phases":1601,"primaryCompletion":1165,"completion":952,"start":1602,"enrollment":841,"conditions":1603,"interventions":1605},"NCT05356104","GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)",[91],"2022-05-25",[1604],"Cerebral Small Vessel Disease",[1590],{"trials":1607,"activeCount":102},[],{"trials":1609,"activeCount":102},[],{"trials":1611,"activeCount":102},[],{"intervention":1613,"totalTrials":121,"cells":1614},"eOCT implantation",{"EARLY_PHASE1":1615,"PHASE1":1617,"PHASE2":1628,"PHASE3":1630,"PHASE4":1632,"NA":1634},{"trials":1616,"activeCount":102},[],{"trials":1618,"activeCount":121,"soonestReadout":1623},[1619],{"nctId":1620,"briefTitle":1621,"status":112,"phases":1622,"primaryCompletion":1623,"completion":269,"start":1624,"enrollment":1034,"conditions":1625,"interventions":1627},"NCT06400862","Treating Patients With Traumatic Chondral Lesions With Autologous Bone Marrow Cells Derived Engineered Tissues - Engineered Osteochondral Tissue",[90],"2026-06-30","2024-02-26",[1626],"Traumatic Cartilage Injury",[1613],{"trials":1629,"activeCount":102},[],{"trials":1631,"activeCount":102},[],{"trials":1633,"activeCount":102},[],{"trials":1635,"activeCount":102},[],{"intervention":1637,"totalTrials":98,"cells":1638},"Vitamin D",{"EARLY_PHASE1":1639,"PHASE1":1641,"PHASE2":1643,"PHASE3":1645,"PHASE4":1647,"NA":1649},{"trials":1640,"activeCount":102},[],{"trials":1642,"activeCount":102},[],{"trials":1644,"activeCount":102},[],{"trials":1646,"activeCount":102},[],{"trials":1648,"activeCount":102},[],{"trials":1650,"activeCount":121,"soonestReadout":1655},[1651,1661],{"nctId":1652,"briefTitle":1653,"status":127,"phases":1654,"primaryCompletion":1655,"completion":1656,"start":1657,"enrollment":1116,"conditions":1658,"interventions":1660},"NCT06984068","Effect of Vitamin D Supplementation on the Rehabilitation of Patients After Rotator Cuff Tear Repair",[94],"2028-05","2028-11","2025-06",[1659],"Rotator Cuff Tear",[1637],{"nctId":1662,"briefTitle":1663,"status":189,"phases":1664,"primaryCompletion":1665,"completion":1666,"start":1667,"enrollment":1668,"conditions":1669,"interventions":1673},"NCT05981534","The Effectiveness of Vitamin D Supplementation in Patients With End-stage Knee Osteoarthritis",[94],"2025-06-30","2025-11-30","2024-03-17",56,[1670,1671,1672],"Vitamin D Deficiency","Sarcopenia","Knee Osteoarthritis",[1637],{"intervention":1675,"totalTrials":98,"cells":1676},"Entecavir",{"EARLY_PHASE1":1677,"PHASE1":1679,"PHASE2":1681,"PHASE3":1683,"PHASE4":1685,"NA":1687},{"trials":1678,"activeCount":102},[],{"trials":1680,"activeCount":102},[],{"trials":1682,"activeCount":102},[],{"trials":1684,"activeCount":102},[],{"trials":1686,"activeCount":102},[],{"trials":1688,"activeCount":121,"soonestReadout":77},[1689,1695],{"nctId":75,"briefTitle":76,"status":467,"phases":1690,"primaryCompletion":77,"completion":269,"start":1691,"enrollment":1692,"conditions":1693,"interventions":1694},[],"2022-09-01",1800,[674],[78,1675],{"nctId":1696,"briefTitle":1697,"status":203,"phases":1698,"primaryCompletion":1699,"completion":1700,"start":1701,"enrollment":1702,"conditions":1703,"interventions":1705},"NCT01918631","A Randomized Controlled Trial on the Efficacy of Tenofovir Disoproxil Fumarate (TDF)-Switch Therapy in Chronic Hepatitis B Patients With Incomplete Response to Entecavir",[94],"2017-01","2017-01-31","2013-08",36,[1704],"Chronic Heptitis B",[1706,1675],"tenofovir disoproxil fumarate",{"intervention":1708,"totalTrials":121,"cells":1709},"Levobupivacaine 0.25%",{"EARLY_PHASE1":1710,"PHASE1":1712,"PHASE2":1714,"PHASE3":1716,"PHASE4":1718,"NA":1720},{"trials":1711,"activeCount":102},[],{"trials":1713,"activeCount":102},[],{"trials":1715,"activeCount":102},[],{"trials":1717,"activeCount":102},[],{"trials":1719,"activeCount":102},[],{"trials":1721,"activeCount":121,"soonestReadout":1726},[1722],{"nctId":1723,"briefTitle":1724,"status":127,"phases":1725,"primaryCompletion":1726,"completion":1726,"start":1727,"enrollment":996,"conditions":1728,"interventions":1730},"NCT06926764","Intertransverse Process Block to Improve Quality of Recovery After Cardiac Surgery With Sternotomy",[94],"2027-11","2025-11",[1729],"Acute Postoperative Pain",[1708,1731],"Sodium Chloride (NaCl) 0.9 %",{"intervention":1731,"totalTrials":121,"cells":1733},{"EARLY_PHASE1":1734,"PHASE1":1736,"PHASE2":1738,"PHASE3":1740,"PHASE4":1742,"NA":1744},{"trials":1735,"activeCount":102},[],{"trials":1737,"activeCount":102},[],{"trials":1739,"activeCount":102},[],{"trials":1741,"activeCount":102},[],{"trials":1743,"activeCount":102},[],{"trials":1745,"activeCount":121,"soonestReadout":1726},[1746],{"nctId":1723,"briefTitle":1724,"status":127,"phases":1747,"primaryCompletion":1726,"completion":1726,"start":1727,"enrollment":996,"conditions":1748,"interventions":1749},[94],[1729],[1708,1731],{"intervention":83,"totalTrials":121,"cells":1751},{"EARLY_PHASE1":1752,"PHASE1":1754,"PHASE2":1756,"PHASE3":1758,"PHASE4":1760,"NA":1762},{"trials":1753,"activeCount":102},[],{"trials":1755,"activeCount":102},[],{"trials":1757,"activeCount":102},[],{"trials":1759,"activeCount":102},[],{"trials":1761,"activeCount":102},[],{"trials":1763,"activeCount":121,"soonestReadout":82},[1764],{"nctId":80,"briefTitle":81,"status":1260,"phases":1765,"primaryCompletion":82,"completion":82,"start":1766,"enrollment":1075,"conditions":1767,"interventions":1769},[],"2012-11-16",[1768],"Neuro-Degenerative Disease",[83],{"intervention":1771,"totalTrials":121,"cells":1772},"Gene expression or biomarkers exploration",{"EARLY_PHASE1":1773,"PHASE1":1775,"PHASE2":1777,"PHASE3":1779,"PHASE4":1781,"NA":1783},{"trials":1774,"activeCount":102},[],{"trials":1776,"activeCount":102},[],{"trials":1778,"activeCount":102},[],{"trials":1780,"activeCount":102},[],{"trials":1782,"activeCount":102},[],{"trials":1784,"activeCount":121,"soonestReadout":269},[1785],{"nctId":1786,"briefTitle":1787,"status":112,"phases":1788,"primaryCompletion":269,"completion":374,"start":1789,"enrollment":1790,"conditions":1791,"interventions":1795},"NCT03291392","CUHK Stroke Biobank",[],"2015-06-15",500,[1792,1793,1794],"Stroke, Ischemic","Genetic Disease","Atherosclerosis, Cerebral",[1771],{"intervention":1797,"totalTrials":121,"cells":1798},"No intervention",{"EARLY_PHASE1":1799,"PHASE1":1801,"PHASE2":1803,"PHASE3":1805,"PHASE4":1807,"NA":1809},{"trials":1800,"activeCount":102},[],{"trials":1802,"activeCount":102},[],{"trials":1804,"activeCount":102},[],{"trials":1806,"activeCount":102},[],{"trials":1808,"activeCount":102},[],{"trials":1810,"activeCount":121,"soonestReadout":1815},[1811],{"nctId":1812,"briefTitle":1813,"status":112,"phases":1814,"primaryCompletion":1815,"completion":1816,"start":732,"enrollment":1817,"conditions":1818,"interventions":1820},"NCT06196034","Genetic Association With Various Severities, Phenotypes and Endotypes of Asthma.",[],"2028-01-04","2029-01-04",2000,[1819],"Asthma",[1797],{"intervention":1822,"totalTrials":121,"cells":1823},"First line treatment: oral NSAID and anticholinergic agents",{"EARLY_PHASE1":1824,"PHASE1":1826,"PHASE2":1828,"PHASE3":1830,"PHASE4":1832,"NA":1834},{"trials":1825,"activeCount":102},[],{"trials":1827,"activeCount":102},[],{"trials":1829,"activeCount":102},[],{"trials":1831,"activeCount":102},[],{"trials":1833,"activeCount":102},[],{"trials":1835,"activeCount":121,"soonestReadout":269},[1836],{"nctId":1837,"briefTitle":1838,"status":112,"phases":1839,"primaryCompletion":269,"completion":269,"start":1840,"enrollment":1841,"conditions":1842,"interventions":1845},"NCT03913819","Treatment Outcomes Under a Standardized Treatment Protocol in Patients Suffered Substance Abuse Related Voiding Dysfunction",[],"2011-12-10",1000,[1843,1844],"Voiding Dysfunction","Substance Abuse",[1822,1846,1847],"Second line treatment: additional treatment for pain control","Third line treatment: A course of intravesical hyaluronate will be given.",{"intervention":1846,"totalTrials":121,"cells":1849},{"EARLY_PHASE1":1850,"PHASE1":1852,"PHASE2":1854,"PHASE3":1856,"PHASE4":1858,"NA":1860},{"trials":1851,"activeCount":102},[],{"trials":1853,"activeCount":102},[],{"trials":1855,"activeCount":102},[],{"trials":1857,"activeCount":102},[],{"trials":1859,"activeCount":102},[],{"trials":1861,"activeCount":121,"soonestReadout":269},[1862],{"nctId":1837,"briefTitle":1838,"status":112,"phases":1863,"primaryCompletion":269,"completion":269,"start":1840,"enrollment":1841,"conditions":1864,"interventions":1865},[],[1843,1844],[1822,1846,1847],{"intervention":1847,"totalTrials":121,"cells":1867},{"EARLY_PHASE1":1868,"PHASE1":1870,"PHASE2":1872,"PHASE3":1874,"PHASE4":1876,"NA":1878},{"trials":1869,"activeCount":102},[],{"trials":1871,"activeCount":102},[],{"trials":1873,"activeCount":102},[],{"trials":1875,"activeCount":102},[],{"trials":1877,"activeCount":102},[],{"trials":1879,"activeCount":121,"soonestReadout":269},[1880],{"nctId":1837,"briefTitle":1838,"status":112,"phases":1881,"primaryCompletion":269,"completion":269,"start":1840,"enrollment":1841,"conditions":1882,"interventions":1883},[],[1843,1844],[1822,1846,1847],{"intervention":87,"totalTrials":121,"cells":1885},{"EARLY_PHASE1":1886,"PHASE1":1888,"PHASE2":1890,"PHASE3":1892,"PHASE4":1894,"NA":1896},{"trials":1887,"activeCount":102},[],{"trials":1889,"activeCount":102},[],{"trials":1891,"activeCount":102},[],{"trials":1893,"activeCount":102},[],{"trials":1895,"activeCount":102},[],{"trials":1897,"activeCount":121,"soonestReadout":82},[1898],{"nctId":85,"briefTitle":86,"status":112,"phases":1899,"primaryCompletion":82,"completion":1286,"start":1900,"enrollment":1901,"conditions":1902,"interventions":1904},[],"2020-12-01",50,[1903],"Atrial Fibrillation",[87],{"intervention":63,"totalTrials":121,"cells":1906},{"EARLY_PHASE1":1907,"PHASE1":1909,"PHASE2":1911,"PHASE3":1913,"PHASE4":1915,"NA":1917},{"trials":1908,"activeCount":102},[],{"trials":1910,"activeCount":102},[],{"trials":1912,"activeCount":102},[],{"trials":1914,"activeCount":102},[],{"trials":1916,"activeCount":102},[],{"trials":1918,"activeCount":121,"soonestReadout":62},[1919],{"nctId":60,"briefTitle":61,"status":112,"phases":1920,"primaryCompletion":62,"completion":1921,"start":1922,"enrollment":1923,"conditions":1924,"interventions":1929},[],"2026-02-17","2020-05-22",700,[1925,1926,1927,1928],"Lung Function","Exercise Capacity","Quality of Life","Covid19",[63,1930,1931,1932],"third dose vaccination with BionTech vaccine","Vaccination with Coronavac vaccine","Vaccination with BionTech Vaccine",{"intervention":1930,"totalTrials":121,"cells":1934},{"EARLY_PHASE1":1935,"PHASE1":1937,"PHASE2":1939,"PHASE3":1941,"PHASE4":1943,"NA":1945},{"trials":1936,"activeCount":102},[],{"trials":1938,"activeCount":102},[],{"trials":1940,"activeCount":102},[],{"trials":1942,"activeCount":102},[],{"trials":1944,"activeCount":102},[],{"trials":1946,"activeCount":121,"soonestReadout":62},[1947],{"nctId":60,"briefTitle":61,"status":112,"phases":1948,"primaryCompletion":62,"completion":1921,"start":1922,"enrollment":1923,"conditions":1949,"interventions":1950},[],[1925,1926,1927,1928],[63,1930,1931,1932],{"intervention":1931,"totalTrials":121,"cells":1952},{"EARLY_PHASE1":1953,"PHASE1":1955,"PHASE2":1957,"PHASE3":1959,"PHASE4":1961,"NA":1963},{"trials":1954,"activeCount":102},[],{"trials":1956,"activeCount":102},[],{"trials":1958,"activeCount":102},[],{"trials":1960,"activeCount":102},[],{"trials":1962,"activeCount":102},[],{"trials":1964,"activeCount":121,"soonestReadout":62},[1965],{"nctId":60,"briefTitle":61,"status":112,"phases":1966,"primaryCompletion":62,"completion":1921,"start":1922,"enrollment":1923,"conditions":1967,"interventions":1968},[],[1925,1926,1927,1928],[63,1930,1931,1932],{"intervention":1932,"totalTrials":121,"cells":1970},{"EARLY_PHASE1":1971,"PHASE1":1973,"PHASE2":1975,"PHASE3":1977,"PHASE4":1979,"NA":1981},{"trials":1972,"activeCount":102},[],{"trials":1974,"activeCount":102},[],{"trials":1976,"activeCount":102},[],{"trials":1978,"activeCount":102},[],{"trials":1980,"activeCount":102},[],{"trials":1982,"activeCount":121,"soonestReadout":62},[1983],{"nctId":60,"briefTitle":61,"status":112,"phases":1984,"primaryCompletion":62,"completion":1921,"start":1922,"enrollment":1923,"conditions":1985,"interventions":1986},[],[1925,1926,1927,1928],[63,1930,1931,1932],{"intervention":1988,"totalTrials":121,"cells":1989},"RNA-seq",{"EARLY_PHASE1":1990,"PHASE1":1992,"PHASE2":1994,"PHASE3":1996,"PHASE4":1998,"NA":2000},{"trials":1991,"activeCount":102},[],{"trials":1993,"activeCount":102},[],{"trials":1995,"activeCount":102},[],{"trials":1997,"activeCount":102},[],{"trials":1999,"activeCount":102},[],{"trials":2001,"activeCount":121,"soonestReadout":2006},[2002],{"nctId":2003,"briefTitle":2004,"status":112,"phases":2005,"primaryCompletion":2006,"completion":2006,"start":2007,"enrollment":403,"conditions":2008,"interventions":2010},"NCT04478006","Advanced Translational Research on Childhood Leukemia",[],"2028-06-01","2020-07-01",[2009],"Childhood Leukemia",[1988,2011],"whole exon sequencing",{"intervention":2011,"totalTrials":121,"cells":2013},{"EARLY_PHASE1":2014,"PHASE1":2016,"PHASE2":2018,"PHASE3":2020,"PHASE4":2022,"NA":2024},{"trials":2015,"activeCount":102},[],{"trials":2017,"activeCount":102},[],{"trials":2019,"activeCount":102},[],{"trials":2021,"activeCount":102},[],{"trials":2023,"activeCount":102},[],{"trials":2025,"activeCount":121,"soonestReadout":2006},[2026],{"nctId":2003,"briefTitle":2004,"status":112,"phases":2027,"primaryCompletion":2006,"completion":2006,"start":2007,"enrollment":403,"conditions":2028,"interventions":2029},[],[2009],[1988,2011],{"intervention":2031,"totalTrials":121,"cells":2032},"alteplase or tenecteplase",{"EARLY_PHASE1":2033,"PHASE1":2035,"PHASE2":2037,"PHASE3":2039,"PHASE4":2041,"NA":2043},{"trials":2034,"activeCount":102},[],{"trials":2036,"activeCount":102},[],{"trials":2038,"activeCount":102},[],{"trials":2040,"activeCount":102},[],{"trials":2042,"activeCount":102},[],{"trials":2044,"activeCount":121,"soonestReadout":2049},[2045],{"nctId":2046,"briefTitle":2047,"status":112,"phases":2048,"primaryCompletion":2049,"completion":798,"start":2050,"enrollment":2051,"conditions":2052,"interventions":2054},"NCT06241677","Intravenous Thrombolytic Therapy in Acute Ischemic Stroke Patients on DOAC",[94],"2028-12-12","2024-04-15",260,[2053],"CVA (Cerebrovascular Accident)",[2031],{"intervention":78,"totalTrials":121,"cells":2056},{"EARLY_PHASE1":2057,"PHASE1":2059,"PHASE2":2061,"PHASE3":2063,"PHASE4":2065,"NA":2067},{"trials":2058,"activeCount":102},[],{"trials":2060,"activeCount":102},[],{"trials":2062,"activeCount":102},[],{"trials":2064,"activeCount":102},[],{"trials":2066,"activeCount":102},[],{"trials":2068,"activeCount":121,"soonestReadout":77},[2069],{"nctId":75,"briefTitle":76,"status":467,"phases":2070,"primaryCompletion":77,"completion":269,"start":1691,"enrollment":1692,"conditions":2071,"interventions":2072},[],[674],[78,1675],{"intervention":2074,"totalTrials":121,"cells":2075},"Androgen deprivation therapy - GnRH agonist",{"EARLY_PHASE1":2076,"PHASE1":2078,"PHASE2":2080,"PHASE3":2082,"PHASE4":2084,"NA":2086},{"trials":2077,"activeCount":102},[],{"trials":2079,"activeCount":102},[],{"trials":2081,"activeCount":102},[],{"trials":2083,"activeCount":102},[],{"trials":2085,"activeCount":102},[],{"trials":2087,"activeCount":121,"soonestReadout":82},[2088],{"nctId":2089,"briefTitle":2090,"status":467,"phases":2091,"primaryCompletion":82,"completion":1286,"start":2092,"enrollment":403,"conditions":2093,"interventions":2094},"NCT03703778","Real-life Evaluation of the Effect of ADT in Prostate Cancer Patients in Asia (READT Asia Study)",[],"2016-05-22",[18],[2074,2095],"Androgen deprivation therapy - GnRH antagonist",{"intervention":2095,"totalTrials":121,"cells":2097},{"EARLY_PHASE1":2098,"PHASE1":2100,"PHASE2":2102,"PHASE3":2104,"PHASE4":2106,"NA":2108},{"trials":2099,"activeCount":102},[],{"trials":2101,"activeCount":102},[],{"trials":2103,"activeCount":102},[],{"trials":2105,"activeCount":102},[],{"trials":2107,"activeCount":102},[],{"trials":2109,"activeCount":121,"soonestReadout":82},[2110],{"nctId":2089,"briefTitle":2090,"status":467,"phases":2111,"primaryCompletion":82,"completion":1286,"start":2092,"enrollment":403,"conditions":2112,"interventions":2113},[],[18],[2074,2095],{"intervention":2115,"totalTrials":1002,"cells":2116},"Alendronate",{"EARLY_PHASE1":2117,"PHASE1":2119,"PHASE2":2121,"PHASE3":2123,"PHASE4":2134,"NA":2153},{"trials":2118,"activeCount":102},[],{"trials":2120,"activeCount":102},[],{"trials":2122,"activeCount":102},[],{"trials":2124,"activeCount":102},[2125],{"nctId":2126,"briefTitle":2127,"status":189,"phases":2128,"completion":2129,"start":2130,"enrollment":996,"conditions":2131,"interventions":2133},"NCT00391404","Fosamax for Childhood Cancer Survivors",[92],"2008-10","2006-05",[2132],"Osteoporosis",[2115],{"trials":2135,"activeCount":102},[2136,2145],{"nctId":2137,"briefTitle":2138,"status":203,"phases":2139,"primaryCompletion":2140,"completion":2140,"start":2141,"enrollment":156,"conditions":2142,"interventions":2143},"NCT01770106","RA Denosumab on Bone Microstructure Study",[93],"2014-06","2012-12",[550],[2144,2115],"Denosumab",{"nctId":2146,"briefTitle":2147,"status":189,"phases":2148,"primaryCompletion":773,"completion":82,"start":2149,"enrollment":1538,"conditions":2150,"interventions":2152},"NCT05527548","A Single-blind RCT to Investigate the Effect of Alendronate on Knee Function Following ACLR",[93],"2022-12-22",[2151],"ACL Reconstruction",[2115],{"trials":2154,"activeCount":102},[],{"intervention":2156,"totalTrials":1002,"cells":2157},"Oseltamivir",{"EARLY_PHASE1":2158,"PHASE1":2160,"PHASE2":2162,"PHASE3":2164,"PHASE4":2188,"NA":2200},{"trials":2159,"activeCount":102},[],{"trials":2161,"activeCount":102},[],{"trials":2163,"activeCount":102},[],{"trials":2165,"activeCount":102},[2166,2179],{"nctId":2167,"briefTitle":2168,"status":2169,"phases":2170,"primaryCompletion":2171,"completion":2172,"start":2173,"enrollment":176,"conditions":2174,"interventions":2177},"NCT00979667","A Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As First Line Treatment For Human Swine Influenza Infection","TERMINATED",[92],"2010-08","2010-10","2009-10",[2175,2176],"Upper Respiratory Tract Infection","Influenza",[2156,2178],"Zanamivir",{"nctId":2180,"briefTitle":2181,"status":189,"phases":2182,"primaryCompletion":773,"completion":82,"start":2183,"enrollment":2184,"conditions":2185,"interventions":2186},"NCT03901001","Adjunctive Sirolimus and Oseltamivir Versus Oseltamivir Alone for Treatment of Influenza",[92],"2023-05-08",160,[2176],[2187,2156],"sirolimus and oseltamivir",{"trials":2189,"activeCount":102},[2190],{"nctId":2191,"briefTitle":2192,"status":203,"phases":2193,"primaryCompletion":2194,"completion":2194,"start":2195,"enrollment":2196,"conditions":2197,"interventions":2199},"NCT01052961","A Study on Higher-dose Oseltamivir Treatment's Impact on Viral Clearance and Clinical Recovery in Adults Hospitalized With Influenza",[93],"2012-06","2010-01",157,[2176,2198],"Respiratory Tract Infections",[2156],{"trials":2201,"activeCount":102},[],{"intervention":2144,"totalTrials":98,"cells":2203},{"EARLY_PHASE1":2204,"PHASE1":2206,"PHASE2":2208,"PHASE3":2218,"PHASE4":2220,"NA":2226},{"trials":2205,"activeCount":102},[],{"trials":2207,"activeCount":102},[],{"trials":2209,"activeCount":102},[2210],{"nctId":2211,"briefTitle":2212,"status":203,"phases":2213,"primaryCompletion":2214,"completion":2214,"start":2215,"enrollment":841,"conditions":2216,"interventions":2217},"NCT03239080","Effect of Denosumab in Erosion Healing in RA",[91],"2020-05-24","2017-06-19",[550],[2144],{"trials":2219,"activeCount":102},[],{"trials":2221,"activeCount":102},[2222],{"nctId":2137,"briefTitle":2138,"status":203,"phases":2223,"primaryCompletion":2140,"completion":2140,"start":2141,"enrollment":156,"conditions":2224,"interventions":2225},[93],[550],[2144,2115],{"trials":2227,"activeCount":102},[],{"intervention":2229,"totalTrials":98,"cells":2230},"Calcitriol",{"EARLY_PHASE1":2231,"PHASE1":2233,"PHASE2":2235,"PHASE3":2237,"PHASE4":2239,"NA":2263},{"trials":2232,"activeCount":102},[],{"trials":2234,"activeCount":102},[],{"trials":2236,"activeCount":102},[],{"trials":2238,"activeCount":102},[],{"trials":2240,"activeCount":102},[2241,2250],{"nctId":2242,"briefTitle":2243,"status":203,"phases":2244,"primaryCompletion":2245,"completion":2245,"start":2130,"enrollment":2246,"conditions":2247,"interventions":2249},"NCT00319761","Calcitriol in the Treatment of Immunoglobulin A (IgA) Nephropathy",[93],"2007-09",10,[2248],"IGA Nephropathy",[2229],{"nctId":2251,"briefTitle":2252,"status":2253,"phases":2254,"primaryCompletion":2255,"completion":2255,"start":2256,"enrollment":102,"conditions":2257,"interventions":2261},"NCT00508898","The Efficacy and Safety of Calcitriol for the Treatment of Lupus Nephritis and Persistent Proteinuria","WITHDRAWN",[93],"2009-09","2008-05",[2258,2259,2260],"Systemic Lupus Erythematosus","Nephritis","Proteinuria",[2229,2262],"Multivitamin",{"trials":2264,"activeCount":102},[],{"intervention":2266,"totalTrials":98,"cells":2267},"Famotidine",{"EARLY_PHASE1":2268,"PHASE1":2270,"PHASE2":2272,"PHASE3":2274,"PHASE4":2288,"NA":2301},{"trials":2269,"activeCount":102},[],{"trials":2271,"activeCount":102},[],{"trials":2273,"activeCount":102},[],{"trials":2275,"activeCount":102},[2276],{"nctId":2277,"briefTitle":2278,"status":203,"phases":2279,"primaryCompletion":2280,"completion":2281,"start":2282,"enrollment":2283,"conditions":2284,"interventions":2286},"NCT01408186","ASP (PPI_H2RA) Study-H2RA Versus PPI for the Prevention of Recurrent UGIB in High-risk Users of Low-dose ASA",[92],"2015-11","2016-11","2011-01",264,[2285],"Upper Gastrointestinal Bleeding",[2287,2266],"Rabeprazole",{"trials":2289,"activeCount":102},[2290],{"nctId":2291,"briefTitle":2292,"status":203,"phases":2293,"primaryCompletion":2294,"completion":2294,"start":2295,"enrollment":2296,"conditions":2297,"interventions":2299},"NCT01180179","PPI vs H2RA in Patients With Helicobacter Pylori-Negative Idiopathic Bleeding Ulcers",[93],"2019-05","2010-06",228,[2298],"Peptic Ulcer",[2300,2266],"Lansoprazole",{"trials":2302,"activeCount":102},[],{"intervention":2304,"totalTrials":121,"cells":2305},"Pegyinterferon-alfa-2a",{"EARLY_PHASE1":2306,"PHASE1":2308,"PHASE2":2310,"PHASE3":2312,"PHASE4":2314,"NA":2326},{"trials":2307,"activeCount":102},[],{"trials":2309,"activeCount":102},[],{"trials":2311,"activeCount":102},[],{"trials":2313,"activeCount":102},[],{"trials":2315,"activeCount":102},[2316],{"nctId":2317,"briefTitle":2318,"status":203,"phases":2319,"primaryCompletion":2320,"completion":2320,"start":2321,"enrollment":2322,"conditions":2323,"interventions":2325},"NCT02068365","An Open-label Trial of 48-week Peginterferon Alfa-2a (PEGASYS) to Assess the Sustained Response of Chronic Hepatitis B Patients With HBeAg Seroconversion on Nucleot(s)Ide Analogue Therapy",[93],"2019-06","2013-06",41,[2324],"Chronic Hepaititis B",[2304],{"trials":2327,"activeCount":102},[],{"intervention":2329,"totalTrials":121,"cells":2330},"thalidomide",{"EARLY_PHASE1":2331,"PHASE1":2333,"PHASE2":2335,"PHASE3":2337,"PHASE4":2339,"NA":2350},{"trials":2332,"activeCount":102},[],{"trials":2334,"activeCount":102},[],{"trials":2336,"activeCount":102},[],{"trials":2338,"activeCount":102},[],{"trials":2340,"activeCount":102},[2341],{"nctId":2342,"briefTitle":2343,"status":2253,"phases":2344,"completion":2345,"start":2346,"enrollment":102,"conditions":2347,"interventions":2349},"NCT00390247","Thalidomide for the Treatment of Malnutrition Inflammation Syndrome in Peritoneal Dialysis Patients",[93],"2008-12","2007-01",[523,2348],"Malnutrition",[2329],{"trials":2351,"activeCount":102},[],{"intervention":2353,"totalTrials":121,"cells":2354},"Secukinumab",{"EARLY_PHASE1":2355,"PHASE1":2357,"PHASE2":2359,"PHASE3":2361,"PHASE4":2363,"NA":2374},{"trials":2356,"activeCount":102},[],{"trials":2358,"activeCount":102},[],{"trials":2360,"activeCount":102},[],{"trials":2362,"activeCount":102},[],{"trials":2364,"activeCount":102},[2365],{"nctId":2366,"briefTitle":2367,"status":203,"phases":2368,"primaryCompletion":2369,"completion":2369,"start":2370,"enrollment":156,"conditions":2371,"interventions":2373},"NCT03623867","PsA Secukinumab XCT Structural Progression Study",[93],"2022-09-30","2020-05-18",[2372],"Psoriatic Arthritis",[2353],{"trials":2375,"activeCount":102},[],{"intervention":2377,"totalTrials":121,"cells":2378},"Montelukast Oral",{"EARLY_PHASE1":2379,"PHASE1":2381,"PHASE2":2383,"PHASE3":2385,"PHASE4":2387,"NA":2400},{"trials":2380,"activeCount":102},[],{"trials":2382,"activeCount":102},[],{"trials":2384,"activeCount":102},[],{"trials":2386,"activeCount":102},[],{"trials":2388,"activeCount":102},[2389],{"nctId":2390,"briefTitle":2391,"status":189,"phases":2392,"primaryCompletion":2393,"completion":2394,"start":2395,"enrollment":1075,"conditions":2396,"interventions":2398},"NCT04762472","Air Pollution (PM2.5) on Accelerated Atherosclerosis: A Montelukast Interventional Study in Modernizing China",[93],"2024-12-30","2025-12-30","2023-09",[2397],"Atherosclerosis, Coronary",[2377,2399],"Montelukast Placebo Oral",{"trials":2401,"activeCount":102},[],{"intervention":2399,"totalTrials":121,"cells":2403},{"EARLY_PHASE1":2404,"PHASE1":2406,"PHASE2":2408,"PHASE3":2410,"PHASE4":2412,"NA":2418},{"trials":2405,"activeCount":102},[],{"trials":2407,"activeCount":102},[],{"trials":2409,"activeCount":102},[],{"trials":2411,"activeCount":102},[],{"trials":2413,"activeCount":102},[2414],{"nctId":2390,"briefTitle":2391,"status":189,"phases":2415,"primaryCompletion":2393,"completion":2394,"start":2395,"enrollment":1075,"conditions":2416,"interventions":2417},[93],[2397],[2377,2399],{"trials":2419,"activeCount":102},[],{"intervention":2421,"totalTrials":121,"cells":2422},"Icodextrin",{"EARLY_PHASE1":2423,"PHASE1":2425,"PHASE2":2427,"PHASE3":2429,"PHASE4":2431,"NA":2442},{"trials":2424,"activeCount":102},[],{"trials":2426,"activeCount":102},[],{"trials":2428,"activeCount":102},[],{"trials":2430,"activeCount":102},[],{"trials":2432,"activeCount":102},[2433],{"nctId":2434,"briefTitle":2435,"status":203,"phases":2436,"primaryCompletion":2437,"completion":257,"start":2195,"enrollment":1668,"conditions":2438,"interventions":2440},"NCT01044446","Effect of Icodextrin on the Treatment Outcome of Peritoneal Dialysis Patients During Acute Peritonitis",[93],"2012-08",[2439],"Peritonitis",[2421,2441],"glucose-based peritoneal dialysate",{"trials":2443,"activeCount":102},[],{"intervention":2441,"totalTrials":121,"cells":2445},{"EARLY_PHASE1":2446,"PHASE1":2448,"PHASE2":2450,"PHASE3":2452,"PHASE4":2454,"NA":2460},{"trials":2447,"activeCount":102},[],{"trials":2449,"activeCount":102},[],{"trials":2451,"activeCount":102},[],{"trials":2453,"activeCount":102},[],{"trials":2455,"activeCount":102},[2456],{"nctId":2434,"briefTitle":2435,"status":203,"phases":2457,"primaryCompletion":2437,"completion":257,"start":2195,"enrollment":1668,"conditions":2458,"interventions":2459},[93],[2439],[2421,2441],{"trials":2461,"activeCount":102},[],{"intervention":2463,"totalTrials":121,"cells":2464},"Cinacalcet",{"EARLY_PHASE1":2465,"PHASE1":2467,"PHASE2":2469,"PHASE3":2471,"PHASE4":2473,"NA":2484},{"trials":2466,"activeCount":102},[],{"trials":2468,"activeCount":102},[],{"trials":2470,"activeCount":102},[],{"trials":2472,"activeCount":102},[],{"trials":2474,"activeCount":102},[2475],{"nctId":2476,"briefTitle":2477,"status":203,"phases":2478,"primaryCompletion":2479,"completion":2479,"start":2295,"enrollment":1116,"conditions":2480,"interventions":2483},"NCT01143987","Cincalcet and Vascular Arterial Stiffness Among Peritoneal Dialysis Patients With Secondary Hyperparathyroidism",[93],"2013-02",[2481,2482],"Hyperparathyroidism","Arterial Stiffness",[2463],{"trials":2485,"activeCount":102},[],{"intervention":2487,"totalTrials":121,"cells":2488},"Pegylated Interferon-alfa-2a",{"EARLY_PHASE1":2489,"PHASE1":2491,"PHASE2":2493,"PHASE3":2495,"PHASE4":2497,"NA":2507},{"trials":2490,"activeCount":102},[],{"trials":2492,"activeCount":102},[],{"trials":2494,"activeCount":102},[],{"trials":2496,"activeCount":102},[],{"trials":2498,"activeCount":102},[2499],{"nctId":2500,"briefTitle":2501,"status":203,"phases":2502,"primaryCompletion":2503,"completion":2503,"start":2504,"enrollment":1901,"conditions":2505,"interventions":2506},"NCT00226382","Treatment With Peginterferon Alfa-2a (40 KD) of Chronic Hepatitis B Patients, Who Have Failed Anti-viral Treatment",[93],"2008-04","2005-01",[674],[2487],{"trials":2508,"activeCount":102},[],{"intervention":2510,"totalTrials":121,"cells":2511},"Etanercept",{"EARLY_PHASE1":2512,"PHASE1":2514,"PHASE2":2516,"PHASE3":2518,"PHASE4":2520,"NA":2529},{"trials":2513,"activeCount":102},[],{"trials":2515,"activeCount":102},[],{"trials":2517,"activeCount":102},[],{"trials":2519,"activeCount":102},[],{"trials":2521,"activeCount":102},[2522],{"nctId":2523,"briefTitle":2524,"status":203,"phases":2525,"primaryCompletion":2526,"completion":2526,"start":2130,"enrollment":156,"conditions":2527,"interventions":2528},"NCT00432406","Tumor Necrosis Factors (TNF)-α Blockade for Psoriatic Arthritis",[93],"2009-03",[2372],[703,2510],{"trials":2530,"activeCount":102},[],{"intervention":2532,"totalTrials":121,"cells":2533},"Infliximab and MTX",{"EARLY_PHASE1":2534,"PHASE1":2536,"PHASE2":2538,"PHASE3":2540,"PHASE4":2542,"NA":2555},{"trials":2535,"activeCount":102},[],{"trials":2537,"activeCount":102},[],{"trials":2539,"activeCount":102},[],{"trials":2541,"activeCount":102},[],{"trials":2543,"activeCount":102},[2544],{"nctId":2545,"briefTitle":2546,"status":203,"phases":2547,"primaryCompletion":2548,"completion":2549,"start":2550,"enrollment":2551,"conditions":2552,"interventions":2554},"NCT00432432","Combination Methotrexate and Infliximab",[93],"2006-08","2006-10","2005-02",38,[2553],"Ankylosing Spondylitis",[2532],{"trials":2556,"activeCount":102},[],{"intervention":2558,"totalTrials":121,"cells":2559},"Omeprazole",{"EARLY_PHASE1":2560,"PHASE1":2562,"PHASE2":2564,"PHASE3":2566,"PHASE4":2568,"NA":2579},{"trials":2561,"activeCount":102},[],{"trials":2563,"activeCount":102},[],{"trials":2565,"activeCount":102},[],{"trials":2567,"activeCount":102},[],{"trials":2569,"activeCount":102},[2570],{"nctId":2571,"briefTitle":2572,"status":203,"phases":2573,"completion":2574,"start":2575,"enrollment":2576,"conditions":2577,"interventions":2578},"NCT00164866","Administration of High-Dose Intravenous Proton Pump Inhibitor for Upper Gastrointestinal Bleeding Prior to Endoscopy",[93],"2005-09","2004-02",638,[2298],[2558],{"trials":2580,"activeCount":102},[],{"intervention":2582,"totalTrials":121,"cells":2583},"Engerix-B",{"EARLY_PHASE1":2584,"PHASE1":2586,"PHASE2":2588,"PHASE3":2590,"PHASE4":2592,"NA":2604},{"trials":2585,"activeCount":102},[],{"trials":2587,"activeCount":102},[],{"trials":2589,"activeCount":102},[],{"trials":2591,"activeCount":102},[],{"trials":2593,"activeCount":102},[2594],{"nctId":2595,"briefTitle":2596,"status":203,"phases":2597,"primaryCompletion":2598,"completion":2598,"start":2599,"enrollment":2600,"conditions":2601,"interventions":2603},"NCT00125775","Does Extra-High Dose Hepatitis B Vaccination Confer Longer Serological Protection in Peritoneal Dialysis Patients?",[93],"2009-12","2005-05",130,[523,2602],"Renal Disease, End-Stage",[2582],{"trials":2605,"activeCount":102},[],{"intervention":2607,"totalTrials":121,"cells":2608},"Janumet, Lantus",{"EARLY_PHASE1":2609,"PHASE1":2611,"PHASE2":2613,"PHASE3":2615,"PHASE4":2617,"NA":2631},{"trials":2610,"activeCount":102},[],{"trials":2612,"activeCount":102},[],{"trials":2614,"activeCount":102},[],{"trials":2616,"activeCount":102},[],{"trials":2618,"activeCount":102},[2619],{"nctId":2620,"briefTitle":2621,"status":203,"phases":2622,"primaryCompletion":2623,"completion":2624,"start":2625,"enrollment":2626,"conditions":2627,"interventions":2629},"NCT01269996","JanUmet Before Insulin Lantus In Eastern Population Evaluation Program (JUBILEE) In Type 2 Diabetic Patients",[93],"2014-07","2015-02","2011-05",71,[2628],"Type 2 Diabetes Mellitus",[2607,2630],"metformin, gliclazide, protaphane",{"trials":2632,"activeCount":102},[],{"intervention":2630,"totalTrials":121,"cells":2634},{"EARLY_PHASE1":2635,"PHASE1":2637,"PHASE2":2639,"PHASE3":2641,"PHASE4":2643,"NA":2649},{"trials":2636,"activeCount":102},[],{"trials":2638,"activeCount":102},[],{"trials":2640,"activeCount":102},[],{"trials":2642,"activeCount":102},[],{"trials":2644,"activeCount":102},[2645],{"nctId":2620,"briefTitle":2621,"status":203,"phases":2646,"primaryCompletion":2623,"completion":2624,"start":2625,"enrollment":2626,"conditions":2647,"interventions":2648},[93],[2628],[2607,2630],{"trials":2650,"activeCount":102},[],{"intervention":2652,"totalTrials":121,"cells":2653},"Esomeprazole 20mg",{"EARLY_PHASE1":2654,"PHASE1":2656,"PHASE2":2658,"PHASE3":2660,"PHASE4":2662,"NA":2675},{"trials":2655,"activeCount":102},[],{"trials":2657,"activeCount":102},[],{"trials":2659,"activeCount":102},[],{"trials":2661,"activeCount":102},[],{"trials":2663,"activeCount":102},[2664],{"nctId":2665,"briefTitle":2666,"status":203,"phases":2667,"primaryCompletion":2668,"completion":2669,"start":2670,"enrollment":2600,"conditions":2671,"interventions":2674},"NCT01349413","BRAVO Study for Functional Dyspepsia",[93],"2017-12-30","2018-07-19","2011-08-24",[2672,2673],"Dyspepsia","Gastroesophageal Reflux",[2652],{"trials":2676,"activeCount":102},[],{"intervention":2678,"totalTrials":121,"cells":2679},"tacrolimus",{"EARLY_PHASE1":2680,"PHASE1":2682,"PHASE2":2684,"PHASE3":2686,"PHASE4":2688,"NA":2701},{"trials":2681,"activeCount":102},[],{"trials":2683,"activeCount":102},[],{"trials":2685,"activeCount":102},[],{"trials":2687,"activeCount":102},[],{"trials":2689,"activeCount":102},[2690],{"nctId":2691,"briefTitle":2692,"status":203,"phases":2693,"primaryCompletion":2694,"completion":2695,"start":2696,"enrollment":28,"conditions":2697,"interventions":2700},"NCT00125307","Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis",[93],"2007-10","2008-02","2004-01",[2698,2699],"Lupus Nephritis","Lupus Erythematosus, Systemic",[2678],{"trials":2702,"activeCount":102},[],{"intervention":2704,"totalTrials":121,"cells":2705},"clopidogrel",{"EARLY_PHASE1":2706,"PHASE1":2708,"PHASE2":2710,"PHASE3":2712,"PHASE4":2714,"NA":2726},{"trials":2707,"activeCount":102},[],{"trials":2709,"activeCount":102},[],{"trials":2711,"activeCount":102},[],{"trials":2713,"activeCount":102},[],{"trials":2715,"activeCount":102},[2716],{"nctId":2717,"briefTitle":2718,"status":203,"phases":2719,"primaryCompletion":2720,"completion":2720,"start":2721,"enrollment":2722,"conditions":2723,"interventions":2725},"NCT01806090","Uninterrupted Clopidogrel Therapy Before Elective Colonoscopy Will Increase the Risk of Post-polypectomy Bleeding",[93],"2018-04","2012-02",216,[2724],"Gastrointestinal Bleeding",[2704],{"trials":2727,"activeCount":102},[],{"intervention":2729,"totalTrials":121,"cells":2730},"everolimus",{"EARLY_PHASE1":2731,"PHASE1":2733,"PHASE2":2735,"PHASE3":2737,"PHASE4":2739,"NA":2749},{"trials":2732,"activeCount":102},[],{"trials":2734,"activeCount":102},[],{"trials":2736,"activeCount":102},[],{"trials":2738,"activeCount":102},[],{"trials":2740,"activeCount":102},[2741],{"nctId":2742,"briefTitle":2743,"status":203,"phases":2744,"primaryCompletion":2745,"completion":2321,"start":2503,"enrollment":34,"conditions":2746,"interventions":2748},"NCT01046045","Everolimus Rescue Immunosuppression in the Treatment of Chronic Allograft Dysfunction in Renal Transplant Recipients",[93],"2011-11",[2747],"Chronic Allograft Dysfunction in Renal Transplantation",[2729],{"trials":2750,"activeCount":102},[],{"intervention":2752,"totalTrials":121,"cells":2753},"Extended antibiotics",{"EARLY_PHASE1":2754,"PHASE1":2756,"PHASE2":2758,"PHASE3":2760,"PHASE4":2762,"NA":2775},{"trials":2755,"activeCount":102},[],{"trials":2757,"activeCount":102},[],{"trials":2759,"activeCount":102},[],{"trials":2761,"activeCount":102},[],{"trials":2763,"activeCount":102},[2764],{"nctId":2765,"briefTitle":2766,"status":203,"phases":2767,"primaryCompletion":2768,"completion":2769,"start":2770,"enrollment":2771,"conditions":2772,"interventions":2773},"NCT02593201","The Efficacy of Prolonged Antibiotic Therapy for the Prevention of Relapsing Peritonitis in Peritoneal Dialysis Patients With High Dialysis Effluent Bacterial DNA Fragment Levels",[93],"2018-12-31","2019-06-30","2016-02-26",358,[523],[2752,2774],"Usual antibiotics",{"trials":2776,"activeCount":102},[],{"intervention":2774,"totalTrials":121,"cells":2778},{"EARLY_PHASE1":2779,"PHASE1":2781,"PHASE2":2783,"PHASE3":2785,"PHASE4":2787,"NA":2793},{"trials":2780,"activeCount":102},[],{"trials":2782,"activeCount":102},[],{"trials":2784,"activeCount":102},[],{"trials":2786,"activeCount":102},[],{"trials":2788,"activeCount":102},[2789],{"nctId":2765,"briefTitle":2766,"status":203,"phases":2790,"primaryCompletion":2768,"completion":2769,"start":2770,"enrollment":2771,"conditions":2791,"interventions":2792},[93],[523],[2752,2774],{"trials":2794,"activeCount":102},[],{"intervention":2796,"totalTrials":121,"cells":2797},"Simvastatin 20 mg",{"EARLY_PHASE1":2798,"PHASE1":2800,"PHASE2":2802,"PHASE3":2804,"PHASE4":2806,"NA":2819},{"trials":2799,"activeCount":102},[],{"trials":2801,"activeCount":102},[],{"trials":2803,"activeCount":102},[],{"trials":2805,"activeCount":102},[],{"trials":2807,"activeCount":102},[2808],{"nctId":2809,"briefTitle":2810,"status":203,"phases":2811,"primaryCompletion":2812,"completion":2813,"start":2814,"enrollment":2551,"conditions":2815,"interventions":2817},"NCT05072405","The Interaction of Herbs and Statins",[93],"2013-12-30","2021-08-28","2013-01-11",[2816],"Drug Interaction",[2796,2818],"rosuvastatin 10 mg",{"trials":2820,"activeCount":102},[],{"intervention":2818,"totalTrials":121,"cells":2822},{"EARLY_PHASE1":2823,"PHASE1":2825,"PHASE2":2827,"PHASE3":2829,"PHASE4":2831,"NA":2837},{"trials":2824,"activeCount":102},[],{"trials":2826,"activeCount":102},[],{"trials":2828,"activeCount":102},[],{"trials":2830,"activeCount":102},[],{"trials":2832,"activeCount":102},[2833],{"nctId":2809,"briefTitle":2810,"status":203,"phases":2834,"primaryCompletion":2812,"completion":2813,"start":2814,"enrollment":2551,"conditions":2835,"interventions":2836},[93],[2816],[2796,2818],{"trials":2838,"activeCount":102},[],{"intervention":2840,"totalTrials":121,"cells":2841},"ACEi, ARB",{"EARLY_PHASE1":2842,"PHASE1":2844,"PHASE2":2846,"PHASE3":2848,"PHASE4":2850,"NA":2861},{"trials":2843,"activeCount":102},[],{"trials":2845,"activeCount":102},[],{"trials":2847,"activeCount":102},[],{"trials":2849,"activeCount":102},[],{"trials":2851,"activeCount":102},[2852],{"nctId":2853,"briefTitle":2854,"status":2169,"phases":2855,"primaryCompletion":2856,"completion":2856,"start":2857,"enrollment":176,"conditions":2858,"interventions":2860},"NCT03284099","Bedtime ACEIs\u002FARBs Versus Morning ACEIs\u002FARBs for Reverting Non-dipping Hypertension",[93],"2019-12-31","2017-12-01",[27,2859],"Non-Dipping",[2840],{"trials":2862,"activeCount":102},[],{"intervention":2300,"totalTrials":121,"cells":2864},{"EARLY_PHASE1":2865,"PHASE1":2867,"PHASE2":2869,"PHASE3":2871,"PHASE4":2873,"NA":2879},{"trials":2866,"activeCount":102},[],{"trials":2868,"activeCount":102},[],{"trials":2870,"activeCount":102},[],{"trials":2872,"activeCount":102},[],{"trials":2874,"activeCount":102},[2875],{"nctId":2291,"briefTitle":2292,"status":203,"phases":2876,"primaryCompletion":2294,"completion":2294,"start":2295,"enrollment":2296,"conditions":2877,"interventions":2878},[93],[2298],[2300,2266],{"trials":2880,"activeCount":102},[],{"intervention":2882,"totalTrials":121,"cells":2883},"Long-acting tacrolimus",{"EARLY_PHASE1":2884,"PHASE1":2886,"PHASE2":2888,"PHASE3":2890,"PHASE4":2892,"NA":2902},{"trials":2885,"activeCount":102},[],{"trials":2887,"activeCount":102},[],{"trials":2889,"activeCount":102},[],{"trials":2891,"activeCount":102},[],{"trials":2893,"activeCount":102},[2894],{"nctId":2895,"briefTitle":2896,"status":203,"phases":2897,"primaryCompletion":2898,"completion":2721,"start":2899,"enrollment":98,"conditions":2900,"interventions":2901},"NCT01206569","Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis",[93],"2011-12","2010-09",[2698],[2882],{"trials":2903,"activeCount":102},[],{"intervention":2905,"totalTrials":121,"cells":2906},"Cilostazol",{"EARLY_PHASE1":2907,"PHASE1":2909,"PHASE2":2911,"PHASE3":2913,"PHASE4":2915,"NA":2927},{"trials":2908,"activeCount":102},[],{"trials":2910,"activeCount":102},[],{"trials":2912,"activeCount":102},[],{"trials":2914,"activeCount":102},[],{"trials":2916,"activeCount":102},[2917],{"nctId":2918,"briefTitle":2919,"status":203,"phases":2920,"primaryCompletion":2921,"completion":2921,"start":2922,"enrollment":2923,"conditions":2924,"interventions":2926},"NCT00272831","The Use of Cilostazol in Patients With Diabetic Nephropathy",[93],"2007-12","2005-12",62,[1100,2925],"Diabetes Complications",[2905],{"trials":2928,"activeCount":102},[],{"intervention":2930,"totalTrials":121,"cells":2931},"Macrolide treatment",{"EARLY_PHASE1":2932,"PHASE1":2934,"PHASE2":2936,"PHASE3":2938,"PHASE4":2940,"NA":2951},{"trials":2933,"activeCount":102},[],{"trials":2935,"activeCount":102},[],{"trials":2937,"activeCount":102},[],{"trials":2939,"activeCount":102},[],{"trials":2941,"activeCount":102},[2942],{"nctId":2943,"briefTitle":2944,"status":203,"phases":2945,"primaryCompletion":2946,"completion":2946,"start":2479,"enrollment":2947,"conditions":2948,"interventions":2950},"NCT01779570","Anti-inflammatory Effects of Macrolide Treatment in Influenza Lower Respiratory Tract Infections",[93],"2016-04",68,[2176,2949],"Lower Respiratory Tract Infection",[2930],{"trials":2952,"activeCount":102},[],{"intervention":2954,"totalTrials":121,"cells":2955},"Lamivudine\u002F Placebo 100mg daily",{"EARLY_PHASE1":2956,"PHASE1":2958,"PHASE2":2960,"PHASE3":2962,"PHASE4":2964,"NA":2973},{"trials":2957,"activeCount":102},[],{"trials":2959,"activeCount":102},[],{"trials":2961,"activeCount":102},[],{"trials":2963,"activeCount":102},[],{"trials":2965,"activeCount":102},[2966],{"nctId":2967,"briefTitle":2968,"status":203,"phases":2969,"completion":2504,"start":2970,"conditions":2971,"interventions":2972},"NCT00338780","Trial of Lamivudine Treatment in HBeAg Negative Chronic Hepatitis B Patients (in Asia)",[93],"2000-11",[674],[2954],{"trials":2974,"activeCount":102},[],{"intervention":2976,"totalTrials":121,"cells":2977},"Bisoprolol 2.5 mg",{"EARLY_PHASE1":2978,"PHASE1":2980,"PHASE2":2982,"PHASE3":2984,"PHASE4":2986,"NA":2996},{"trials":2979,"activeCount":102},[],{"trials":2981,"activeCount":102},[],{"trials":2983,"activeCount":102},[],{"trials":2985,"activeCount":102},[],{"trials":2987,"activeCount":102},[2988],{"nctId":2989,"briefTitle":2990,"status":203,"phases":2991,"primaryCompletion":2992,"completion":2992,"start":2993,"enrollment":996,"conditions":2994,"interventions":2995},"NCT02398929","BRAVE Study With Uncontrolled Essential Hypertension (BRAVE Study)",[93],"2021-01-05","2013-01",[27],[2976],{"trials":2997,"activeCount":102},[],{"intervention":2262,"totalTrials":121,"cells":2999},{"EARLY_PHASE1":3000,"PHASE1":3002,"PHASE2":3004,"PHASE3":3006,"PHASE4":3008,"NA":3014},{"trials":3001,"activeCount":102},[],{"trials":3003,"activeCount":102},[],{"trials":3005,"activeCount":102},[],{"trials":3007,"activeCount":102},[],{"trials":3009,"activeCount":102},[3010],{"nctId":2251,"briefTitle":2252,"status":2253,"phases":3011,"primaryCompletion":2255,"completion":2255,"start":2256,"enrollment":102,"conditions":3012,"interventions":3013},[93],[2258,2259,2260],[2229,2262],{"trials":3015,"activeCount":102},[],{"intervention":3017,"totalTrials":121,"cells":3018},"Nicotine patch",{"EARLY_PHASE1":3019,"PHASE1":3021,"PHASE2":3023,"PHASE3":3025,"PHASE4":3027,"NA":3039},{"trials":3020,"activeCount":102},[],{"trials":3022,"activeCount":102},[],{"trials":3024,"activeCount":102},[],{"trials":3026,"activeCount":102},[],{"trials":3028,"activeCount":102},[3029],{"nctId":3030,"briefTitle":3031,"status":203,"phases":3032,"primaryCompletion":3033,"completion":3033,"start":3034,"enrollment":3035,"conditions":3036,"interventions":3038},"NCT03879889","Smoking Reduction Intervention for Smoking Parents of Paediatric Patients in Hong Kong",[93],"2019-07-31","2017-02-01",210,[3037],"Smoking, Tobacco",[3017],{"trials":3040,"activeCount":102},[],{"intervention":3042,"totalTrials":121,"cells":3043},"Ibandronate+alfacalcidol+calcium",{"EARLY_PHASE1":3044,"PHASE1":3046,"PHASE2":3048,"PHASE3":3050,"PHASE4":3052,"NA":3062},{"trials":3045,"activeCount":102},[],{"trials":3047,"activeCount":102},[],{"trials":3049,"activeCount":102},[],{"trials":3051,"activeCount":102},[],{"trials":3053,"activeCount":102},[3054],{"nctId":3055,"briefTitle":3056,"status":203,"phases":3057,"primaryCompletion":3058,"completion":3058,"start":3059,"enrollment":156,"conditions":3060,"interventions":3061},"NCT00668330","Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus",[93],"2009-05","2007-04",[2258],[3042],{"trials":3063,"activeCount":102},[],{"intervention":3065,"totalTrials":121,"cells":3066},"Simponi",{"EARLY_PHASE1":3067,"PHASE1":3069,"PHASE2":3071,"PHASE3":3073,"PHASE4":3075,"NA":3085},{"trials":3068,"activeCount":102},[],{"trials":3070,"activeCount":102},[],{"trials":3072,"activeCount":102},[],{"trials":3074,"activeCount":102},[],{"trials":3076,"activeCount":102},[3077],{"nctId":3078,"briefTitle":3079,"status":203,"phases":3080,"primaryCompletion":3081,"completion":3081,"start":2172,"enrollment":1901,"conditions":3082,"interventions":3084},"NCT01212653","Effect of Anti-TNF (Alpha) Treatment on Vascular Stiffness in Ankylosing Spondylitis (AS)",[93],"2013-05",[3083],"Ankylosing Spondylitis(AS)",[3065],{"trials":3086,"activeCount":102},[],{"intervention":3088,"totalTrials":121,"cells":3089},"Cefazolin",{"EARLY_PHASE1":3090,"PHASE1":3092,"PHASE2":3094,"PHASE3":3096,"PHASE4":3098,"NA":3109},{"trials":3091,"activeCount":102},[],{"trials":3093,"activeCount":102},[],{"trials":3095,"activeCount":102},[],{"trials":3097,"activeCount":102},[],{"trials":3099,"activeCount":102},[3100],{"nctId":3101,"briefTitle":3102,"status":2253,"phases":3103,"primaryCompletion":3104,"completion":3104,"start":3105,"enrollment":102,"conditions":3106,"interventions":3108},"NCT03675854","Defining the Optimal Duration of Treatment for \"Low-Risk\" Peritoneal Dialysis-Related Peritonitis",[93],"2019-09-30","2019-01-01",[3107],"Peritoneal Dialysis-associated Peritonitis",[3088],{"trials":3110,"activeCount":102},[],{"intervention":3112,"totalTrials":121,"cells":3113},"Sodium valproate",{"EARLY_PHASE1":3114,"PHASE1":3116,"PHASE2":3118,"PHASE3":3120,"PHASE4":3122,"NA":3134},{"trials":3115,"activeCount":102},[],{"trials":3117,"activeCount":102},[],{"trials":3119,"activeCount":102},[],{"trials":3121,"activeCount":102},[],{"trials":3123,"activeCount":102},[3124],{"nctId":3125,"briefTitle":3126,"status":189,"phases":3127,"completion":3128,"start":3129,"enrollment":11,"conditions":3130,"interventions":3132},"NCT00137709","Hormone Profiles in Adults With Newly Diagnosed Epilepsy",[93],"2008-07","2004-11",[3131],"Epilepsy",[3112,3133],"Lamotrigine",{"trials":3135,"activeCount":102},[],{"intervention":3133,"totalTrials":121,"cells":3137},{"EARLY_PHASE1":3138,"PHASE1":3140,"PHASE2":3142,"PHASE3":3144,"PHASE4":3146,"NA":3152},{"trials":3139,"activeCount":102},[],{"trials":3141,"activeCount":102},[],{"trials":3143,"activeCount":102},[],{"trials":3145,"activeCount":102},[],{"trials":3147,"activeCount":102},[3148],{"nctId":3125,"briefTitle":3126,"status":189,"phases":3149,"completion":3128,"start":3129,"enrollment":11,"conditions":3150,"interventions":3151},[93],[3131],[3112,3133],{"trials":3153,"activeCount":102},[],{"intervention":3155,"totalTrials":121,"cells":3156},"Growth hormone",{"EARLY_PHASE1":3157,"PHASE1":3159,"PHASE2":3161,"PHASE3":3163,"PHASE4":3165,"NA":3175},{"trials":3158,"activeCount":102},[],{"trials":3160,"activeCount":102},[],{"trials":3162,"activeCount":102},[],{"trials":3164,"activeCount":102},[],{"trials":3166,"activeCount":102},[3167],{"nctId":3168,"briefTitle":3169,"status":189,"phases":3170,"completion":3171,"start":2548,"enrollment":1216,"conditions":3172,"interventions":3174},"NCT00307411","Effect of Growth Hormone in Metabolic Syndrome",[93],"2007-07",[3173],"Metabolic Syndrome",[3155],{"trials":3176,"activeCount":102},[],{"intervention":3178,"totalTrials":121,"cells":3179},"Angiotensin converting enzyme inhibitor",{"EARLY_PHASE1":3180,"PHASE1":3182,"PHASE2":3184,"PHASE3":3186,"PHASE4":3188,"NA":3199},{"trials":3181,"activeCount":102},[],{"trials":3183,"activeCount":102},[],{"trials":3185,"activeCount":102},[],{"trials":3187,"activeCount":102},[],{"trials":3189,"activeCount":102},[3190],{"nctId":3191,"briefTitle":3192,"status":2169,"phases":3193,"primaryCompletion":2141,"completion":2141,"start":2899,"enrollment":3194,"conditions":3195,"interventions":3198},"NCT02358642","Drug to Prevent Pneumonia in the Tube Fed",[93],93,[3196,3197],"Pneumonia","Neurological Dysphagia",[3178],{"trials":3200,"activeCount":102},[],{"intervention":3202,"totalTrials":121,"cells":3203},"treatment arm",{"EARLY_PHASE1":3204,"PHASE1":3206,"PHASE2":3208,"PHASE3":3210,"PHASE4":3212,"NA":3224},{"trials":3205,"activeCount":102},[],{"trials":3207,"activeCount":102},[],{"trials":3209,"activeCount":102},[],{"trials":3211,"activeCount":102},[],{"trials":3213,"activeCount":102},[3214],{"nctId":3215,"briefTitle":3216,"status":2253,"phases":3217,"primaryCompletion":3218,"completion":3219,"start":3220,"enrollment":102,"conditions":3221,"interventions":3223},"NCT02168283","Treatment of Asymptomatic Fluid Overload in Peritoneal Dialysis Patients",[93],"2017-09","2018-09","2015-12",[3222,523],"Chronic Kidney Disease",[3202],{"trials":3225,"activeCount":102},[],{"intervention":2287,"totalTrials":98,"cells":3227},{"EARLY_PHASE1":3228,"PHASE1":3230,"PHASE2":3232,"PHASE3":3234,"PHASE4":3251,"NA":3253},{"trials":3229,"activeCount":102},[],{"trials":3231,"activeCount":102},[],{"trials":3233,"activeCount":102},[],{"trials":3235,"activeCount":102},[3236,3247],{"nctId":3237,"briefTitle":3238,"status":203,"phases":3239,"primaryCompletion":3240,"completion":3241,"start":3058,"enrollment":131,"conditions":3242,"interventions":3245},"NCT01140828","A Study of Rabeprazole for Prevention of Non Steroidal Anti-inflammatory Drug -Associated Gastroduodenal Injury",[92],"2012-10","2015-06",[3243,3244,2672],"Osteoarthritis","Arthritis, Rheumatoid",[2287,3246],"Rabeprazole Placebo",{"nctId":2277,"briefTitle":2278,"status":203,"phases":3248,"primaryCompletion":2280,"completion":2281,"start":2282,"enrollment":2283,"conditions":3249,"interventions":3250},[92],[2285],[2287,2266],{"trials":3252,"activeCount":102},[],{"trials":3254,"activeCount":102},[],{"intervention":3256,"totalTrials":98,"cells":3257},"Oral esomeprazole",{"EARLY_PHASE1":3258,"PHASE1":3260,"PHASE2":3262,"PHASE3":3274,"PHASE4":3287,"NA":3289},{"trials":3259,"activeCount":102},[],{"trials":3261,"activeCount":102},[],{"trials":3263,"activeCount":102},[3264],{"nctId":3265,"briefTitle":3266,"status":2169,"phases":3267,"primaryCompletion":2282,"completion":2282,"start":3268,"enrollment":3269,"conditions":3270,"interventions":3272},"NCT00164788","A Comparison of Gastric pH Control With High Dose Intravenous or Oral Esomeprazole",[91],"2004-07",7,[3271],"Gastrointestinal Hemorrhage",[3273,3256],"Intravenous bolus injection of esomeprazole",{"trials":3275,"activeCount":102},[3276],{"nctId":3277,"briefTitle":3278,"status":203,"phases":3279,"primaryCompletion":3280,"completion":2623,"start":3281,"enrollment":3282,"conditions":3283,"interventions":3285},"NCT01142245","Effect of IV and Oral Esomeprazole in Prevention of Recurrent Bleeding From Peptic Ulcers After Endoscopic Therapy",[92],"2013-12","2008-01",263,[2298,3284],"Bleeding",[3256,3286],"Intravenous Esomeprazole",{"trials":3288,"activeCount":102},[],{"trials":3290,"activeCount":102},[],{"intervention":3292,"totalTrials":98,"cells":3293},"Celecoxib",{"EARLY_PHASE1":3294,"PHASE1":3296,"PHASE2":3298,"PHASE3":3300,"PHASE4":3328,"NA":3330},{"trials":3295,"activeCount":102},[],{"trials":3297,"activeCount":102},[],{"trials":3299,"activeCount":102},[],{"trials":3301,"activeCount":102},[3302,3316],{"nctId":3303,"briefTitle":3304,"status":203,"phases":3305,"primaryCompletion":3306,"completion":3307,"start":3308,"enrollment":3309,"conditions":3310,"interventions":3314},"NCT00153660","Celecoxib Versus Naproxen for Prevention of Recurrent Ulcer Bleeding in Arthritis Patients",[92],"2014-11","2016-12","2005-06",514,[3311,3312,3313],"Arthritis","Cardiovascular Diseases","Cerebrovascular Disorders",[3292,3315],"Naproxen",{"nctId":3317,"briefTitle":3318,"status":203,"phases":3319,"primaryCompletion":3320,"completion":3321,"start":3322,"enrollment":1075,"conditions":3323,"interventions":3325},"NCT00153673","Effect of Selective COX-2 Inhibition on Ulcer Healing",[92],"2016-12-28","2017-04-12","2001-02",[3311,3324],"Gastric Ulcer",[3326,3327],"celecoxib","Dologesics",{"trials":3329,"activeCount":102},[],{"trials":3331,"activeCount":102},[],{"intervention":3333,"totalTrials":121,"cells":3334},"Angong Niuhuang Wan",{"EARLY_PHASE1":3335,"PHASE1":3337,"PHASE2":3339,"PHASE3":3341,"PHASE4":3354,"NA":3356},{"trials":3336,"activeCount":102},[],{"trials":3338,"activeCount":102},[],{"trials":3340,"activeCount":102},[],{"trials":3342,"activeCount":102},[3343],{"nctId":3344,"briefTitle":3345,"status":189,"phases":3346,"primaryCompletion":3347,"completion":3348,"start":3349,"enrollment":996,"conditions":3350,"interventions":3352},"NCT04236427","Efficacy and Safety of Angong Niuhuang Wan for Stroke",[91,92],"2022-12-30","2023-06-30","2019-10-15",[3351],"Stroke (CVA) or TIA",[3333,3353],"Angong Niuhuang Wan Placebo",{"trials":3355,"activeCount":102},[],{"trials":3357,"activeCount":102},[],{"intervention":3353,"totalTrials":121,"cells":3359},{"EARLY_PHASE1":3360,"PHASE1":3362,"PHASE2":3364,"PHASE3":3366,"PHASE4":3372,"NA":3374},{"trials":3361,"activeCount":102},[],{"trials":3363,"activeCount":102},[],{"trials":3365,"activeCount":102},[],{"trials":3367,"activeCount":102},[3368],{"nctId":3344,"briefTitle":3345,"status":189,"phases":3369,"primaryCompletion":3347,"completion":3348,"start":3349,"enrollment":996,"conditions":3370,"interventions":3371},[91,92],[3351],[3333,3353],{"trials":3373,"activeCount":102},[],{"trials":3375,"activeCount":102},[],{"intervention":3377,"totalTrials":121,"cells":3378},"Vioxx",{"EARLY_PHASE1":3379,"PHASE1":3381,"PHASE2":3383,"PHASE3":3385,"PHASE4":3396,"NA":3398},{"trials":3380,"activeCount":102},[],{"trials":3382,"activeCount":102},[],{"trials":3384,"activeCount":102},[],{"trials":3386,"activeCount":102},[3387],{"nctId":3388,"briefTitle":3389,"status":189,"phases":3390,"start":3391,"enrollment":3392,"conditions":3393,"interventions":3395},"NCT00165048","Selective COX-II Inhibitor as a Palliative Therapy in Patients With R1 or R2 Resection for Disseminated Stomach Cancer - A Multi-Centre Prospective Randomized Controlled Trial",[92],"2004-10",206,[3394],"Cancer of Stomach",[3377],{"trials":3397,"activeCount":102},[],{"trials":3399,"activeCount":102},[],{"intervention":3401,"totalTrials":121,"cells":3402},"Aliskiren",{"EARLY_PHASE1":3403,"PHASE1":3405,"PHASE2":3407,"PHASE3":3409,"PHASE4":3422,"NA":3424},{"trials":3404,"activeCount":102},[],{"trials":3406,"activeCount":102},[],{"trials":3408,"activeCount":102},[],{"trials":3410,"activeCount":102},[3411],{"nctId":3412,"briefTitle":3413,"status":203,"phases":3414,"primaryCompletion":3415,"completion":3416,"start":3417,"enrollment":3418,"conditions":3419,"interventions":3421},"NCT00870493","Aliskiren for Immunoglobulin A (IgA) Nephropathy",[92],"2012-03","2012-07","2009-04",22,[3420],"IgA Nephropathy",[3401],{"trials":3423,"activeCount":102},[],{"trials":3425,"activeCount":102},[],{"intervention":3427,"totalTrials":121,"cells":3428},"Intravenous magnesium sulfate",{"EARLY_PHASE1":3429,"PHASE1":3431,"PHASE2":3433,"PHASE3":3435,"PHASE4":3447,"NA":3449},{"trials":3430,"activeCount":102},[],{"trials":3432,"activeCount":102},[],{"trials":3434,"activeCount":102},[],{"trials":3436,"activeCount":102},[3437],{"nctId":3438,"briefTitle":3439,"status":203,"phases":3440,"primaryCompletion":2345,"completion":3441,"start":3442,"enrollment":3443,"conditions":3444,"interventions":3446},"NCT00124150","Intravenous Magnesium Sulfate in Aneurysmal Subarachnoid Haemorrhage (IMASH)",[92],"2009-06","2002-06",327,[3445],"Subarachnoid Hemorrhage",[3427],{"trials":3448,"activeCount":102},[],{"trials":3450,"activeCount":102},[],{"intervention":3452,"totalTrials":121,"cells":3453},"paricalcitol",{"EARLY_PHASE1":3454,"PHASE1":3456,"PHASE2":3458,"PHASE3":3460,"PHASE4":3468,"NA":3470},{"trials":3455,"activeCount":102},[],{"trials":3457,"activeCount":102},[],{"trials":3459,"activeCount":102},[],{"trials":3461,"activeCount":102},[3462],{"nctId":3463,"briefTitle":3464,"status":2253,"phases":3465,"primaryCompletion":2173,"completion":2598,"start":3281,"enrollment":102,"conditions":3466,"interventions":3467},"NCT00599963","Paricalcitol for the Treatment of Immunoglobulin A Nephropathy",[92],[3420],[3452],{"trials":3469,"activeCount":102},[],{"trials":3471,"activeCount":102},[],{"intervention":197,"totalTrials":121,"cells":3473},{"EARLY_PHASE1":3474,"PHASE1":3476,"PHASE2":3478,"PHASE3":3480,"PHASE4":3486,"NA":3488},{"trials":3475,"activeCount":102},[],{"trials":3477,"activeCount":102},[],{"trials":3479,"activeCount":102},[],{"trials":3481,"activeCount":102},[3482],{"nctId":187,"briefTitle":188,"status":189,"phases":3483,"primaryCompletion":191,"completion":191,"start":192,"enrollment":193,"conditions":3484,"interventions":3485},[92],[195],[175,197,198,199],{"trials":3487,"activeCount":102},[],{"trials":3489,"activeCount":102},[],{"intervention":199,"totalTrials":121,"cells":3491},{"EARLY_PHASE1":3492,"PHASE1":3494,"PHASE2":3496,"PHASE3":3498,"PHASE4":3504,"NA":3506},{"trials":3493,"activeCount":102},[],{"trials":3495,"activeCount":102},[],{"trials":3497,"activeCount":102},[],{"trials":3499,"activeCount":102},[3500],{"nctId":187,"briefTitle":188,"status":189,"phases":3501,"primaryCompletion":191,"completion":191,"start":192,"enrollment":193,"conditions":3502,"interventions":3503},[92],[195],[175,197,198,199],{"trials":3505,"activeCount":102},[],{"trials":3507,"activeCount":102},[],{"intervention":3509,"totalTrials":121,"cells":3510},"Peramivir",{"EARLY_PHASE1":3511,"PHASE1":3513,"PHASE2":3515,"PHASE3":3517,"PHASE4":3528,"NA":3530},{"trials":3512,"activeCount":102},[],{"trials":3514,"activeCount":102},[],{"trials":3516,"activeCount":102},[],{"trials":3518,"activeCount":102},[3519],{"nctId":3520,"briefTitle":3521,"status":203,"phases":3522,"primaryCompletion":3523,"completion":3523,"start":3524,"enrollment":3525,"conditions":3526,"interventions":3527},"NCT02665351","Peramivir Treatment Response in Adults Hospitalized for Influenza-associated Lower Respiratory Tract Infections",[91,92],"2014-03","2011-02",16,[2176],[3509],{"trials":3529,"activeCount":102},[],{"trials":3531,"activeCount":102},[],{"intervention":3533,"totalTrials":121,"cells":3534},"Levobupivacaine",{"EARLY_PHASE1":3535,"PHASE1":3537,"PHASE2":3539,"PHASE3":3541,"PHASE4":3552,"NA":3554},{"trials":3536,"activeCount":102},[],{"trials":3538,"activeCount":102},[],{"trials":3540,"activeCount":102},[],{"trials":3542,"activeCount":102},[3543],{"nctId":3544,"briefTitle":3545,"status":2169,"phases":3546,"primaryCompletion":3547,"completion":3547,"start":3548,"enrollment":1002,"conditions":3549,"interventions":3551},"NCT02356640","EUS-guided CGN for Inoperable Cancer",[91,92],"2019-01-29","2014-08",[3550],"Intractable Abdominal Pain Secondary to Inoperable Malignancy",[3533],{"trials":3553,"activeCount":102},[],{"trials":3555,"activeCount":102},[],{"intervention":3557,"totalTrials":121,"cells":3558},"celecoxib, esomeprazole",{"EARLY_PHASE1":3559,"PHASE1":3561,"PHASE2":3563,"PHASE3":3565,"PHASE4":3576,"NA":3578},{"trials":3560,"activeCount":102},[],{"trials":3562,"activeCount":102},[],{"trials":3564,"activeCount":102},[],{"trials":3566,"activeCount":102},[3567],{"nctId":3568,"briefTitle":3569,"status":203,"phases":3570,"completion":3308,"start":3571,"enrollment":3572,"conditions":3573,"interventions":3575},"NCT00365313","Preventing Recurrent Ulcer Bleeding in Arthritis Patients Using Esomeprazole Plus Celecoxib",[92],"2002-08",273,[3311,3574],"Bleeding Ulcer",[3557],{"trials":3577,"activeCount":102},[],{"trials":3579,"activeCount":102},[],{"intervention":3581,"totalTrials":121,"cells":3582},"Simvastatin",{"EARLY_PHASE1":3583,"PHASE1":3585,"PHASE2":3587,"PHASE3":3589,"PHASE4":3599,"NA":3601},{"trials":3584,"activeCount":102},[],{"trials":3586,"activeCount":102},[],{"trials":3588,"activeCount":102},[],{"trials":3590,"activeCount":102},[3591],{"nctId":3592,"briefTitle":3593,"status":203,"phases":3594,"primaryCompletion":2321,"completion":3595,"start":2899,"enrollment":3596,"conditions":3597,"interventions":3598},"NCT01077206","High-dose Simvastatin for Aneurysmal Subarachnoid Haemorrhage",[91,92],"2013-09",255,[3445],[3581],{"trials":3600,"activeCount":102},[],{"trials":3602,"activeCount":102},[],{"intervention":3604,"totalTrials":121,"cells":3605},"Gabapentin",{"EARLY_PHASE1":3606,"PHASE1":3608,"PHASE2":3610,"PHASE3":3612,"PHASE4":3623,"NA":3625},{"trials":3607,"activeCount":102},[],{"trials":3609,"activeCount":102},[],{"trials":3611,"activeCount":102},[],{"trials":3613,"activeCount":102},[3614],{"nctId":3615,"briefTitle":3616,"status":203,"phases":3617,"completion":3618,"start":3619,"enrollment":954,"conditions":3620,"interventions":3622},"NCT00137735","Gabapentin for Carpal Tunnel Syndrome",[92],"2006-12","2003-10",[3621],"Carpal Tunnel Syndrome",[3604],{"trials":3624,"activeCount":102},[],{"trials":3626,"activeCount":102},[],{"intervention":3628,"totalTrials":121,"cells":3629},"Adjuvant chemotherapy",{"EARLY_PHASE1":3630,"PHASE1":3632,"PHASE2":3634,"PHASE3":3636,"PHASE4":3648,"NA":3650},{"trials":3631,"activeCount":102},[],{"trials":3633,"activeCount":102},[],{"trials":3635,"activeCount":102},[],{"trials":3637,"activeCount":102},[3638],{"nctId":3639,"briefTitle":3640,"status":203,"phases":3641,"primaryCompletion":3642,"completion":3642,"start":3643,"enrollment":3644,"conditions":3645,"interventions":3647},"NCT00370890","A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy",[92],"2021-10-26","2006-09-04",104,[3646],"Nasopharyngeal Cancer",[3628],{"trials":3649,"activeCount":102},[],{"trials":3651,"activeCount":102},[],{"intervention":3246,"totalTrials":121,"cells":3653},{"EARLY_PHASE1":3654,"PHASE1":3656,"PHASE2":3658,"PHASE3":3660,"PHASE4":3666,"NA":3668},{"trials":3655,"activeCount":102},[],{"trials":3657,"activeCount":102},[],{"trials":3659,"activeCount":102},[],{"trials":3661,"activeCount":102},[3662],{"nctId":3237,"briefTitle":3238,"status":203,"phases":3663,"primaryCompletion":3240,"completion":3241,"start":3058,"enrollment":131,"conditions":3664,"interventions":3665},[92],[3243,3244,2672],[2287,3246],{"trials":3667,"activeCount":102},[],{"trials":3669,"activeCount":102},[],{"intervention":3671,"totalTrials":121,"cells":3672},"Desmopressin",{"EARLY_PHASE1":3673,"PHASE1":3675,"PHASE2":3677,"PHASE3":3679,"PHASE4":3689,"NA":3691},{"trials":3674,"activeCount":102},[],{"trials":3676,"activeCount":102},[],{"trials":3678,"activeCount":102},[],{"trials":3680,"activeCount":102},[3681],{"nctId":3682,"briefTitle":3683,"status":2169,"phases":3684,"primaryCompletion":2624,"completion":2624,"start":3415,"enrollment":1034,"conditions":3685,"interventions":3688},"NCT01530451","Clinical Trial of Desmopressin on Nocturia in Obstructive Sleep Apnoea Patients",[92],[3686,3687],"Nocturia","Obstructive Sleep Apnoea",[3671],{"trials":3690,"activeCount":102},[],{"trials":3692,"activeCount":102},[],{"intervention":3694,"totalTrials":121,"cells":3695},"Apalutamide",{"EARLY_PHASE1":3696,"PHASE1":3698,"PHASE2":3700,"PHASE3":3702,"PHASE4":3714,"NA":3716},{"trials":3697,"activeCount":102},[],{"trials":3699,"activeCount":102},[],{"trials":3701,"activeCount":102},[],{"trials":3703,"activeCount":102},[3704],{"nctId":3705,"briefTitle":3706,"status":2169,"phases":3707,"primaryCompletion":3708,"completion":3708,"start":3709,"enrollment":3710,"conditions":3711,"interventions":3712},"NCT04409288","Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer",[92],"2023-10-16","2020-07-20",74,[18],[3694,3713],"Enzalutamide",{"trials":3715,"activeCount":102},[],{"trials":3717,"activeCount":102},[],{"intervention":3713,"totalTrials":121,"cells":3719},{"EARLY_PHASE1":3720,"PHASE1":3722,"PHASE2":3724,"PHASE3":3726,"PHASE4":3732,"NA":3734},{"trials":3721,"activeCount":102},[],{"trials":3723,"activeCount":102},[],{"trials":3725,"activeCount":102},[],{"trials":3727,"activeCount":102},[3728],{"nctId":3705,"briefTitle":3706,"status":2169,"phases":3729,"primaryCompletion":3708,"completion":3708,"start":3709,"enrollment":3710,"conditions":3730,"interventions":3731},[92],[18],[3694,3713],{"trials":3733,"activeCount":102},[],{"trials":3735,"activeCount":102},[],{"intervention":3737,"totalTrials":121,"cells":3738},"Intravenous omeprazole",{"EARLY_PHASE1":3739,"PHASE1":3741,"PHASE2":3743,"PHASE3":3745,"PHASE4":3755,"NA":3757},{"trials":3740,"activeCount":102},[],{"trials":3742,"activeCount":102},[],{"trials":3744,"activeCount":102},[],{"trials":3746,"activeCount":102},[3747],{"nctId":3748,"briefTitle":3749,"status":203,"phases":3750,"start":3619,"enrollment":3751,"conditions":3752,"interventions":3754},"NCT00164931","A Study Comparing High Dose Omeprazole Infusion Against Scheduled Second Endoscopy for Bleeding Peptic Ulcer",[92],240,[3753],"Peptic Ulcer Hemorrhage",[3737],{"trials":3756,"activeCount":102},[],{"trials":3758,"activeCount":102},[],{"intervention":3760,"totalTrials":121,"cells":3761},"Modified Qing-Ying Decoction",{"EARLY_PHASE1":3762,"PHASE1":3764,"PHASE2":3766,"PHASE3":3768,"PHASE4":3781,"NA":3783},{"trials":3763,"activeCount":102},[],{"trials":3765,"activeCount":102},[],{"trials":3767,"activeCount":102},[],{"trials":3769,"activeCount":102},[3770],{"nctId":3771,"briefTitle":3772,"status":189,"phases":3773,"primaryCompletion":3774,"completion":3775,"start":3776,"enrollment":1538,"conditions":3777,"interventions":3779},"NCT04419584","Evaluate the Efficacy of Using Modified Qing-Ying Decoction in Atopic Dermatitis Children",[91,92],"2022-12-31","2023-05","2020-09-10",[3778],"Atopic Dermatitis",[3760,3780],"Identical looking placebo",{"trials":3782,"activeCount":102},[],{"trials":3784,"activeCount":102},[],{"intervention":3780,"totalTrials":121,"cells":3786},{"EARLY_PHASE1":3787,"PHASE1":3789,"PHASE2":3791,"PHASE3":3793,"PHASE4":3799,"NA":3801},{"trials":3788,"activeCount":102},[],{"trials":3790,"activeCount":102},[],{"trials":3792,"activeCount":102},[],{"trials":3794,"activeCount":102},[3795],{"nctId":3771,"briefTitle":3772,"status":189,"phases":3796,"primaryCompletion":3774,"completion":3775,"start":3776,"enrollment":1538,"conditions":3797,"interventions":3798},[91,92],[3778],[3760,3780],{"trials":3800,"activeCount":102},[],{"trials":3802,"activeCount":102},[],{"intervention":3804,"totalTrials":121,"cells":3805},"Botulinum toxin A injection or normal saline",{"EARLY_PHASE1":3806,"PHASE1":3808,"PHASE2":3810,"PHASE3":3812,"PHASE4":3823,"NA":3825},{"trials":3807,"activeCount":102},[],{"trials":3809,"activeCount":102},[],{"trials":3811,"activeCount":102},[],{"trials":3813,"activeCount":102},[3814],{"nctId":3815,"briefTitle":3816,"status":203,"phases":3817,"completion":3818,"start":3819,"enrollment":548,"conditions":3820,"interventions":3822},"NCT00119704","Treatment of Tennis Elbow With Botulinum Toxin",[92],"2005-03","2002-09",[3821],"Epicondylitis, Lateral Humeral",[3804],{"trials":3824,"activeCount":102},[],{"trials":3826,"activeCount":102},[],{"intervention":3828,"totalTrials":121,"cells":3829},"Escitalopram",{"EARLY_PHASE1":3830,"PHASE1":3832,"PHASE2":3834,"PHASE3":3836,"PHASE4":3847,"NA":3849},{"trials":3831,"activeCount":102},[],{"trials":3833,"activeCount":102},[],{"trials":3835,"activeCount":102},[],{"trials":3837,"activeCount":102},[3838],{"nctId":3839,"briefTitle":3840,"status":203,"phases":3841,"primaryCompletion":2768,"completion":3842,"start":3843,"enrollment":2626,"conditions":3844,"interventions":3846},"NCT02153567","SSRI Study for Functional Dyspepsia (SS)",[92],"2019-01-09","2013-12-06",[2672,3845,21],"Anxiety",[3828],{"trials":3848,"activeCount":102},[],{"trials":3850,"activeCount":102},[],{"intervention":2178,"totalTrials":121,"cells":3852},{"EARLY_PHASE1":3853,"PHASE1":3855,"PHASE2":3857,"PHASE3":3859,"PHASE4":3865,"NA":3867},{"trials":3854,"activeCount":102},[],{"trials":3856,"activeCount":102},[],{"trials":3858,"activeCount":102},[],{"trials":3860,"activeCount":102},[3861],{"nctId":2167,"briefTitle":2168,"status":2169,"phases":3862,"primaryCompletion":2171,"completion":2172,"start":2173,"enrollment":176,"conditions":3863,"interventions":3864},[92],[2175,2176],[2156,2178],{"trials":3866,"activeCount":102},[],{"trials":3868,"activeCount":102},[],{"intervention":3870,"totalTrials":121,"cells":3871},"Insulin",{"EARLY_PHASE1":3872,"PHASE1":3874,"PHASE2":3876,"PHASE3":3878,"PHASE4":3888,"NA":3890},{"trials":3873,"activeCount":102},[],{"trials":3875,"activeCount":102},[],{"trials":3877,"activeCount":102},[],{"trials":3879,"activeCount":102},[3880],{"nctId":3881,"briefTitle":3882,"status":189,"phases":3883,"primaryCompletion":3884,"completion":700,"start":2173,"enrollment":3885,"conditions":3886,"interventions":3887},"NCT00975533","Gastric Modulator (TANTALUS® System) Versus Insulin Treatment in Obese Type 2 Diabetic Patients - a Randomized Control Trial",[92],"2011-07",24,[2628],[3870],{"trials":3889,"activeCount":102},[],{"trials":3891,"activeCount":102},[],{"intervention":3893,"totalTrials":121,"cells":3894},"N-acetyl cysteine",{"EARLY_PHASE1":3895,"PHASE1":3897,"PHASE2":3899,"PHASE3":3901,"PHASE4":3910,"NA":3912},{"trials":3896,"activeCount":102},[],{"trials":3898,"activeCount":102},[],{"trials":3900,"activeCount":102},[],{"trials":3902,"activeCount":102},[3903],{"nctId":3904,"briefTitle":3905,"status":189,"phases":3906,"primaryCompletion":773,"completion":82,"start":2183,"enrollment":2184,"conditions":3907,"interventions":3908},"NCT03900988","Intravenous N-acetylcysteine and Oseltamivir Versus Oseltamivir in Adults Hospitalized With Influenza and Pneumonia",[92],[2176],[3893,3909],"5% Dextrose",{"trials":3911,"activeCount":102},[],{"trials":3913,"activeCount":102},[],{"intervention":3909,"totalTrials":121,"cells":3915},{"EARLY_PHASE1":3916,"PHASE1":3918,"PHASE2":3920,"PHASE3":3922,"PHASE4":3928,"NA":3930},{"trials":3917,"activeCount":102},[],{"trials":3919,"activeCount":102},[],{"trials":3921,"activeCount":102},[],{"trials":3923,"activeCount":102},[3924],{"nctId":3904,"briefTitle":3905,"status":189,"phases":3925,"primaryCompletion":773,"completion":82,"start":2183,"enrollment":2184,"conditions":3926,"interventions":3927},[92],[2176],[3893,3909],{"trials":3929,"activeCount":102},[],{"trials":3931,"activeCount":102},[],{"intervention":3933,"totalTrials":121,"cells":3934},"Chinese herbal medicine",{"EARLY_PHASE1":3935,"PHASE1":3937,"PHASE2":3939,"PHASE3":3941,"PHASE4":3950,"NA":3952},{"trials":3936,"activeCount":102},[],{"trials":3938,"activeCount":102},[],{"trials":3940,"activeCount":102},[],{"trials":3942,"activeCount":102},[3943],{"nctId":3944,"briefTitle":3945,"status":203,"phases":3946,"primaryCompletion":2625,"completion":2625,"start":3058,"enrollment":3525,"conditions":3947,"interventions":3949},"NCT01389362","The Healing Effect of a Two-Herb Recipe on Foot Ulcer in Chinese Patients With Type 2 Diabetes",[91,92],[3948],"Diabetic Foot Ulcer",[3933],{"trials":3951,"activeCount":102},[],{"trials":3953,"activeCount":102},[],{"intervention":3955,"totalTrials":121,"cells":3956},"Atorvastatin 20mg",{"EARLY_PHASE1":3957,"PHASE1":3959,"PHASE2":3961,"PHASE3":3963,"PHASE4":3977,"NA":3979},{"trials":3958,"activeCount":102},[],{"trials":3960,"activeCount":102},[],{"trials":3962,"activeCount":102},[],{"trials":3964,"activeCount":102},[3965],{"nctId":3966,"briefTitle":3967,"status":189,"phases":3968,"primaryCompletion":3969,"completion":3970,"start":3971,"enrollment":3972,"conditions":3973,"interventions":3975},"NCT03956368","Efficacy of Atorvastatin in Chronic Subdural Haematoma",[92],"2022-09-16","2023-03-16","2020-01-09",690,[3974],"Chronic Subdural Hematoma",[3955,3976],"Placebos",{"trials":3978,"activeCount":102},[],{"trials":3980,"activeCount":102},[],{"intervention":3976,"totalTrials":121,"cells":3982},{"EARLY_PHASE1":3983,"PHASE1":3985,"PHASE2":3987,"PHASE3":3989,"PHASE4":3995,"NA":3997},{"trials":3984,"activeCount":102},[],{"trials":3986,"activeCount":102},[],{"trials":3988,"activeCount":102},[],{"trials":3990,"activeCount":102},[3991],{"nctId":3966,"briefTitle":3967,"status":189,"phases":3992,"primaryCompletion":3969,"completion":3970,"start":3971,"enrollment":3972,"conditions":3993,"interventions":3994},[92],[3974],[3955,3976],{"trials":3996,"activeCount":102},[],{"trials":3998,"activeCount":102},[],{"intervention":3315,"totalTrials":121,"cells":4000},{"EARLY_PHASE1":4001,"PHASE1":4003,"PHASE2":4005,"PHASE3":4007,"PHASE4":4013,"NA":4015},{"trials":4002,"activeCount":102},[],{"trials":4004,"activeCount":102},[],{"trials":4006,"activeCount":102},[],{"trials":4008,"activeCount":102},[4009],{"nctId":3303,"briefTitle":3304,"status":203,"phases":4010,"primaryCompletion":3306,"completion":3307,"start":3308,"enrollment":3309,"conditions":4011,"interventions":4012},[92],[3311,3312,3313],[3292,3315],{"trials":4014,"activeCount":102},[],{"trials":4016,"activeCount":102},[],{"intervention":4018,"totalTrials":121,"cells":4019},"Ramipril",{"EARLY_PHASE1":4020,"PHASE1":4022,"PHASE2":4024,"PHASE3":4026,"PHASE4":4039,"NA":4041},{"trials":4021,"activeCount":102},[],{"trials":4023,"activeCount":102},[],{"trials":4025,"activeCount":102},[],{"trials":4027,"activeCount":102},[4028],{"nctId":4029,"briefTitle":4030,"status":203,"phases":4031,"primaryCompletion":2295,"completion":2172,"start":4032,"enrollment":548,"conditions":4033,"interventions":4038},"NCT01225445","Treatment of Early Immunoglobulin A Nephropathy by Angiotensin Converting Enzyme Inhibitor - A Randomized Controlled Trial",[92],"2002-04",[4034,4035,4036,4037],"Biopsy-confirmed IgA Nephropathy","Proteinuria Less Than 0.5 g Per Day","Normal Blood Pressure","Serum Creatinine Below 120 Umol\u002Fl",[4018],{"trials":4040,"activeCount":102},[],{"trials":4042,"activeCount":102},[],{"intervention":2187,"totalTrials":121,"cells":4044},{"EARLY_PHASE1":4045,"PHASE1":4047,"PHASE2":4049,"PHASE3":4051,"PHASE4":4057,"NA":4059},{"trials":4046,"activeCount":102},[],{"trials":4048,"activeCount":102},[],{"trials":4050,"activeCount":102},[],{"trials":4052,"activeCount":102},[4053],{"nctId":2180,"briefTitle":2181,"status":189,"phases":4054,"primaryCompletion":773,"completion":82,"start":2183,"enrollment":2184,"conditions":4055,"interventions":4056},[92],[2176],[2187,2156],{"trials":4058,"activeCount":102},[],{"trials":4060,"activeCount":102},[],{"intervention":4062,"totalTrials":121,"cells":4063},"Rifaximin",{"EARLY_PHASE1":4064,"PHASE1":4066,"PHASE2":4068,"PHASE3":4070,"PHASE4":4082,"NA":4084},{"trials":4065,"activeCount":102},[],{"trials":4067,"activeCount":102},[],{"trials":4069,"activeCount":102},[],{"trials":4071,"activeCount":102},[4072],{"nctId":4073,"briefTitle":4074,"status":189,"phases":4075,"primaryCompletion":4076,"completion":3348,"start":4077,"enrollment":4078,"conditions":4079,"interventions":4081},"NCT03962283","Rifaximin and Misoprostol Combination Therapy for Healing of Small Bowel Ulcers in Aspirin Users",[91,92],"2022-06-30","2019-08-02",78,[4080,4062],"Small Bowel Disease",[4062],{"trials":4083,"activeCount":102},[],{"trials":4085,"activeCount":102},[],{"intervention":4087,"totalTrials":121,"cells":4088},"LingZhi",{"EARLY_PHASE1":4089,"PHASE1":4091,"PHASE2":4093,"PHASE3":4095,"PHASE4":4105,"NA":4107},{"trials":4090,"activeCount":102},[],{"trials":4092,"activeCount":102},[],{"trials":4094,"activeCount":102},[],{"trials":4096,"activeCount":102},[4097],{"nctId":4098,"briefTitle":4099,"status":203,"phases":4100,"completion":2245,"start":3819,"enrollment":4101,"conditions":4102,"interventions":4104},"NCT00575926","Lingzhi for Cancer Children",[92],58,[4103],"Pediatric Cancers",[4087],{"trials":4106,"activeCount":102},[],{"trials":4108,"activeCount":102},[],{"intervention":4110,"totalTrials":121,"cells":4111},"Shaoyao Gancao Decoction with Addition",{"EARLY_PHASE1":4112,"PHASE1":4114,"PHASE2":4116,"PHASE3":4118,"PHASE4":4129,"NA":4131},{"trials":4113,"activeCount":102},[],{"trials":4115,"activeCount":102},[],{"trials":4117,"activeCount":102},[],{"trials":4119,"activeCount":102},[4120],{"nctId":4121,"briefTitle":4122,"status":189,"phases":4123,"primaryCompletion":4124,"completion":67,"start":4125,"enrollment":548,"conditions":4126,"interventions":4128},"NCT05980637","Effectiveness and Safety of Shaoyao Gancao Decoction With Addition on the Sleep-related Leg Cramps",[91,92],"2025-02-28","2023-09-01",[4127],"Sleep-related Leg Cramps",[4110],{"trials":4130,"activeCount":102},[],{"trials":4132,"activeCount":102},[],{"intervention":4134,"totalTrials":121,"cells":4135},"Andrographis Paniculata",{"EARLY_PHASE1":4136,"PHASE1":4138,"PHASE2":4140,"PHASE3":4142,"PHASE4":4153,"NA":4155},{"trials":4137,"activeCount":102},[],{"trials":4139,"activeCount":102},[],{"trials":4141,"activeCount":102},[],{"trials":4143,"activeCount":102},[4144],{"nctId":4145,"briefTitle":4146,"status":203,"phases":4147,"primaryCompletion":4148,"completion":4149,"start":995,"enrollment":497,"conditions":4150,"interventions":4152},"NCT04196075","The Effect of Andrographis Paniculata (AP) on Palliative Management of Advanced Esophageal Cancer",[92],"2021-02-28","2021-06-30",[4151],"Squamous Cell Carcinoma of Esophagus",[4134],{"trials":4154,"activeCount":102},[],{"trials":4156,"activeCount":102},[],{"intervention":4158,"totalTrials":121,"cells":4159},"Imipramine",{"EARLY_PHASE1":4160,"PHASE1":4162,"PHASE2":4164,"PHASE3":4166,"PHASE4":4176,"NA":4178},{"trials":4161,"activeCount":102},[],{"trials":4163,"activeCount":102},[],{"trials":4165,"activeCount":102},[],{"trials":4167,"activeCount":102},[4168],{"nctId":4169,"briefTitle":4170,"status":203,"phases":4171,"primaryCompletion":2171,"completion":2171,"start":3308,"enrollment":4172,"conditions":4173,"interventions":4175},"NCT00164775","The Efficacy of Imipramine in Treatment of Refractory Functional Dyspepsia",[92],107,[4174],"Functional Gastrointestinal Disorder",[4158],{"trials":4177,"activeCount":102},[],{"trials":4179,"activeCount":102},[],{"intervention":4181,"totalTrials":121,"cells":4182},"Oral Vioxx",{"EARLY_PHASE1":4183,"PHASE1":4185,"PHASE2":4187,"PHASE3":4189,"PHASE4":4198,"NA":4200},{"trials":4184,"activeCount":102},[],{"trials":4186,"activeCount":102},[],{"trials":4188,"activeCount":102},[],{"trials":4190,"activeCount":102},[4191],{"nctId":4192,"briefTitle":4193,"status":189,"phases":4194,"start":3391,"enrollment":4195,"conditions":4196,"interventions":4197},"NCT00164892","Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial",[92],214,[3394],[4181],{"trials":4199,"activeCount":102},[],{"trials":4201,"activeCount":102},[],{"intervention":3327,"totalTrials":121,"cells":4203},{"EARLY_PHASE1":4204,"PHASE1":4206,"PHASE2":4208,"PHASE3":4210,"PHASE4":4216,"NA":4218},{"trials":4205,"activeCount":102},[],{"trials":4207,"activeCount":102},[],{"trials":4209,"activeCount":102},[],{"trials":4211,"activeCount":102},[4212],{"nctId":3317,"briefTitle":3318,"status":203,"phases":4213,"primaryCompletion":3320,"completion":3321,"start":3322,"enrollment":1075,"conditions":4214,"interventions":4215},[92],[3311,3324],[3326,3327],{"trials":4217,"activeCount":102},[],{"trials":4219,"activeCount":102},[],{"intervention":3286,"totalTrials":121,"cells":4221},{"EARLY_PHASE1":4222,"PHASE1":4224,"PHASE2":4226,"PHASE3":4228,"PHASE4":4234,"NA":4236},{"trials":4223,"activeCount":102},[],{"trials":4225,"activeCount":102},[],{"trials":4227,"activeCount":102},[],{"trials":4229,"activeCount":102},[4230],{"nctId":3277,"briefTitle":3278,"status":203,"phases":4231,"primaryCompletion":3280,"completion":2623,"start":3281,"enrollment":3282,"conditions":4232,"interventions":4233},[92],[2298,3284],[3256,3286],{"trials":4235,"activeCount":102},[],{"trials":4237,"activeCount":102},[],{"intervention":4239,"totalTrials":1002,"cells":4240},"rituximab",{"EARLY_PHASE1":4241,"PHASE1":4243,"PHASE2":4245,"PHASE3":4272,"PHASE4":4274,"NA":4276},{"trials":4242,"activeCount":102},[],{"trials":4244,"activeCount":102},[],{"trials":4246,"activeCount":102},[4247,4254,4261],{"nctId":4248,"briefTitle":4249,"status":203,"phases":4250,"primaryCompletion":2598,"completion":2598,"start":4251,"enrollment":28,"conditions":4252,"interventions":4253},"NCT00556192","Can Targeted Elimination of B-cell Depletion Therapy and\u002For Combination Therapy on Systemic Lupus Erythematosus",[91],"2006-06",[2258],[4239],{"nctId":4255,"briefTitle":4256,"status":203,"phases":4257,"primaryCompletion":2256,"completion":2256,"start":4258,"enrollment":2246,"conditions":4259,"interventions":4260},"NCT00555542","An Analysis of Peripheral Blood T Cell Subsets on Rheumatoid Arthritis",[91],"2006-07",[550],[4239],{"nctId":4262,"briefTitle":4263,"status":203,"phases":4264,"primaryCompletion":4265,"completion":4265,"start":4266,"enrollment":4267,"conditions":4268,"interventions":4270},"NCT04224571","CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children",[91],"2023-02-15","2018-09-14",208,[4269],"Acute Lymphoblastic Leukemia, in Relapse",[4271,4239],"Bortezomib",{"trials":4273,"activeCount":102},[],{"trials":4275,"activeCount":102},[],{"trials":4277,"activeCount":102},[],{"intervention":4279,"totalTrials":1002,"cells":4280},"Axitinib",{"EARLY_PHASE1":4281,"PHASE1":4283,"PHASE2":4285,"PHASE3":4315,"PHASE4":4317,"NA":4319},{"trials":4282,"activeCount":102},[],{"trials":4284,"activeCount":102},[],{"trials":4286,"activeCount":102},[4287,4295,4307],{"nctId":4288,"briefTitle":4289,"status":203,"phases":4290,"primaryCompletion":4291,"completion":4291,"start":4292,"enrollment":1901,"conditions":4293,"interventions":4294},"NCT01352728","Hepatocellular Carcinoma (HCC) Transarterial Chemoembolisation (TACE) +Axitinib",[91],"2018-06-07","2011-05-18",[33],[4279],{"nctId":4296,"briefTitle":4297,"status":203,"phases":4298,"primaryCompletion":4299,"completion":4300,"start":4301,"enrollment":4302,"conditions":4303,"interventions":4305},"NCT04562441","NPC - AXEL Study : Axitinib-Avelumab",[91],"2024-10-31","2024-11-07","2021-05-06",13,[4304],"Recurrent or Metastatic NPC",[4279,4306],"Avelumab",{"nctId":4308,"briefTitle":4309,"status":203,"phases":4310,"primaryCompletion":3307,"completion":3307,"start":4311,"enrollment":1017,"conditions":4312,"interventions":4313},"NCT01249547","Nasopharyngeal Carcinoma (NPC) Axitinib",[91],"2010-12",[4304],[4314],"axitinib",{"trials":4316,"activeCount":102},[],{"trials":4318,"activeCount":102},[],{"trials":4320,"activeCount":102},[],{"intervention":4322,"totalTrials":98,"cells":4323},"DBT-Danggui Buxue Tang",{"EARLY_PHASE1":4324,"PHASE1":4326,"PHASE2":4328,"PHASE3":4346,"PHASE4":4348,"NA":4350},{"trials":4325,"activeCount":102},[],{"trials":4327,"activeCount":102},[],{"trials":4329,"activeCount":102},[4330,4337],{"nctId":4331,"briefTitle":4332,"status":203,"phases":4333,"primaryCompletion":2921,"completion":2921,"start":4251,"enrollment":548,"conditions":4334,"interventions":4336},"NCT00420576","Dose Finding Study of Danggui Buxue Tang (Herbal Formula)on the Treatment of Menopausal Symptoms",[91],[4335],"Postmenopausal",[4322],{"nctId":4338,"briefTitle":4339,"status":203,"phases":4340,"completion":4341,"start":4342,"enrollment":996,"conditions":4343,"interventions":4345},"NCT00421564","Study the Effect of Danggui Buxue Tang on Menopausal Symptoms",[91],"2004-12","2003-02",[4344],"Menopause",[4322],{"trials":4347,"activeCount":102},[],{"trials":4349,"activeCount":102},[],{"trials":4351,"activeCount":102},[],{"intervention":4353,"totalTrials":98,"cells":4354},"Traditional Chinese Medicine",{"EARLY_PHASE1":4355,"PHASE1":4357,"PHASE2":4359,"PHASE3":4381,"PHASE4":4383,"NA":4385},{"trials":4356,"activeCount":102},[],{"trials":4358,"activeCount":102},[],{"trials":4360,"activeCount":102},[4361,4372],{"nctId":4362,"briefTitle":4363,"status":203,"phases":4364,"primaryCompletion":4365,"completion":4366,"start":4367,"enrollment":3644,"conditions":4368,"interventions":4370},"NCT00676975","The Efficacy of Tradition Chinese Medicine in Patients With Irritable Bowel Syndrome",[91],"2010-12-30","2011-08-30","2008-05-26",[4369],"Irritable Bowel Syndrome",[4353,4371],"Traditional Chinese Medicine Placebo",{"nctId":4373,"briefTitle":4374,"status":203,"phases":4375,"primaryCompletion":4376,"completion":4376,"start":2574,"enrollment":117,"conditions":4377,"interventions":4379},"NCT00153751","The Efficacy of Herbal Medicine in Relieving Symptoms and Change of Quality of Life of Patients With Irritable Bowel Syndrome (IBS)",[91],"2007-05",[4378],"Colonic Diseases, Functional",[4353,4380],"Holopon",{"trials":4382,"activeCount":102},[],{"trials":4384,"activeCount":102},[],{"trials":4386,"activeCount":102},[],{"intervention":4388,"totalTrials":121,"cells":4389},"Temoporfin",{"EARLY_PHASE1":4390,"PHASE1":4392,"PHASE2":4394,"PHASE3":4408,"PHASE4":4410,"NA":4412},{"trials":4391,"activeCount":102},[],{"trials":4393,"activeCount":102},[],{"trials":4395,"activeCount":102},[4396],{"nctId":4397,"briefTitle":4398,"status":203,"phases":4399,"primaryCompletion":4400,"completion":4401,"start":4402,"enrollment":2246,"conditions":4403,"interventions":4407},"NCT03003065","Safety and Tumoricidal Effect of Low Dose Foscan PDT in Patients With Inoperable Bile Duct Cancers",[91],"2023-04-12","2023-08-12","2014-03-28",[4404,4405,4406],"Cholangiocarcinoma","Tumor","Klatskin Tumor",[4388],{"trials":4409,"activeCount":102},[],{"trials":4411,"activeCount":102},[],{"trials":4413,"activeCount":102},[],{"intervention":4415,"totalTrials":121,"cells":4416},"SUNPHENON EGCg",{"EARLY_PHASE1":4417,"PHASE1":4419,"PHASE2":4421,"PHASE3":4433,"PHASE4":4435,"NA":4437},{"trials":4418,"activeCount":102},[],{"trials":4420,"activeCount":102},[],{"trials":4422,"activeCount":102},[4423],{"nctId":4424,"briefTitle":4425,"status":203,"phases":4426,"primaryCompletion":4427,"completion":4427,"start":4428,"enrollment":4429,"conditions":4430,"interventions":4432},"NCT02832271","Green Tea Extract for Endometriosis Treatment",[91],"2022-12","2016-12-08",185,[4431],"Endometriosis",[4415],{"trials":4434,"activeCount":102},[],{"trials":4436,"activeCount":102},[],{"trials":4438,"activeCount":102},[],{"intervention":4440,"totalTrials":121,"cells":4441},"Qingyan Lihou Decoction",{"EARLY_PHASE1":4442,"PHASE1":4444,"PHASE2":4446,"PHASE3":4458,"PHASE4":4460,"NA":4462},{"trials":4443,"activeCount":102},[],{"trials":4445,"activeCount":102},[],{"trials":4447,"activeCount":102},[4448],{"nctId":4449,"briefTitle":4450,"status":189,"phases":4451,"primaryCompletion":4452,"completion":4453,"start":4454,"enrollment":3710,"conditions":4455,"interventions":4457},"NCT05665777","Chinese Medicine for Treating Chronic Pharyngolaryngitis",[91],"2025-01-31","2025-07-31","2023-03-30",[4456],"Chronic Pharyngolaryngitis (Disorder)",[4440],{"trials":4459,"activeCount":102},[],{"trials":4461,"activeCount":102},[],{"trials":4463,"activeCount":102},[],{"intervention":4465,"totalTrials":121,"cells":4466},"HKIIM-KU formula",{"EARLY_PHASE1":4467,"PHASE1":4469,"PHASE2":4471,"PHASE3":4483,"PHASE4":4485,"NA":4487},{"trials":4468,"activeCount":102},[],{"trials":4470,"activeCount":102},[],{"trials":4472,"activeCount":102},[4473],{"nctId":4474,"briefTitle":4475,"status":189,"phases":4476,"primaryCompletion":4477,"completion":4478,"start":4479,"enrollment":11,"conditions":4480,"interventions":4482},"NCT05499312","An Innovative Chinese Herbal Formula for the Treatment of Gout",[91],"2024-08","2025-02","2022-10-11",[4481],"Gout",[4465],{"trials":4484,"activeCount":102},[],{"trials":4486,"activeCount":102},[],{"trials":4488,"activeCount":102},[],{"intervention":4490,"totalTrials":121,"cells":4491},"TCM",{"EARLY_PHASE1":4492,"PHASE1":4494,"PHASE2":4496,"PHASE3":4506,"PHASE4":4508,"NA":4510},{"trials":4493,"activeCount":102},[],{"trials":4495,"activeCount":102},[],{"trials":4497,"activeCount":102},[4498],{"nctId":4499,"briefTitle":4500,"status":203,"phases":4501,"primaryCompletion":4502,"completion":4502,"start":2970,"enrollment":11,"conditions":4503,"interventions":4505},"NCT00393510","Herbal Preparation Used as Adjuvant Therapy on Diabetic Ulcers",[91],"2006-03",[3948,4504],"Amputation",[4490],{"trials":4507,"activeCount":102},[],{"trials":4509,"activeCount":102},[],{"trials":4511,"activeCount":102},[],{"intervention":4513,"totalTrials":121,"cells":4514},"PDO-guided treatment",{"EARLY_PHASE1":4515,"PHASE1":4517,"PHASE2":4519,"PHASE3":4531,"PHASE4":4533,"NA":4535},{"trials":4516,"activeCount":102},[],{"trials":4518,"activeCount":102},[],{"trials":4520,"activeCount":102},[4521],{"nctId":4522,"briefTitle":4523,"status":2253,"phases":4524,"primaryCompletion":4525,"completion":4525,"start":4526,"enrollment":102,"conditions":4527,"interventions":4529},"NCT05378048","Patient-derived-organoid (PDO) Guided Versus Conventional Therapy for Advanced Inoperable Abdominal Tumors",[91],"2025-07-03","2022-07-04",[4528],"Organoids",[4513,4530],"standard of care",{"trials":4532,"activeCount":102},[],{"trials":4534,"activeCount":102},[],{"trials":4536,"activeCount":102},[],{"intervention":4530,"totalTrials":121,"cells":4538},{"EARLY_PHASE1":4539,"PHASE1":4541,"PHASE2":4543,"PHASE3":4549,"PHASE4":4551,"NA":4553},{"trials":4540,"activeCount":102},[],{"trials":4542,"activeCount":102},[],{"trials":4544,"activeCount":102},[4545],{"nctId":4522,"briefTitle":4523,"status":2253,"phases":4546,"primaryCompletion":4525,"completion":4525,"start":4526,"enrollment":102,"conditions":4547,"interventions":4548},[91],[4528],[4513,4530],{"trials":4550,"activeCount":102},[],{"trials":4552,"activeCount":102},[],{"trials":4554,"activeCount":102},[],{"intervention":4556,"totalTrials":121,"cells":4557},"RAD001",{"EARLY_PHASE1":4558,"PHASE1":4560,"PHASE2":4562,"PHASE3":4573,"PHASE4":4575,"NA":4577},{"trials":4559,"activeCount":102},[],{"trials":4561,"activeCount":102},[],{"trials":4563,"activeCount":102},[4564],{"nctId":4565,"briefTitle":4566,"status":203,"phases":4567,"primaryCompletion":4568,"completion":4568,"start":4569,"enrollment":19,"conditions":4570,"interventions":4572},"NCT01514110","Gastric Cancer RAD001 Study",[90,91],"2019-03-06","2008-01-23",[4571],"Gastric Cancer",[4556],{"trials":4574,"activeCount":102},[],{"trials":4576,"activeCount":102},[],{"trials":4578,"activeCount":102},[],{"intervention":4580,"totalTrials":121,"cells":4581},"Semaglutide",{"EARLY_PHASE1":4582,"PHASE1":4584,"PHASE2":4586,"PHASE3":4598,"PHASE4":4600,"NA":4602},{"trials":4583,"activeCount":102},[],{"trials":4585,"activeCount":102},[],{"trials":4587,"activeCount":102},[4588],{"nctId":4589,"briefTitle":4590,"status":203,"phases":4591,"primaryCompletion":4592,"completion":4592,"start":4593,"enrollment":775,"conditions":4594,"interventions":4597},"NCT05920889","Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies",[91],"2024-10-25","2023-08-01",[15,4595,1792,4596],"Stroke, Acute","Brain Diseases",[4580],{"trials":4599,"activeCount":102},[],{"trials":4601,"activeCount":102},[],{"trials":4603,"activeCount":102},[],{"intervention":4605,"totalTrials":121,"cells":4606},"Lingzhi and Sen Miao San",{"EARLY_PHASE1":4607,"PHASE1":4609,"PHASE2":4611,"PHASE3":4619,"PHASE4":4621,"NA":4623},{"trials":4608,"activeCount":102},[],{"trials":4610,"activeCount":102},[],{"trials":4612,"activeCount":102},[4613],{"nctId":4614,"briefTitle":4615,"status":203,"phases":4616,"primaryCompletion":3618,"completion":3618,"start":2599,"enrollment":1379,"conditions":4617,"interventions":4618},"NCT00432484","Lingzhi and Sen Miao San for the Treatment of Rheumatoid Arthritis",[91],[550],[4605],{"trials":4620,"activeCount":102},[],{"trials":4622,"activeCount":102},[],{"trials":4624,"activeCount":102},[],{"intervention":4626,"totalTrials":121,"cells":4627},"Modified Guizhi Fuling granules",{"EARLY_PHASE1":4628,"PHASE1":4630,"PHASE2":4632,"PHASE3":4642,"PHASE4":4644,"NA":4646},{"trials":4629,"activeCount":102},[],{"trials":4631,"activeCount":102},[],{"trials":4633,"activeCount":102},[4634],{"nctId":4635,"briefTitle":4636,"status":189,"phases":4637,"primaryCompletion":773,"completion":4638,"start":4639,"enrollment":4078,"conditions":4640,"interventions":4641},"NCT06074809","RCT on the Treatment of Menopausal Syndrome With Chinese Medicine",[91],"2026-01-31","2023-11-01",[4344],[4626],{"trials":4643,"activeCount":102},[],{"trials":4645,"activeCount":102},[],{"trials":4647,"activeCount":102},[],{"intervention":4649,"totalTrials":121,"cells":4650},"Traditional Chinese medicine treatment",{"EARLY_PHASE1":4651,"PHASE1":4653,"PHASE2":4655,"PHASE3":4665,"PHASE4":4667,"NA":4669},{"trials":4652,"activeCount":102},[],{"trials":4654,"activeCount":102},[],{"trials":4656,"activeCount":102},[4657],{"nctId":4658,"briefTitle":4659,"status":189,"phases":4660,"primaryCompletion":1666,"completion":469,"start":547,"enrollment":1405,"conditions":4661,"interventions":4663},"NCT06095258","A Practical RCT of TCM in the Treatment of LCOVID and Analysis of Syndrome Types and Medication Characteristics.",[91],[4662],"Long COVID",[4649,4664],"Western medicine treatment",{"trials":4666,"activeCount":102},[],{"trials":4668,"activeCount":102},[],{"trials":4670,"activeCount":102},[],{"intervention":4664,"totalTrials":121,"cells":4672},{"EARLY_PHASE1":4673,"PHASE1":4675,"PHASE2":4677,"PHASE3":4683,"PHASE4":4685,"NA":4687},{"trials":4674,"activeCount":102},[],{"trials":4676,"activeCount":102},[],{"trials":4678,"activeCount":102},[4679],{"nctId":4658,"briefTitle":4659,"status":189,"phases":4680,"primaryCompletion":1666,"completion":469,"start":547,"enrollment":1405,"conditions":4681,"interventions":4682},[91],[4662],[4649,4664],{"trials":4684,"activeCount":102},[],{"trials":4686,"activeCount":102},[],{"trials":4688,"activeCount":102},[],{"intervention":4690,"totalTrials":121,"cells":4691},"Torisel",{"EARLY_PHASE1":4692,"PHASE1":4694,"PHASE2":4696,"PHASE3":4707,"PHASE4":4709,"NA":4711},{"trials":4693,"activeCount":102},[],{"trials":4695,"activeCount":102},[],{"trials":4697,"activeCount":102},[4698],{"nctId":4699,"briefTitle":4700,"status":203,"phases":4701,"primaryCompletion":4702,"completion":4702,"start":2173,"enrollment":4703,"conditions":4704,"interventions":4706},"NCT01251458","Hepatocellular Carcinoma (HCC)_Torisel_",[90,91],"2016-01",46,[4705],"Inoperable HCC",[4690],{"trials":4708,"activeCount":102},[],{"trials":4710,"activeCount":102},[],{"trials":4712,"activeCount":102},[],{"intervention":4714,"totalTrials":121,"cells":4715},"FMT",{"EARLY_PHASE1":4716,"PHASE1":4718,"PHASE2":4720,"PHASE3":4732,"PHASE4":4734,"NA":4736},{"trials":4717,"activeCount":102},[],{"trials":4719,"activeCount":102},[],{"trials":4721,"activeCount":102},[4722],{"nctId":4723,"briefTitle":4724,"status":203,"phases":4725,"primaryCompletion":4726,"completion":4726,"start":4727,"enrollment":31,"conditions":4728,"interventions":4731},"NCT03479710","Fecal Microbiota Transplantation for CRE\u002FVRE",[91],"2022-07-31","2018-02-10",[4729,4730],"Antimicrobial Resistance","Colonization",[4714],{"trials":4733,"activeCount":102},[],{"trials":4735,"activeCount":102},[],{"trials":4737,"activeCount":102},[],{"intervention":4739,"totalTrials":121,"cells":4740},"BTI320",{"EARLY_PHASE1":4741,"PHASE1":4743,"PHASE2":4745,"PHASE3":4756,"PHASE4":4758,"NA":4760},{"trials":4742,"activeCount":102},[],{"trials":4744,"activeCount":102},[],{"trials":4746,"activeCount":102},[4747],{"nctId":4748,"briefTitle":4749,"status":203,"phases":4750,"primaryCompletion":4751,"completion":218,"start":4752,"enrollment":548,"conditions":4753,"interventions":4755},"NCT02358668","BTI320 (SUGARDOWN®) on Post-Prandial Hyperglycaemia in Subjects With Pre-Diabetes",[91],"2016-02","2015-03-30",[4754],"Pre-Diabetes",[4739],{"trials":4757,"activeCount":102},[],{"trials":4759,"activeCount":102},[],{"trials":4761,"activeCount":102},[],{"intervention":4763,"totalTrials":121,"cells":4764},"SDD formula",{"EARLY_PHASE1":4765,"PHASE1":4767,"PHASE2":4769,"PHASE3":4781,"PHASE4":4783,"NA":4785},{"trials":4766,"activeCount":102},[],{"trials":4768,"activeCount":102},[],{"trials":4770,"activeCount":102},[4771],{"nctId":4772,"briefTitle":4773,"status":189,"phases":4774,"primaryCompletion":4775,"completion":4776,"start":4777,"enrollment":4101,"conditions":4778,"interventions":4780},"NCT05815797","Shuiniujiao Dihuang Decoction With Variation for the Treatment of Psoriasis",[91],"2025-04","2025-10","2024-05",[4779],"Psoriasis Vulgaris",[4763],{"trials":4782,"activeCount":102},[],{"trials":4784,"activeCount":102},[],{"trials":4786,"activeCount":102},[],{"intervention":4788,"totalTrials":121,"cells":4789},"Inflammatory skin disease formula",{"EARLY_PHASE1":4790,"PHASE1":4792,"PHASE2":4794,"PHASE3":4806,"PHASE4":4808,"NA":4810},{"trials":4791,"activeCount":102},[],{"trials":4793,"activeCount":102},[],{"trials":4795,"activeCount":102},[4796],{"nctId":4797,"briefTitle":4798,"status":189,"phases":4799,"primaryCompletion":4800,"completion":4801,"start":4802,"enrollment":548,"conditions":4803,"interventions":4805},"NCT05295979","Chinese Medicine for Patients With Psoriasis",[91],"2024-02-29","2024-08-31","2023-03-20",[4804],"Psoriasis",[4788],{"trials":4807,"activeCount":102},[],{"trials":4809,"activeCount":102},[],{"trials":4811,"activeCount":102},[],{"intervention":4813,"totalTrials":121,"cells":4814},"Danshen Gegen",{"EARLY_PHASE1":4815,"PHASE1":4817,"PHASE2":4819,"PHASE3":4831,"PHASE4":4833,"NA":4835},{"trials":4816,"activeCount":102},[],{"trials":4818,"activeCount":102},[],{"trials":4820,"activeCount":102},[4821],{"nctId":4822,"briefTitle":4823,"status":203,"phases":4824,"primaryCompletion":4825,"completion":4825,"start":4826,"enrollment":4172,"conditions":4827,"interventions":4830},"NCT02380794","Novel Treatment of Intermittent Claudication in Patients With Peripheral Arterial Disease Using Danshen Gegen (D&G) Capsule",[91],"2017-06-02","2015-10-28",[4828,4829],"Peripheral Arterial Disease","Intermittent Claudication",[4813],{"trials":4832,"activeCount":102},[],{"trials":4834,"activeCount":102},[],{"trials":4836,"activeCount":102},[],{"intervention":4838,"totalTrials":121,"cells":4839},"D&G 2g",{"EARLY_PHASE1":4840,"PHASE1":4842,"PHASE2":4844,"PHASE3":4855,"PHASE4":4857,"NA":4859},{"trials":4841,"activeCount":102},[],{"trials":4843,"activeCount":102},[],{"trials":4845,"activeCount":102},[4846],{"nctId":4847,"briefTitle":4848,"status":203,"phases":4849,"primaryCompletion":2256,"completion":2256,"start":4850,"enrollment":4851,"conditions":4852,"interventions":4853},"NCT01033630","Cardiovascular-Protective Effects of Herbal Medicine Danshen-Gegen",[91],"2006-01",90,[27],[4838,4854],"D&G 1g",{"trials":4856,"activeCount":102},[],{"trials":4858,"activeCount":102},[],{"trials":4860,"activeCount":102},[],{"intervention":4854,"totalTrials":121,"cells":4862},{"EARLY_PHASE1":4863,"PHASE1":4865,"PHASE2":4867,"PHASE3":4873,"PHASE4":4875,"NA":4877},{"trials":4864,"activeCount":102},[],{"trials":4866,"activeCount":102},[],{"trials":4868,"activeCount":102},[4869],{"nctId":4847,"briefTitle":4848,"status":203,"phases":4870,"primaryCompletion":2256,"completion":2256,"start":4850,"enrollment":4851,"conditions":4871,"interventions":4872},[91],[27],[4838,4854],{"trials":4874,"activeCount":102},[],{"trials":4876,"activeCount":102},[],{"trials":4878,"activeCount":102},[],{"intervention":4880,"totalTrials":121,"cells":4881},"modified Shenling Baizhu San",{"EARLY_PHASE1":4882,"PHASE1":4884,"PHASE2":4886,"PHASE3":4898,"PHASE4":4900,"NA":4902},{"trials":4883,"activeCount":102},[],{"trials":4885,"activeCount":102},[],{"trials":4887,"activeCount":102},[4888],{"nctId":4889,"briefTitle":4890,"status":189,"phases":4891,"primaryCompletion":4892,"completion":4893,"start":4894,"enrollment":1379,"conditions":4895,"interventions":4897},"NCT05122702","An Innovative Chinese Herbal Formula for Macular Edema",[91],"2024-07-31","2025-01-01","2022-07-12",[4896],"Macula Edema",[4880],{"trials":4899,"activeCount":102},[],{"trials":4901,"activeCount":102},[],{"trials":4903,"activeCount":102},[],{"intervention":3273,"totalTrials":121,"cells":4905},{"EARLY_PHASE1":4906,"PHASE1":4908,"PHASE2":4910,"PHASE3":4916,"PHASE4":4918,"NA":4920},{"trials":4907,"activeCount":102},[],{"trials":4909,"activeCount":102},[],{"trials":4911,"activeCount":102},[4912],{"nctId":3265,"briefTitle":3266,"status":2169,"phases":4913,"primaryCompletion":2282,"completion":2282,"start":3268,"enrollment":3269,"conditions":4914,"interventions":4915},[91],[3271],[3273,3256],{"trials":4917,"activeCount":102},[],{"trials":4919,"activeCount":102},[],{"trials":4921,"activeCount":102},[],{"intervention":4923,"totalTrials":121,"cells":4924},"Shi-Bi-Lin",{"EARLY_PHASE1":4925,"PHASE1":4927,"PHASE2":4929,"PHASE3":4941,"PHASE4":4943,"NA":4945},{"trials":4926,"activeCount":102},[],{"trials":4928,"activeCount":102},[],{"trials":4930,"activeCount":102},[4931],{"nctId":4932,"briefTitle":4933,"status":203,"phases":4934,"primaryCompletion":4935,"completion":4935,"start":4936,"enrollment":4937,"conditions":4938,"interventions":4940},"NCT00456755","Herbal Treatment for Perennial Allergic Rhinitis",[91],"2006-04","2004-03",126,[4939],"Perennial Allergic Rhinitis",[4923],{"trials":4942,"activeCount":102},[],{"trials":4944,"activeCount":102},[],{"trials":4946,"activeCount":102},[],{"intervention":4948,"totalTrials":121,"cells":4949},"Curcumin and ginkgo extract",{"EARLY_PHASE1":4950,"PHASE1":4952,"PHASE2":4954,"PHASE3":4963,"PHASE4":4965,"NA":4967},{"trials":4951,"activeCount":102},[],{"trials":4953,"activeCount":102},[],{"trials":4955,"activeCount":102},[4956],{"nctId":4957,"briefTitle":4958,"status":203,"phases":4959,"primaryCompletion":4258,"completion":4258,"start":3391,"enrollment":1702,"conditions":4960,"interventions":4962},"NCT00164749","A Pilot Study of Curcumin and Ginkgo for Treating Alzheimer's Disease",[90,91],[4961],"Alzheimer's Disease",[4948,4948],{"trials":4964,"activeCount":102},[],{"trials":4966,"activeCount":102},[],{"trials":4968,"activeCount":102},[],{"intervention":4970,"totalTrials":121,"cells":4971},"Paracetamol",{"EARLY_PHASE1":4972,"PHASE1":4974,"PHASE2":4976,"PHASE3":4989,"PHASE4":4991,"NA":4993},{"trials":4973,"activeCount":102},[],{"trials":4975,"activeCount":102},[],{"trials":4977,"activeCount":102},[4978],{"nctId":4979,"briefTitle":4980,"status":203,"phases":4981,"primaryCompletion":2345,"completion":2345,"start":2504,"enrollment":4982,"conditions":4983,"interventions":4985},"NCT00528658","Cost-effectiveness of Two Painkillers for Treating Pain After Limb Injuries",[91],782,[4984],"Soft Tissue Injuries",[4970,4986,4987,4988],"Ibuprofen","Paracetamol Placebo","Ibuprofen placebo",{"trials":4990,"activeCount":102},[],{"trials":4992,"activeCount":102},[],{"trials":4994,"activeCount":102},[],{"intervention":4986,"totalTrials":121,"cells":4996},{"EARLY_PHASE1":4997,"PHASE1":4999,"PHASE2":5001,"PHASE3":5007,"PHASE4":5009,"NA":5011},{"trials":4998,"activeCount":102},[],{"trials":5000,"activeCount":102},[],{"trials":5002,"activeCount":102},[5003],{"nctId":4979,"briefTitle":4980,"status":203,"phases":5004,"primaryCompletion":2345,"completion":2345,"start":2504,"enrollment":4982,"conditions":5005,"interventions":5006},[91],[4984],[4970,4986,4987,4988],{"trials":5008,"activeCount":102},[],{"trials":5010,"activeCount":102},[],{"trials":5012,"activeCount":102},[],{"intervention":4987,"totalTrials":121,"cells":5014},{"EARLY_PHASE1":5015,"PHASE1":5017,"PHASE2":5019,"PHASE3":5025,"PHASE4":5027,"NA":5029},{"trials":5016,"activeCount":102},[],{"trials":5018,"activeCount":102},[],{"trials":5020,"activeCount":102},[5021],{"nctId":4979,"briefTitle":4980,"status":203,"phases":5022,"primaryCompletion":2345,"completion":2345,"start":2504,"enrollment":4982,"conditions":5023,"interventions":5024},[91],[4984],[4970,4986,4987,4988],{"trials":5026,"activeCount":102},[],{"trials":5028,"activeCount":102},[],{"trials":5030,"activeCount":102},[],{"intervention":4988,"totalTrials":121,"cells":5032},{"EARLY_PHASE1":5033,"PHASE1":5035,"PHASE2":5037,"PHASE3":5043,"PHASE4":5045,"NA":5047},{"trials":5034,"activeCount":102},[],{"trials":5036,"activeCount":102},[],{"trials":5038,"activeCount":102},[5039],{"nctId":4979,"briefTitle":4980,"status":203,"phases":5040,"primaryCompletion":2345,"completion":2345,"start":2504,"enrollment":4982,"conditions":5041,"interventions":5042},[91],[4984],[4970,4986,4987,4988],{"trials":5044,"activeCount":102},[],{"trials":5046,"activeCount":102},[],{"trials":5048,"activeCount":102},[],{"intervention":4371,"totalTrials":121,"cells":5050},{"EARLY_PHASE1":5051,"PHASE1":5053,"PHASE2":5055,"PHASE3":5061,"PHASE4":5063,"NA":5065},{"trials":5052,"activeCount":102},[],{"trials":5054,"activeCount":102},[],{"trials":5056,"activeCount":102},[5057],{"nctId":4362,"briefTitle":4363,"status":203,"phases":5058,"primaryCompletion":4365,"completion":4366,"start":4367,"enrollment":3644,"conditions":5059,"interventions":5060},[91],[4369],[4353,4371],{"trials":5062,"activeCount":102},[],{"trials":5064,"activeCount":102},[],{"trials":5066,"activeCount":102},[],{"intervention":4306,"totalTrials":121,"cells":5068},{"EARLY_PHASE1":5069,"PHASE1":5071,"PHASE2":5073,"PHASE3":5079,"PHASE4":5081,"NA":5083},{"trials":5070,"activeCount":102},[],{"trials":5072,"activeCount":102},[],{"trials":5074,"activeCount":102},[5075],{"nctId":4296,"briefTitle":4297,"status":203,"phases":5076,"primaryCompletion":4299,"completion":4300,"start":4301,"enrollment":4302,"conditions":5077,"interventions":5078},[91],[4304],[4279,4306],{"trials":5080,"activeCount":102},[],{"trials":5082,"activeCount":102},[],{"trials":5084,"activeCount":102},[],{"intervention":5086,"totalTrials":121,"cells":5087},"Granules Dendrobii",{"EARLY_PHASE1":5088,"PHASE1":5090,"PHASE2":5092,"PHASE3":5103,"PHASE4":5105,"NA":5107},{"trials":5089,"activeCount":102},[],{"trials":5091,"activeCount":102},[],{"trials":5093,"activeCount":102},[5094],{"nctId":5095,"briefTitle":5096,"status":189,"phases":5097,"primaryCompletion":5098,"completion":4477,"start":5099,"enrollment":28,"conditions":5100,"interventions":5102},"NCT05209633","Efficacy and Safety of Using Granules Dendrobii for the Treatment of Chronic Atrophic Gastritis",[91],"2024-01","2022-11-01",[5101],"Atrophic Gastritis",[5086],{"trials":5104,"activeCount":102},[],{"trials":5106,"activeCount":102},[],{"trials":5108,"activeCount":102},[],{"intervention":5110,"totalTrials":121,"cells":5111},"Chinese Medicine Oral Rinse Formula-I",{"EARLY_PHASE1":5112,"PHASE1":5114,"PHASE2":5116,"PHASE3":5129,"PHASE4":5131,"NA":5133},{"trials":5113,"activeCount":102},[],{"trials":5115,"activeCount":102},[],{"trials":5117,"activeCount":102},[5118],{"nctId":5119,"briefTitle":5120,"status":189,"phases":5121,"primaryCompletion":1073,"completion":5122,"start":5123,"enrollment":156,"conditions":5124,"interventions":5128},"NCT05664906","Evaluating Chinese Medicine Oral Rinse for Irradiated Oral Mucositis in Head & Neck Cancer Patients",[90,91],"2024-11-30","2023-01-31",[5125,5126,5127],"Head and Neck Neoplasms","Oral Mucositis (Ulcerative) Due to Radiation","Chinese Medicine Oral Rinse",[5110],{"trials":5130,"activeCount":102},[],{"trials":5132,"activeCount":102},[],{"trials":5134,"activeCount":102},[],{"intervention":5136,"totalTrials":121,"cells":5137},"CUF2",{"EARLY_PHASE1":5138,"PHASE1":5140,"PHASE2":5142,"PHASE3":5152,"PHASE4":5154,"NA":5156},{"trials":5139,"activeCount":102},[],{"trials":5141,"activeCount":102},[],{"trials":5143,"activeCount":102},[5144],{"nctId":5145,"briefTitle":5146,"status":203,"phases":5147,"primaryCompletion":5148,"completion":5148,"start":5149,"enrollment":4851,"conditions":5150,"interventions":5151},"NCT00636103","Efficacy Study of Herbal Formula CUF2 to Treat Childhood Asthma",[90,91],"2003-08","2002-07",[1819],[5136],{"trials":5153,"activeCount":102},[],{"trials":5155,"activeCount":102},[],{"trials":5157,"activeCount":102},[],{"intervention":5159,"totalTrials":121,"cells":5160},"Recombinant Epstein-Barr Virus (EBV) Vaccine",{"EARLY_PHASE1":5161,"PHASE1":5163,"PHASE2":5165,"PHASE3":5176,"PHASE4":5178,"NA":5180},{"trials":5162,"activeCount":102},[],{"trials":5164,"activeCount":102},[],{"trials":5166,"activeCount":102},[5167],{"nctId":5168,"briefTitle":5169,"status":203,"phases":5170,"primaryCompletion":5171,"completion":5171,"start":5172,"enrollment":170,"conditions":5173,"interventions":5175},"NCT01094405","Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy",[91],"2020-08-27","2010-03-31",[3646,5174],"Epstein-Barr Virus Infections",[5159],{"trials":5177,"activeCount":102},[],{"trials":5179,"activeCount":102},[],{"trials":5181,"activeCount":102},[],{"intervention":4271,"totalTrials":121,"cells":5183},{"EARLY_PHASE1":5184,"PHASE1":5186,"PHASE2":5188,"PHASE3":5194,"PHASE4":5196,"NA":5198},{"trials":5185,"activeCount":102},[],{"trials":5187,"activeCount":102},[],{"trials":5189,"activeCount":102},[5190],{"nctId":4262,"briefTitle":4263,"status":203,"phases":5191,"primaryCompletion":4265,"completion":4265,"start":4266,"enrollment":4267,"conditions":5192,"interventions":5193},[91],[4269],[4271,4239],{"trials":5195,"activeCount":102},[],{"trials":5197,"activeCount":102},[],{"trials":5199,"activeCount":102},[],{"intervention":5201,"totalTrials":121,"cells":5202},"SJC",{"EARLY_PHASE1":5203,"PHASE1":5205,"PHASE2":5207,"PHASE3":5217,"PHASE4":5219,"NA":5221},{"trials":5204,"activeCount":102},[],{"trials":5206,"activeCount":102},[],{"trials":5208,"activeCount":102},[5209],{"nctId":5210,"briefTitle":5211,"status":189,"phases":5212,"primaryCompletion":1378,"completion":1657,"start":5213,"enrollment":1379,"conditions":5214,"interventions":5216},"NCT05799391","RCT for the Efficacy of Soothing Cream Jel in Improving Upper Limb Pain and Motion",[91],"2023-07-10",[5215],"Upper Extremity Problem",[5201],{"trials":5218,"activeCount":102},[],{"trials":5220,"activeCount":102},[],{"trials":5222,"activeCount":102},[],{"intervention":5224,"totalTrials":121,"cells":5225},"SIRT Yttrium-90",{"EARLY_PHASE1":5226,"PHASE1":5228,"PHASE2":5230,"PHASE3":5241,"PHASE4":5243,"NA":5245},{"trials":5227,"activeCount":102},[],{"trials":5229,"activeCount":102},[],{"trials":5231,"activeCount":102},[5232],{"nctId":5233,"briefTitle":5234,"status":203,"phases":5235,"primaryCompletion":5123,"completion":5236,"start":5237,"enrollment":3885,"conditions":5238,"interventions":5240},"NCT02167711","Treatment for Bile Duct Cancer in the Liver",[91],"2023-02-08","2014-09-17",[5239],"Cholangio Carcinoma",[5224],{"trials":5242,"activeCount":102},[],{"trials":5244,"activeCount":102},[],{"trials":5246,"activeCount":102},[],{"intervention":5248,"totalTrials":121,"cells":5249},"Cisplatin",{"EARLY_PHASE1":5250,"PHASE1":5252,"PHASE2":5254,"PHASE3":5263,"PHASE4":5265,"NA":5267},{"trials":5251,"activeCount":102},[],{"trials":5253,"activeCount":102},[],{"trials":5255,"activeCount":102},[5256],{"nctId":5257,"briefTitle":5258,"status":2169,"phases":5259,"primaryCompletion":5260,"completion":5260,"start":2721,"enrollment":3885,"conditions":5261,"interventions":5262},"NCT02821533","Chemoembolization for Hepatocellular Carcinoma",[91],"2017-08",[33],[5248],{"trials":5264,"activeCount":102},[],{"trials":5266,"activeCount":102},[],{"trials":5268,"activeCount":102},[],{"intervention":5270,"totalTrials":121,"cells":5271},"Chinese Herb",{"EARLY_PHASE1":5272,"PHASE1":5274,"PHASE2":5276,"PHASE3":5288,"PHASE4":5290,"NA":5292},{"trials":5273,"activeCount":102},[],{"trials":5275,"activeCount":102},[],{"trials":5277,"activeCount":102},[5278],{"nctId":5279,"briefTitle":5280,"status":189,"phases":5281,"primaryCompletion":5282,"completion":5283,"start":5284,"enrollment":193,"conditions":5285,"interventions":5287},"NCT05787327","RCT for Yinqiaosan-Maxingganshitang in the Treatment of COVID-19",[91],"2024-04-30","2024-09-30","2023-05-25",[5286],"COVID-19",[5270],{"trials":5289,"activeCount":102},[],{"trials":5291,"activeCount":102},[],{"trials":5293,"activeCount":102},[],{"intervention":5295,"totalTrials":121,"cells":5296},"cetuximab-containing chemotherapy",{"EARLY_PHASE1":5297,"PHASE1":5299,"PHASE2":5301,"PHASE3":5312,"PHASE4":5314,"NA":5316},{"trials":5298,"activeCount":102},[],{"trials":5300,"activeCount":102},[],{"trials":5302,"activeCount":102},[5303],{"nctId":5304,"briefTitle":5305,"status":203,"phases":5306,"primaryCompletion":5307,"completion":5307,"start":5308,"enrollment":34,"conditions":5309,"interventions":5311},"NCT01832467","Cetuximab Rechallenge Study",[91],"2020-04-07","2013-04-24",[5310],"Metastatic Colorectal Cancer",[5295],{"trials":5313,"activeCount":102},[],{"trials":5315,"activeCount":102},[],{"trials":5317,"activeCount":102},[],{"intervention":5319,"totalTrials":121,"cells":5320},"Pegylated Interferon",{"EARLY_PHASE1":5321,"PHASE1":5323,"PHASE2":5325,"PHASE3":5335,"PHASE4":5337,"NA":5339},{"trials":5322,"activeCount":102},[],{"trials":5324,"activeCount":102},[],{"trials":5326,"activeCount":102},[5327],{"nctId":5328,"briefTitle":5329,"status":203,"phases":5330,"primaryCompletion":4258,"completion":4258,"start":5331,"enrollment":497,"conditions":5332,"interventions":5333},"NCT00226447","Different Regimens of Pegylated Interferon and Lamivudine Combination Therapy in Chronic Hepatitis B Patients",[91],"2002-12",[674],[5319,5334],"Lamivudine",{"trials":5336,"activeCount":102},[],{"trials":5338,"activeCount":102},[],{"trials":5340,"activeCount":102},[],{"intervention":5334,"totalTrials":121,"cells":5342},{"EARLY_PHASE1":5343,"PHASE1":5345,"PHASE2":5347,"PHASE3":5353,"PHASE4":5355,"NA":5357},{"trials":5344,"activeCount":102},[],{"trials":5346,"activeCount":102},[],{"trials":5348,"activeCount":102},[5349],{"nctId":5328,"briefTitle":5329,"status":203,"phases":5350,"primaryCompletion":4258,"completion":4258,"start":5331,"enrollment":497,"conditions":5351,"interventions":5352},[91],[674],[5319,5334],{"trials":5354,"activeCount":102},[],{"trials":5356,"activeCount":102},[],{"trials":5358,"activeCount":102},[],{"intervention":5360,"totalTrials":121,"cells":5361},"MK-2206",{"EARLY_PHASE1":5362,"PHASE1":5364,"PHASE2":5366,"PHASE3":5376,"PHASE4":5378,"NA":5380},{"trials":5363,"activeCount":102},[],{"trials":5365,"activeCount":102},[],{"trials":5367,"activeCount":102},[5368],{"nctId":5369,"briefTitle":5370,"status":203,"phases":5371,"primaryCompletion":3307,"completion":1699,"start":3884,"enrollment":5372,"conditions":5373,"interventions":5375},"NCT01370070","MK-2206 in Recurrent Nasopharyngeal Carcinoma",[91],12,[5374],"Recurrent Nasopharyngeal Carcinoma",[5360],{"trials":5377,"activeCount":102},[],{"trials":5379,"activeCount":102},[],{"trials":5381,"activeCount":102},[],{"intervention":5383,"totalTrials":121,"cells":5384},"Modified Huang-Lian-Jie-Du Decoction",{"EARLY_PHASE1":5385,"PHASE1":5387,"PHASE2":5389,"PHASE3":5400,"PHASE4":5402,"NA":5404},{"trials":5386,"activeCount":102},[],{"trials":5388,"activeCount":102},[],{"trials":5390,"activeCount":102},[5391],{"nctId":5392,"briefTitle":5393,"status":189,"phases":5394,"primaryCompletion":5395,"completion":5396,"start":5397,"enrollment":28,"conditions":5398,"interventions":5399},"NCT05613062","Modified Huang-Lian-Jie-Du Decoction (MHLJDD) for Atopic Dermatitis in Children",[90,91],"2023-12","2024-06","2023-04-11",[3778],[5383],{"trials":5401,"activeCount":102},[],{"trials":5403,"activeCount":102},[],{"trials":5405,"activeCount":102},[],{"intervention":5407,"totalTrials":121,"cells":5408},"4 Herbs Formula",{"EARLY_PHASE1":5409,"PHASE1":5411,"PHASE2":5413,"PHASE3":5423,"PHASE4":5425,"NA":5427},{"trials":5410,"activeCount":102},[],{"trials":5412,"activeCount":102},[],{"trials":5414,"activeCount":102},[5415],{"nctId":5416,"briefTitle":5417,"status":189,"phases":5418,"primaryCompletion":47,"completion":4893,"start":5419,"enrollment":1702,"conditions":5420,"interventions":5422},"NCT06023420","Efficacy of a Herbal Formula for Bone Metastases",[90,91],"2024-02-01",[5421],"Bone Metastases",[5407],{"trials":5424,"activeCount":102},[],{"trials":5426,"activeCount":102},[],{"trials":5428,"activeCount":102},[],{"intervention":5430,"totalTrials":121,"cells":5431},"COVID Rehab Formula granules",{"EARLY_PHASE1":5432,"PHASE1":5434,"PHASE2":5436,"PHASE3":5445,"PHASE4":5447,"NA":5449},{"trials":5433,"activeCount":102},[],{"trials":5435,"activeCount":102},[],{"trials":5437,"activeCount":102},[5438],{"nctId":5439,"briefTitle":5440,"status":189,"phases":5441,"primaryCompletion":5123,"completion":3348,"start":5442,"enrollment":2947,"conditions":5443,"interventions":5444},"NCT04924881","Chinese Medicine for Patients With LCOVID-19 Symptoms",[91],"2022-01-01",[1928],[5430],{"trials":5446,"activeCount":102},[],{"trials":5448,"activeCount":102},[],{"trials":5450,"activeCount":102},[],{"intervention":5452,"totalTrials":121,"cells":5453},"Oral TKI",{"EARLY_PHASE1":5454,"PHASE1":5456,"PHASE2":5458,"PHASE3":5471,"PHASE4":5473,"NA":5475},{"trials":5455,"activeCount":102},[],{"trials":5457,"activeCount":102},[],{"trials":5459,"activeCount":102},[5460],{"nctId":5461,"briefTitle":5462,"status":203,"phases":5463,"primaryCompletion":5464,"completion":5465,"start":5466,"enrollment":1098,"conditions":5467,"interventions":5470},"NCT01941654","ATOM_local Ablative Therapy",[91],"2017-12-31","2020-05-28","2013-09-18",[5468,5469],"NSCLC","Activating EGFR Mutation",[5452],{"trials":5472,"activeCount":102},[],{"trials":5474,"activeCount":102},[],{"trials":5476,"activeCount":102},[],{"intervention":4380,"totalTrials":121,"cells":5478},{"EARLY_PHASE1":5479,"PHASE1":5481,"PHASE2":5483,"PHASE3":5489,"PHASE4":5491,"NA":5493},{"trials":5480,"activeCount":102},[],{"trials":5482,"activeCount":102},[],{"trials":5484,"activeCount":102},[5485],{"nctId":4373,"briefTitle":4374,"status":203,"phases":5486,"primaryCompletion":4376,"completion":4376,"start":2574,"enrollment":117,"conditions":5487,"interventions":5488},[91],[4378],[4353,4380],{"trials":5490,"activeCount":102},[],{"trials":5492,"activeCount":102},[],{"trials":5494,"activeCount":102},[],{"intervention":5496,"totalTrials":121,"cells":5497},"MVA Vaccine",{"EARLY_PHASE1":5498,"PHASE1":5500,"PHASE2":5510,"PHASE3":5512,"PHASE4":5514,"NA":5516},{"trials":5499,"activeCount":102},[],{"trials":5501,"activeCount":102},[5502],{"nctId":5503,"briefTitle":5504,"status":203,"phases":5505,"primaryCompletion":2899,"completion":2899,"start":5506,"enrollment":1098,"conditions":5507,"interventions":5509},"NCT01256853","Modified Vaccinia Ankara (MVA) Vaccine Study",[90],"2006-09",[5508,5174],"Nasopharyngeal Neoplasms",[5496],{"trials":5511,"activeCount":102},[],{"trials":5513,"activeCount":102},[],{"trials":5515,"activeCount":102},[],{"trials":5517,"activeCount":102},[],{"intervention":5519,"totalTrials":121,"cells":5520},"Smart Scar Care Pad=Pressure Garment",{"EARLY_PHASE1":5521,"PHASE1":5534,"PHASE2":5536,"PHASE3":5538,"PHASE4":5540,"NA":5542},{"trials":5522,"activeCount":102},[5523],{"nctId":5524,"briefTitle":5525,"status":203,"phases":5526,"primaryCompletion":5527,"completion":5527,"start":5528,"enrollment":548,"conditions":5529,"interventions":5533},"NCT03849274","SMART Dressing for Hypertrophic Scar Treatment Post-Total Knee\u002FHip Arthroplasty",[89],"2021-07-31","2020-01-31",[5530,5531,5532],"Knee Arthropathy","Hip Arthropathy","Hypertrophic Scar",[5519],{"trials":5535,"activeCount":102},[],{"trials":5537,"activeCount":102},[],{"trials":5539,"activeCount":102},[],{"trials":5541,"activeCount":102},[],{"trials":5543,"activeCount":102},[],{"intervention":5545,"totalTrials":121,"cells":5546},"Autologous Mesenchymal Stem Cells Treatment",{"EARLY_PHASE1":5547,"PHASE1":5560,"PHASE2":5562,"PHASE3":5564,"PHASE4":5566,"NA":5568},{"trials":5548,"activeCount":102},[5549],{"nctId":5550,"briefTitle":5551,"status":203,"phases":5552,"primaryCompletion":5553,"completion":5554,"start":5555,"enrollment":28,"conditions":5556,"interventions":5558},"NCT04326985","RCT Mesenchymal Stem Cells Versus Hyaluronic Acid in OA Knee):",[89],"2019-01-30","2019-02-28","2015-01-31",[5557],"Osteoarthritis, Knee",[5545,5559],"Hyaluronic acid",{"trials":5561,"activeCount":102},[],{"trials":5563,"activeCount":102},[],{"trials":5565,"activeCount":102},[],{"trials":5567,"activeCount":102},[],{"trials":5569,"activeCount":102},[],{"intervention":5559,"totalTrials":121,"cells":5571},{"EARLY_PHASE1":5572,"PHASE1":5578,"PHASE2":5580,"PHASE3":5582,"PHASE4":5584,"NA":5586},{"trials":5573,"activeCount":102},[5574],{"nctId":5550,"briefTitle":5551,"status":203,"phases":5575,"primaryCompletion":5553,"completion":5554,"start":5555,"enrollment":28,"conditions":5576,"interventions":5577},[89],[5557],[5545,5559],{"trials":5579,"activeCount":102},[],{"trials":5581,"activeCount":102},[],{"trials":5583,"activeCount":102},[],{"trials":5585,"activeCount":102},[],{"trials":5587,"activeCount":102},[],{"intervention":5589,"totalTrials":1002,"cells":5590},"Epinephrine",{"EARLY_PHASE1":5591,"PHASE1":5593,"PHASE2":5595,"PHASE3":5597,"PHASE4":5620,"NA":5622},{"trials":5592,"activeCount":102},[],{"trials":5594,"activeCount":102},[],{"trials":5596,"activeCount":102},[],{"trials":5598,"activeCount":102},[5599,5609],{"nctId":5600,"briefTitle":5601,"status":203,"phases":5602,"primaryCompletion":3774,"completion":5123,"start":5603,"enrollment":5604,"conditions":5605,"interventions":5608},"NCT04032119","RCT of Gastric ESD With or Without Epineprhine Added Solution",[92],"2020-01-10",800,[5606,5607],"Gastric Neoplasm","Early Gastric Cancer",[5589],{"nctId":5610,"briefTitle":5611,"status":203,"phases":5612,"primaryCompletion":5613,"completion":5614,"start":5615,"enrollment":5616,"conditions":5617,"interventions":5619},"NCT02534571","To Compare a Hemostatic Powder TC-325 and Standard Treatment in the Control of Acute Upper Gastrointestinal Bleeding From Nonvariceal Causes",[92],"2019-01-14","2019-04-30","2015-09-07",224,[5618],"Acute Upper Gastrointestinal Bleeding",[5589],{"trials":5621,"activeCount":102},[],{"trials":5623,"activeCount":102},[5624],{"nctId":5625,"briefTitle":5626,"status":203,"phases":5627,"primaryCompletion":5628,"completion":5628,"start":5629,"enrollment":5630,"conditions":5631,"interventions":5633},"NCT03216395","Over-the-scope Clips and Standard Treatments in Endoscopic Control of Acute Bleeding From Non-variceal Upper GI Causes",[94],"2021-01-16","2018-01-02",191,[5618,5632],"Tumor Bleeding",[5589],{"intervention":5635,"totalTrials":1002,"cells":5636},"Chemotherapy",{"EARLY_PHASE1":5637,"PHASE1":5639,"PHASE2":5641,"PHASE3":5649,"PHASE4":5651,"NA":5653},{"trials":5638,"activeCount":102},[],{"trials":5640,"activeCount":102},[],{"trials":5642,"activeCount":102},[5643],{"nctId":5644,"briefTitle":5645,"status":203,"phases":5646,"primaryCompletion":3240,"completion":3240,"start":2245,"enrollment":548,"conditions":5647,"interventions":5648},"NCT01243047","Intermittent Versus Continuous Tarceva Study",[91],[5310],[5635],{"trials":5650,"activeCount":102},[],{"trials":5652,"activeCount":102},[],{"trials":5654,"activeCount":102},[5655,5663],{"nctId":5656,"briefTitle":5657,"status":203,"phases":5658,"primaryCompletion":5659,"completion":5659,"start":3884,"enrollment":1379,"conditions":5660,"interventions":5662},"NCT01365208","New Approach of Assessing Drug Response for Treatment of Nasopharyngeal Cancer",[],"2017-03-03",[5661],"Advanced Nasopharyngeal Carcinoma",[5635],{"nctId":5664,"briefTitle":5665,"status":203,"phases":5666,"primaryCompletion":5667,"completion":5667,"start":5668,"enrollment":117,"conditions":5669,"interventions":5671},"NCT01163305","PET-CT and Circulating Tumor Cells in Colorectal Cancer",[],"2017-04-27","2010-06-30",[24,5670],"Metastasis",[5635],{"intervention":5673,"totalTrials":98,"cells":5674},"Topiramate",{"EARLY_PHASE1":5675,"PHASE1":5677,"PHASE2":5679,"PHASE3":5681,"PHASE4":5683,"NA":5693},{"trials":5676,"activeCount":102},[],{"trials":5678,"activeCount":102},[],{"trials":5680,"activeCount":102},[],{"trials":5682,"activeCount":102},[],{"trials":5684,"activeCount":102},[5685],{"nctId":5686,"briefTitle":5687,"status":189,"phases":5688,"completion":3171,"start":5689,"enrollment":37,"conditions":5690,"interventions":5692},"NCT00153699","Relationship Between Topiramate Use and Ocular Angle Status",[93],"2004-09",[5691],"Glaucoma, Angle-Closure",[5673],{"trials":5694,"activeCount":102},[5695],{"nctId":5696,"briefTitle":5697,"status":189,"phases":5698,"primaryCompletion":2194,"completion":2321,"start":3058,"enrollment":1901,"conditions":5699,"interventions":5700},"NCT00956696","Topiramate Treatment for Patients With Epilepsy and Learning Disability : A Prospective Observational Study",[],[3131],[5701],"topiramate",{"intervention":198,"totalTrials":98,"cells":5703},{"EARLY_PHASE1":5704,"PHASE1":5706,"PHASE2":5708,"PHASE3":5710,"PHASE4":5716,"NA":5718},{"trials":5705,"activeCount":102},[],{"trials":5707,"activeCount":102},[],{"trials":5709,"activeCount":102},[],{"trials":5711,"activeCount":102},[5712],{"nctId":187,"briefTitle":188,"status":189,"phases":5713,"primaryCompletion":191,"completion":191,"start":192,"enrollment":193,"conditions":5714,"interventions":5715},[92],[195],[175,197,198,199],{"trials":5717,"activeCount":102},[],{"trials":5719,"activeCount":102},[5720],{"nctId":5721,"briefTitle":5722,"status":189,"phases":5723,"primaryCompletion":5724,"completion":5724,"start":5725,"enrollment":156,"conditions":5726,"interventions":5728},"NCT04658277","Effect of Long Term Clarithromycin for Prevention of Exacerbations in Non-cystic Fibrosis Bronchiectasis in Asian Populations",[94],"2023-09-30","2020-10-01",[5727],"Bronchiectasis Adult",[198],{"intervention":703,"totalTrials":98,"cells":5730},{"EARLY_PHASE1":5731,"PHASE1":5733,"PHASE2":5735,"PHASE3":5737,"PHASE4":5739,"NA":5745},{"trials":5732,"activeCount":102},[],{"trials":5734,"activeCount":102},[],{"trials":5736,"activeCount":102},[],{"trials":5738,"activeCount":102},[],{"trials":5740,"activeCount":102},[5741],{"nctId":2523,"briefTitle":2524,"status":203,"phases":5742,"primaryCompletion":2526,"completion":2526,"start":2130,"enrollment":156,"conditions":5743,"interventions":5744},[93],[2372],[703,2510],{"trials":5746,"activeCount":102},[5747],{"nctId":697,"briefTitle":698,"status":203,"phases":5748,"primaryCompletion":700,"completion":700,"start":205,"enrollment":156,"conditions":5749,"interventions":5750},[94],[550],[381,703],{"intervention":5752,"totalTrials":98,"cells":5753},"Metformin",{"EARLY_PHASE1":5754,"PHASE1":5756,"PHASE2":5758,"PHASE3":5760,"PHASE4":5762,"NA":5772},{"trials":5755,"activeCount":102},[],{"trials":5757,"activeCount":102},[],{"trials":5759,"activeCount":102},[],{"trials":5761,"activeCount":102},[],{"trials":5763,"activeCount":102},[5764],{"nctId":5765,"briefTitle":5766,"status":203,"phases":5767,"primaryCompletion":67,"completion":72,"start":5768,"enrollment":3885,"conditions":5769,"interventions":5771},"NCT05988684","Effect of Metformin on Carotid Atherosclerosis for Non-diabetic Patients With PsA (CAMPA Study)",[93],"2023-08-30",[5770],"PsA (Psoriatic Arthritis)",[5752],{"trials":5773,"activeCount":102},[5774],{"nctId":5775,"briefTitle":5776,"status":189,"phases":5777,"primaryCompletion":5778,"completion":5778,"start":5779,"enrollment":1841,"conditions":5780,"interventions":5781},"NCT03489317","Gut Microbiomes in Patients With Metabolic Syndrome",[],"2021-12","2017-11-27",[3173],[5752,5782,5783],"Simvastatin 10mg","Amlodipine 5mg",{"intervention":5785,"totalTrials":98,"cells":5786},"Rosuvastatin",{"EARLY_PHASE1":5787,"PHASE1":5789,"PHASE2":5791,"PHASE3":5799,"PHASE4":5801,"NA":5803},{"trials":5788,"activeCount":102},[],{"trials":5790,"activeCount":102},[],{"trials":5792,"activeCount":102},[5793],{"nctId":5794,"briefTitle":5795,"status":203,"phases":5796,"primaryCompletion":2598,"completion":2598,"start":3171,"enrollment":954,"conditions":5797,"interventions":5798},"NCT00555230","Effects of HMG-coA Reductase Inhibitor on Rheumatoid Arthritis",[91],[550],[5785],{"trials":5800,"activeCount":102},[],{"trials":5802,"activeCount":102},[],{"trials":5804,"activeCount":102},[5805],{"nctId":5806,"briefTitle":5807,"status":2253,"phases":5808,"primaryCompletion":3774,"completion":3774,"start":5809,"enrollment":102,"conditions":5810,"interventions":5812},"NCT04176978","PsA T2T Statin Trial on Carotid and Coronary Atherosclerosis",[94],"2021-04-01",[2372,5811],"Atherosclerosis",[5785],{"intervention":5814,"totalTrials":121,"cells":5815},"Erythropoiesis-Stimulating Agent",{"EARLY_PHASE1":5816,"PHASE1":5818,"PHASE2":5820,"PHASE3":5822,"PHASE4":5824,"NA":5826},{"trials":5817,"activeCount":102},[],{"trials":5819,"activeCount":102},[],{"trials":5821,"activeCount":102},[],{"trials":5823,"activeCount":102},[],{"trials":5825,"activeCount":102},[],{"trials":5827,"activeCount":102},[5828],{"nctId":5829,"briefTitle":5830,"status":203,"phases":5831,"primaryCompletion":5832,"completion":5833,"start":5834,"enrollment":4078,"conditions":5835,"interventions":5837},"NCT03427801","Effect of Erythropoiesis-Stimulating Agent Therapy in Patients Receiving Palliative Care of Chronic Kidney Disease",[],"2018-12-01","2018-12-30","2017-03-01",[5836],"Anemia of Chronic Kidney Disease",[5814],{"intervention":5839,"totalTrials":121,"cells":5840},"isoflavones",{"EARLY_PHASE1":5841,"PHASE1":5843,"PHASE2":5845,"PHASE3":5847,"PHASE4":5849,"NA":5851},{"trials":5842,"activeCount":102},[],{"trials":5844,"activeCount":102},[],{"trials":5846,"activeCount":102},[],{"trials":5848,"activeCount":102},[],{"trials":5850,"activeCount":102},[],{"trials":5852,"activeCount":102},[5853],{"nctId":5854,"briefTitle":5855,"status":203,"phases":5856,"primaryCompletion":2245,"completion":2245,"start":5857,"enrollment":5858,"conditions":5859,"interventions":5861},"NCT00861588","Effects of Isoflavone in Patients With Watchful Waiting Benign Prostate Hyperplasia",[94],"2006-02",176,[5860],"Benign Prostate Hyperplasia",[5839],{"intervention":5863,"totalTrials":121,"cells":5864},"Treat to target",{"EARLY_PHASE1":5865,"PHASE1":5867,"PHASE2":5869,"PHASE3":5871,"PHASE4":5873,"NA":5875},{"trials":5866,"activeCount":102},[],{"trials":5868,"activeCount":102},[],{"trials":5870,"activeCount":102},[],{"trials":5872,"activeCount":102},[],{"trials":5874,"activeCount":102},[],{"trials":5876,"activeCount":102},[5877],{"nctId":5878,"briefTitle":5879,"status":189,"phases":5880,"primaryCompletion":5881,"completion":5881,"start":5882,"enrollment":841,"conditions":5883,"interventions":5884},"NCT04324892","Effects of Achieving SDAI Remission on Joint Space Outcomes Progression in Early Rheumatoid Arthritis: an HR-pQCT Study",[],"2024-01-30","2020-07-12",[550],[5863],{"intervention":5886,"totalTrials":121,"cells":5887},"PEANUT OIT: Peanut Flour (50% peanut protein) that is prepared under food manufacturing regulations",{"EARLY_PHASE1":5888,"PHASE1":5890,"PHASE2":5892,"PHASE3":5894,"PHASE4":5896,"NA":5898},{"trials":5889,"activeCount":102},[],{"trials":5891,"activeCount":102},[],{"trials":5893,"activeCount":102},[],{"trials":5895,"activeCount":102},[],{"trials":5897,"activeCount":102},[],{"trials":5899,"activeCount":102},[5900],{"nctId":5901,"briefTitle":5902,"status":189,"phases":5903,"primaryCompletion":5283,"completion":47,"start":5904,"enrollment":4851,"conditions":5905,"interventions":5908},"NCT05165329","A Randomized, Controlled Trial of Probiotic and Peanut Oral Immunotherapy (PPOIT) in Inducing Tolerance in Hong Kong Children With Peanut Allergy Compared With Oral Immunotherapy (OIT) Alone and With Placebo",[94],"2021-11-11",[5906,5907],"Peanut Allergy","Food Allergy in Children",[5886,5886,5909],"PEANUT PLACEBO: Peanut Placebo is maltodextrin powder with food colouring and peanut essence that has similar appearance, taste and smell to the active product.",{"intervention":5909,"totalTrials":121,"cells":5911},{"EARLY_PHASE1":5912,"PHASE1":5914,"PHASE2":5916,"PHASE3":5918,"PHASE4":5920,"NA":5922},{"trials":5913,"activeCount":102},[],{"trials":5915,"activeCount":102},[],{"trials":5917,"activeCount":102},[],{"trials":5919,"activeCount":102},[],{"trials":5921,"activeCount":102},[],{"trials":5923,"activeCount":102},[5924],{"nctId":5901,"briefTitle":5902,"status":189,"phases":5925,"primaryCompletion":5283,"completion":47,"start":5904,"enrollment":4851,"conditions":5926,"interventions":5927},[94],[5906,5907],[5886,5886,5909],{"intervention":5929,"totalTrials":121,"cells":5930},"Tenofovir Disoproxil Fumarate 300 mg \u002F emtricitabine 200 mg",{"EARLY_PHASE1":5931,"PHASE1":5933,"PHASE2":5935,"PHASE3":5937,"PHASE4":5939,"NA":5941},{"trials":5932,"activeCount":102},[],{"trials":5934,"activeCount":102},[],{"trials":5936,"activeCount":102},[],{"trials":5938,"activeCount":102},[],{"trials":5940,"activeCount":102},[],{"trials":5942,"activeCount":102},[5943],{"nctId":5944,"briefTitle":5945,"status":203,"phases":5946,"primaryCompletion":5724,"completion":5947,"start":5948,"enrollment":5949,"conditions":5950,"interventions":5952},"NCT04367688","HIV Pre-exposure Prophylaxis Implementation Hong Kong Study",[],"2024-01-31","2020-03-01",339,[5951],"HIV Infections",[5929],{"intervention":5954,"totalTrials":121,"cells":5955},"Hydrotherapy",{"EARLY_PHASE1":5956,"PHASE1":5958,"PHASE2":5960,"PHASE3":5962,"PHASE4":5964,"NA":5966},{"trials":5957,"activeCount":102},[],{"trials":5959,"activeCount":102},[],{"trials":5961,"activeCount":102},[],{"trials":5963,"activeCount":102},[],{"trials":5965,"activeCount":102},[],{"trials":5967,"activeCount":102},[5968],{"nctId":5969,"briefTitle":5970,"status":203,"phases":5971,"primaryCompletion":5972,"completion":5972,"start":5973,"enrollment":2947,"conditions":5974,"interventions":5975},"NCT06459960","Effect of Hydrotherapy After Unilateral UKA",[94],"2021-12-15","2020-12-15",[5557],[5954,5976],"Convention",{"intervention":5976,"totalTrials":121,"cells":5978},{"EARLY_PHASE1":5979,"PHASE1":5981,"PHASE2":5983,"PHASE3":5985,"PHASE4":5987,"NA":5989},{"trials":5980,"activeCount":102},[],{"trials":5982,"activeCount":102},[],{"trials":5984,"activeCount":102},[],{"trials":5986,"activeCount":102},[],{"trials":5988,"activeCount":102},[],{"trials":5990,"activeCount":102},[5991],{"nctId":5969,"briefTitle":5970,"status":203,"phases":5992,"primaryCompletion":5972,"completion":5972,"start":5973,"enrollment":2947,"conditions":5993,"interventions":5994},[94],[5557],[5954,5976],{"intervention":5996,"totalTrials":121,"cells":5997},"Physiotherapy",{"EARLY_PHASE1":5998,"PHASE1":6000,"PHASE2":6002,"PHASE3":6004,"PHASE4":6006,"NA":6008},{"trials":5999,"activeCount":102},[],{"trials":6001,"activeCount":102},[],{"trials":6003,"activeCount":102},[],{"trials":6005,"activeCount":102},[],{"trials":6007,"activeCount":102},[],{"trials":6009,"activeCount":102},[6010],{"nctId":6011,"briefTitle":6012,"status":189,"phases":6013,"primaryCompletion":47,"completion":47,"start":5528,"enrollment":1901,"conditions":6014,"interventions":6015},"NCT03880344","Investigating the Effectiveness of Vibration Therapy on Sarcopenia in Osteoarthritis Knee Patients",[94],[5530,5557,1672],[5996],{"intervention":6017,"totalTrials":121,"cells":6018},"Topical eye drops",{"EARLY_PHASE1":6019,"PHASE1":6021,"PHASE2":6023,"PHASE3":6025,"PHASE4":6027,"NA":6029},{"trials":6020,"activeCount":102},[],{"trials":6022,"activeCount":102},[],{"trials":6024,"activeCount":102},[],{"trials":6026,"activeCount":102},[],{"trials":6028,"activeCount":102},[],{"trials":6030,"activeCount":102},[6031],{"nctId":6032,"briefTitle":6033,"status":203,"phases":6034,"primaryCompletion":42,"completion":6035,"start":6036,"enrollment":6037,"conditions":6038,"interventions":6040},"NCT05577910","Vectored Thermal Pulsation, Intense Pulsed Light, and Eyelid Warm Compress Therapies for MGD",[94],"2025-01-26","2022-10-08",374,[6039],"Meibomian Gland Dysfunction",[6017],{"intervention":6042,"totalTrials":121,"cells":6043},"Nirmatrelvir\u002Fritonavir",{"EARLY_PHASE1":6044,"PHASE1":6046,"PHASE2":6048,"PHASE3":6050,"PHASE4":6052,"NA":6054},{"trials":6045,"activeCount":102},[],{"trials":6047,"activeCount":102},[],{"trials":6049,"activeCount":102},[],{"trials":6051,"activeCount":102},[],{"trials":6053,"activeCount":102},[],{"trials":6055,"activeCount":102},[6056],{"nctId":6057,"briefTitle":6058,"status":203,"phases":6059,"primaryCompletion":5123,"completion":6060,"start":6061,"enrollment":6062,"conditions":6063,"interventions":6066},"NCT05624840","Safety and Clinical and Virologic Outcomes in CKD Patients Treated With Nirmatrelvir-ritonavir",[],"2023-02-01","2022-11-07",85,[5286,6064,6065],"Chronic Kidney Disease stage4","Chronc Kidney Disease Stage 5",[6042],{"intervention":6068,"totalTrials":121,"cells":6069},"Furosemide",{"EARLY_PHASE1":6070,"PHASE1":6072,"PHASE2":6074,"PHASE3":6076,"PHASE4":6078,"NA":6080},{"trials":6071,"activeCount":102},[],{"trials":6073,"activeCount":102},[],{"trials":6075,"activeCount":102},[],{"trials":6077,"activeCount":102},[],{"trials":6079,"activeCount":102},[],{"trials":6081,"activeCount":102},[6082],{"nctId":6083,"briefTitle":6084,"status":2253,"phases":6085,"primaryCompletion":5778,"completion":6086,"start":1699,"enrollment":102,"conditions":6087,"interventions":6089},"NCT02649998","Short-term Efficacy of Furosemide, Isosorbide Dinitrate and Their Combination in ADHF",[94],"2022-06",[6088],"Heart Decompensation",[6068,6090],"Isosorbide Dinitrate",{"intervention":6090,"totalTrials":121,"cells":6092},{"EARLY_PHASE1":6093,"PHASE1":6095,"PHASE2":6097,"PHASE3":6099,"PHASE4":6101,"NA":6103},{"trials":6094,"activeCount":102},[],{"trials":6096,"activeCount":102},[],{"trials":6098,"activeCount":102},[],{"trials":6100,"activeCount":102},[],{"trials":6102,"activeCount":102},[],{"trials":6104,"activeCount":102},[6105],{"nctId":6083,"briefTitle":6084,"status":2253,"phases":6106,"primaryCompletion":5778,"completion":6086,"start":1699,"enrollment":102,"conditions":6107,"interventions":6108},[94],[6088],[6068,6090],{"intervention":6110,"totalTrials":121,"cells":6111},"Darbepoetin alfa",{"EARLY_PHASE1":6112,"PHASE1":6114,"PHASE2":6116,"PHASE3":6118,"PHASE4":6120,"NA":6122},{"trials":6113,"activeCount":102},[],{"trials":6115,"activeCount":102},[],{"trials":6117,"activeCount":102},[],{"trials":6119,"activeCount":102},[],{"trials":6121,"activeCount":102},[],{"trials":6123,"activeCount":102},[6124],{"nctId":6125,"briefTitle":6126,"status":2169,"phases":6127,"primaryCompletion":3058,"completion":3058,"start":2921,"enrollment":3525,"conditions":6128,"interventions":6130},"NCT00907608","A Proof-of-Concept Study of Darbepoetin Alfa in Partial Correction of Anemia in Chinese With Diabetic Nephropathy",[94],[1118,3222,6129],"Anemia",[6110],{"intervention":6132,"totalTrials":121,"cells":6133},"USG ESPB",{"EARLY_PHASE1":6134,"PHASE1":6136,"PHASE2":6138,"PHASE3":6140,"PHASE4":6142,"NA":6144},{"trials":6135,"activeCount":102},[],{"trials":6137,"activeCount":102},[],{"trials":6139,"activeCount":102},[],{"trials":6141,"activeCount":102},[],{"trials":6143,"activeCount":102},[],{"trials":6145,"activeCount":102},[6146],{"nctId":6147,"briefTitle":6148,"status":203,"phases":6149,"primaryCompletion":6150,"completion":6151,"start":4592,"enrollment":11,"conditions":6152,"interventions":6154},"NCT06490718","Comparing Quality of Recovery Between ESPB and IV Lidocaine After Major Breast Cancer Surgery",[94],"2025-07-17","2025-07-20",[6153],"Breast Neoplasms",[6132,6155],"Intravenous",{"intervention":6155,"totalTrials":121,"cells":6157},{"EARLY_PHASE1":6158,"PHASE1":6160,"PHASE2":6162,"PHASE3":6164,"PHASE4":6166,"NA":6168},{"trials":6159,"activeCount":102},[],{"trials":6161,"activeCount":102},[],{"trials":6163,"activeCount":102},[],{"trials":6165,"activeCount":102},[],{"trials":6167,"activeCount":102},[],{"trials":6169,"activeCount":102},[6170],{"nctId":6147,"briefTitle":6148,"status":203,"phases":6171,"primaryCompletion":6150,"completion":6151,"start":4592,"enrollment":11,"conditions":6172,"interventions":6173},[94],[6153],[6132,6155],{"intervention":6175,"totalTrials":121,"cells":6176},"Du-Huo-Ji-Sheng-Tang",{"EARLY_PHASE1":6177,"PHASE1":6179,"PHASE2":6181,"PHASE3":6183,"PHASE4":6185,"NA":6187},{"trials":6178,"activeCount":102},[],{"trials":6180,"activeCount":102},[],{"trials":6182,"activeCount":102},[],{"trials":6184,"activeCount":102},[],{"trials":6186,"activeCount":102},[],{"trials":6188,"activeCount":102},[6189],{"nctId":6190,"briefTitle":6191,"status":189,"phases":6192,"primaryCompletion":4427,"completion":6193,"start":6194,"enrollment":1379,"conditions":6195,"interventions":6196},"NCT04492670","Tui-na and Oral Chinese Medicine on KOA",[94],"2023-03","2020-09-14",[1672],[6175],{"intervention":6198,"totalTrials":121,"cells":6199},"routine blood test for hs-cTnT",{"EARLY_PHASE1":6200,"PHASE1":6202,"PHASE2":6204,"PHASE3":6206,"PHASE4":6208,"NA":6210},{"trials":6201,"activeCount":102},[],{"trials":6203,"activeCount":102},[],{"trials":6205,"activeCount":102},[],{"trials":6207,"activeCount":102},[],{"trials":6209,"activeCount":102},[],{"trials":6211,"activeCount":102},[6212],{"nctId":6213,"briefTitle":6214,"status":203,"phases":6215,"primaryCompletion":6216,"completion":6216,"start":6217,"enrollment":6218,"conditions":6219,"interventions":6221},"NCT02364271","Early Risk Stratification in ED Chest Pain Patients",[],"2014-10","2013-03",602,[6220],"Acute Coronary Syndrome",[6198],{"intervention":6223,"totalTrials":121,"cells":6224},"Lepicol probiotic & prebiotic formula",{"EARLY_PHASE1":6225,"PHASE1":6227,"PHASE2":6229,"PHASE3":6231,"PHASE4":6233,"NA":6235},{"trials":6226,"activeCount":102},[],{"trials":6228,"activeCount":102},[],{"trials":6230,"activeCount":102},[],{"trials":6232,"activeCount":102},[],{"trials":6234,"activeCount":102},[],{"trials":6236,"activeCount":102},[6237],{"nctId":6238,"briefTitle":6239,"status":203,"phases":6240,"primaryCompletion":6241,"completion":6241,"start":6242,"enrollment":28,"conditions":6243,"interventions":6245},"NCT00870012","Treatment of Nonalcoholic Fatty Liver Disease With Probiotics and Prebiotics",[94],"2012-01","2009-02",[6244],"Nonalcoholic Fatty Liver Disease",[6223],{"intervention":6247,"totalTrials":121,"cells":6248},"Dapagliflozin",{"EARLY_PHASE1":6249,"PHASE1":6251,"PHASE2":6253,"PHASE3":6255,"PHASE4":6257,"NA":6259},{"trials":6250,"activeCount":102},[],{"trials":6252,"activeCount":102},[],{"trials":6254,"activeCount":102},[],{"trials":6256,"activeCount":102},[],{"trials":6258,"activeCount":102},[],{"trials":6260,"activeCount":102},[6261],{"nctId":6262,"briefTitle":6263,"status":189,"phases":6264,"primaryCompletion":6265,"completion":6266,"start":6267,"enrollment":996,"conditions":6268,"interventions":6270},"NCT05759000","Dapa Acute Heart Failure Study",[],"2025-09-09","2025-12-09","2023-04-09",[6269],"Heart Failure",[6247],{"intervention":6272,"totalTrials":121,"cells":6273},"Mesalazine",{"EARLY_PHASE1":6274,"PHASE1":6276,"PHASE2":6278,"PHASE3":6280,"PHASE4":6282,"NA":6284},{"trials":6275,"activeCount":102},[],{"trials":6277,"activeCount":102},[],{"trials":6279,"activeCount":102},[],{"trials":6281,"activeCount":102},[],{"trials":6283,"activeCount":102},[],{"trials":6285,"activeCount":102},[6286],{"nctId":6287,"briefTitle":6288,"status":203,"phases":6289,"primaryCompletion":6290,"completion":6290,"start":6291,"enrollment":6292,"conditions":6293,"interventions":6296},"NCT02537210","Aminosalicylic Acid Withdrawal Study in Long Standing Inactive Ulcerative Colitis",[94],"2021-09-10","2015-09",177,[6294,6295],"Colitis, Ulcerative","Aminosalicylic Acid",[6272],{"intervention":6298,"totalTrials":121,"cells":6299},"Atorvastatin",{"EARLY_PHASE1":6300,"PHASE1":6302,"PHASE2":6304,"PHASE3":6306,"PHASE4":6308,"NA":6310},{"trials":6301,"activeCount":102},[],{"trials":6303,"activeCount":102},[],{"trials":6305,"activeCount":102},[],{"trials":6307,"activeCount":102},[],{"trials":6309,"activeCount":102},[],{"trials":6311,"activeCount":102},[6312],{"nctId":6313,"briefTitle":6314,"status":2253,"phases":6315,"primaryCompletion":6316,"completion":1097,"start":6317,"enrollment":102,"conditions":6318,"interventions":6320},"NCT03625089","Impact of Nurse-led Programme With Carotid Ultrasound on Addressing Cardiovascular Risk in Patients With Arthritis",[94],"2020-06-30","2018-09-01",[3244,6319],"Arthritis, Psoriatic",[6298],{"intervention":6322,"totalTrials":121,"cells":6323},"opioids titration",{"EARLY_PHASE1":6324,"PHASE1":6326,"PHASE2":6328,"PHASE3":6330,"PHASE4":6332,"NA":6334},{"trials":6325,"activeCount":102},[],{"trials":6327,"activeCount":102},[],{"trials":6329,"activeCount":102},[],{"trials":6331,"activeCount":102},[],{"trials":6333,"activeCount":102},[],{"trials":6335,"activeCount":102},[6336],{"nctId":6337,"briefTitle":6338,"status":203,"phases":6339,"primaryCompletion":6340,"completion":6340,"start":6341,"enrollment":98,"conditions":6342,"interventions":6344},"NCT03024515","Opioids Titration Study in Advanced Cancer Patients in Hong Kong",[94],"2020-12-07","2018-08-23",[6343],"Pain Control",[6322,6345],"predefined titration steps",{"intervention":6345,"totalTrials":121,"cells":6347},{"EARLY_PHASE1":6348,"PHASE1":6350,"PHASE2":6352,"PHASE3":6354,"PHASE4":6356,"NA":6358},{"trials":6349,"activeCount":102},[],{"trials":6351,"activeCount":102},[],{"trials":6353,"activeCount":102},[],{"trials":6355,"activeCount":102},[],{"trials":6357,"activeCount":102},[],{"trials":6359,"activeCount":102},[6360],{"nctId":6337,"briefTitle":6338,"status":203,"phases":6361,"primaryCompletion":6340,"completion":6340,"start":6341,"enrollment":98,"conditions":6362,"interventions":6363},[94],[6343],[6322,6345],{"intervention":6365,"totalTrials":121,"cells":6366},"TCM ultrasonic atomization treatment with herbal Compound Decoction",{"EARLY_PHASE1":6367,"PHASE1":6369,"PHASE2":6371,"PHASE3":6373,"PHASE4":6375,"NA":6377},{"trials":6368,"activeCount":102},[],{"trials":6370,"activeCount":102},[],{"trials":6372,"activeCount":102},[],{"trials":6374,"activeCount":102},[],{"trials":6376,"activeCount":102},[],{"trials":6378,"activeCount":102},[6379],{"nctId":6380,"briefTitle":6381,"status":203,"phases":6382,"primaryCompletion":6383,"completion":6383,"start":6384,"enrollment":1075,"conditions":6385,"interventions":6387},"NCT06089317","Traditional Chinese Medicine Ultrasonic Atomization Treatment for Dry Eye Disease",[94],"2025-06-22","2024-07-28",[6386],"Dry Eye Syndromes",[6365,6388,6389,6390],"TCM ultrasonic atomization treatment with Dendrobii Caulis","TCM ultrasonic atomization treatment with Houttuynia Cordata","Artificial Tears",{"intervention":6388,"totalTrials":121,"cells":6392},{"EARLY_PHASE1":6393,"PHASE1":6395,"PHASE2":6397,"PHASE3":6399,"PHASE4":6401,"NA":6403},{"trials":6394,"activeCount":102},[],{"trials":6396,"activeCount":102},[],{"trials":6398,"activeCount":102},[],{"trials":6400,"activeCount":102},[],{"trials":6402,"activeCount":102},[],{"trials":6404,"activeCount":102},[6405],{"nctId":6380,"briefTitle":6381,"status":203,"phases":6406,"primaryCompletion":6383,"completion":6383,"start":6384,"enrollment":1075,"conditions":6407,"interventions":6408},[94],[6386],[6365,6388,6389,6390],{"intervention":6389,"totalTrials":121,"cells":6410},{"EARLY_PHASE1":6411,"PHASE1":6413,"PHASE2":6415,"PHASE3":6417,"PHASE4":6419,"NA":6421},{"trials":6412,"activeCount":102},[],{"trials":6414,"activeCount":102},[],{"trials":6416,"activeCount":102},[],{"trials":6418,"activeCount":102},[],{"trials":6420,"activeCount":102},[],{"trials":6422,"activeCount":102},[6423],{"nctId":6380,"briefTitle":6381,"status":203,"phases":6424,"primaryCompletion":6383,"completion":6383,"start":6384,"enrollment":1075,"conditions":6425,"interventions":6426},[94],[6386],[6365,6388,6389,6390],{"intervention":6390,"totalTrials":121,"cells":6428},{"EARLY_PHASE1":6429,"PHASE1":6431,"PHASE2":6433,"PHASE3":6435,"PHASE4":6437,"NA":6439},{"trials":6430,"activeCount":102},[],{"trials":6432,"activeCount":102},[],{"trials":6434,"activeCount":102},[],{"trials":6436,"activeCount":102},[],{"trials":6438,"activeCount":102},[],{"trials":6440,"activeCount":102},[6441],{"nctId":6380,"briefTitle":6381,"status":203,"phases":6442,"primaryCompletion":6383,"completion":6383,"start":6384,"enrollment":1075,"conditions":6443,"interventions":6444},[94],[6386],[6365,6388,6389,6390],{"intervention":6446,"totalTrials":121,"cells":6447},"Telbivudine",{"EARLY_PHASE1":6448,"PHASE1":6450,"PHASE2":6452,"PHASE3":6454,"PHASE4":6456,"NA":6458},{"trials":6449,"activeCount":102},[],{"trials":6451,"activeCount":102},[],{"trials":6453,"activeCount":102},[],{"trials":6455,"activeCount":102},[],{"trials":6457,"activeCount":102},[],{"trials":6459,"activeCount":102},[6460],{"nctId":6461,"briefTitle":6462,"status":2253,"phases":6463,"primaryCompletion":3241,"completion":3241,"start":3280,"enrollment":102,"conditions":6464,"interventions":6465},"NCT02049736","Effect of Telbivudine on Renal Function and Proteinuria in Patients With CHB & Chronic Renal Diseases",[94],[674],[6446],{"intervention":6467,"totalTrials":121,"cells":6468},"Vancomycin",{"EARLY_PHASE1":6469,"PHASE1":6471,"PHASE2":6473,"PHASE3":6475,"PHASE4":6477,"NA":6479},{"trials":6470,"activeCount":102},[],{"trials":6472,"activeCount":102},[],{"trials":6474,"activeCount":102},[],{"trials":6476,"activeCount":102},[],{"trials":6478,"activeCount":102},[],{"trials":6480,"activeCount":102},[6481],{"nctId":6482,"briefTitle":6483,"status":189,"phases":6484,"primaryCompletion":6485,"completion":6486,"start":6487,"enrollment":497,"conditions":6488,"interventions":6490},"NCT02570477","FMT for Moderate to Severe CDI: A Randomised Study With Concurrent Stool Microbiota Assessment",[94],"2018-01","2024-12","2015-01",[6489],"Clostridium Difficile Infection",[6467],{"intervention":6492,"totalTrials":121,"cells":6493},"75 mg acetylsalicylic acid",{"EARLY_PHASE1":6494,"PHASE1":6496,"PHASE2":6498,"PHASE3":6500,"PHASE4":6502,"NA":6504},{"trials":6495,"activeCount":102},[],{"trials":6497,"activeCount":102},[],{"trials":6499,"activeCount":102},[],{"trials":6501,"activeCount":102},[],{"trials":6503,"activeCount":102},[],{"trials":6505,"activeCount":102},[6506],{"nctId":6507,"briefTitle":6508,"status":189,"phases":6509,"primaryCompletion":4893,"completion":1666,"start":6510,"enrollment":6511,"conditions":6512,"interventions":6514},"NCT05580523","Aspirin Versus Metformin in Pregnancies at High Risk of Preterm Preeclampsia: a 3-arm Randomized Controlled Trial",[94],"2023-07-03",3000,[6513],"Preeclampsia",[6492,6515,6516],"1.5g Metformin","150 mg acetylsalicylic acid",{"intervention":6515,"totalTrials":121,"cells":6518},{"EARLY_PHASE1":6519,"PHASE1":6521,"PHASE2":6523,"PHASE3":6525,"PHASE4":6527,"NA":6529},{"trials":6520,"activeCount":102},[],{"trials":6522,"activeCount":102},[],{"trials":6524,"activeCount":102},[],{"trials":6526,"activeCount":102},[],{"trials":6528,"activeCount":102},[],{"trials":6530,"activeCount":102},[6531],{"nctId":6507,"briefTitle":6508,"status":189,"phases":6532,"primaryCompletion":4893,"completion":1666,"start":6510,"enrollment":6511,"conditions":6533,"interventions":6534},[94],[6513],[6492,6515,6516],{"intervention":6516,"totalTrials":121,"cells":6536},{"EARLY_PHASE1":6537,"PHASE1":6539,"PHASE2":6541,"PHASE3":6543,"PHASE4":6545,"NA":6547},{"trials":6538,"activeCount":102},[],{"trials":6540,"activeCount":102},[],{"trials":6542,"activeCount":102},[],{"trials":6544,"activeCount":102},[],{"trials":6546,"activeCount":102},[],{"trials":6548,"activeCount":102},[6549],{"nctId":6507,"briefTitle":6508,"status":189,"phases":6550,"primaryCompletion":4893,"completion":1666,"start":6510,"enrollment":6511,"conditions":6551,"interventions":6552},[94],[6513],[6492,6515,6516],{"intervention":6554,"totalTrials":121,"cells":6555},"Buscopan 20 milligrams\u002FML Injectable Solution",{"EARLY_PHASE1":6556,"PHASE1":6558,"PHASE2":6560,"PHASE3":6562,"PHASE4":6564,"NA":6566},{"trials":6557,"activeCount":102},[],{"trials":6559,"activeCount":102},[],{"trials":6561,"activeCount":102},[],{"trials":6563,"activeCount":102},[],{"trials":6565,"activeCount":102},[],{"trials":6567,"activeCount":102},[6568],{"nctId":6569,"briefTitle":6570,"status":189,"phases":6571,"primaryCompletion":5282,"completion":6572,"start":6573,"enrollment":6574,"conditions":6575,"interventions":6578},"NCT04751084","Buscopan in Patients Undergoing IVF\u002FIntracytoplasmic Sperm Injection Treatment",[94],"2024-09-14","2020-05-30",675,[6576,6577],"IVF","Intracytoplasmic Sperm Injection",[6554],{"intervention":6580,"totalTrials":121,"cells":6581},"Phyllanthus urinaria",{"EARLY_PHASE1":6582,"PHASE1":6584,"PHASE2":6586,"PHASE3":6588,"PHASE4":6590,"NA":6592},{"trials":6583,"activeCount":102},[],{"trials":6585,"activeCount":102},[],{"trials":6587,"activeCount":102},[],{"trials":6589,"activeCount":102},[],{"trials":6591,"activeCount":102},[],{"trials":6593,"activeCount":102},[6594],{"nctId":6595,"briefTitle":6596,"status":203,"phases":6597,"primaryCompletion":6598,"completion":6598,"start":6599,"enrollment":548,"conditions":6600,"interventions":6601},"NCT01210989","Trial of Hepaguard® in Adults With Nonalcoholic Steatohepatitis",[94],"2012-05","2010-05",[6244],[6580],{"intervention":6603,"totalTrials":121,"cells":6604},"Organoid culture",{"EARLY_PHASE1":6605,"PHASE1":6607,"PHASE2":6609,"PHASE3":6611,"PHASE4":6613,"NA":6615},{"trials":6606,"activeCount":102},[],{"trials":6608,"activeCount":102},[],{"trials":6610,"activeCount":102},[],{"trials":6612,"activeCount":102},[],{"trials":6614,"activeCount":102},[],{"trials":6616,"activeCount":102},[6617],{"nctId":6618,"briefTitle":6619,"status":203,"phases":6620,"primaryCompletion":6621,"completion":6621,"start":6622,"enrollment":28,"conditions":6623,"interventions":6625},"NCT04342286","To Establish a Reproducible Organoid Culture Model With Human Kidney Cancer",[],"2021-02-22","2020-05-01",[6624],"Kidney Cancer",[6603],{"intervention":5782,"totalTrials":121,"cells":6627},{"EARLY_PHASE1":6628,"PHASE1":6630,"PHASE2":6632,"PHASE3":6634,"PHASE4":6636,"NA":6638},{"trials":6629,"activeCount":102},[],{"trials":6631,"activeCount":102},[],{"trials":6633,"activeCount":102},[],{"trials":6635,"activeCount":102},[],{"trials":6637,"activeCount":102},[],{"trials":6639,"activeCount":102},[6640],{"nctId":5775,"briefTitle":5776,"status":189,"phases":6641,"primaryCompletion":5778,"completion":5778,"start":5779,"enrollment":1841,"conditions":6642,"interventions":6643},[],[3173],[5752,5782,5783],{"intervention":5783,"totalTrials":121,"cells":6645},{"EARLY_PHASE1":6646,"PHASE1":6648,"PHASE2":6650,"PHASE3":6652,"PHASE4":6654,"NA":6656},{"trials":6647,"activeCount":102},[],{"trials":6649,"activeCount":102},[],{"trials":6651,"activeCount":102},[],{"trials":6653,"activeCount":102},[],{"trials":6655,"activeCount":102},[],{"trials":6657,"activeCount":102},[6658],{"nctId":5775,"briefTitle":5776,"status":189,"phases":6659,"primaryCompletion":5778,"completion":5778,"start":5779,"enrollment":1841,"conditions":6660,"interventions":6661},[],[3173],[5752,5782,5783],{"intervention":6663,"totalTrials":121,"cells":6664},"a 1: 1 mixture of 2% lidocaine with 5ug\u002Fml epinephrine and 0.5% levobupivacaine",{"EARLY_PHASE1":6665,"PHASE1":6667,"PHASE2":6669,"PHASE3":6671,"PHASE4":6673,"NA":6675},{"trials":6666,"activeCount":102},[],{"trials":6668,"activeCount":102},[],{"trials":6670,"activeCount":102},[],{"trials":6672,"activeCount":102},[],{"trials":6674,"activeCount":102},[],{"trials":6676,"activeCount":102},[6677],{"nctId":6678,"briefTitle":6679,"status":203,"phases":6680,"primaryCompletion":6681,"completion":6682,"start":6683,"enrollment":170,"conditions":6684,"interventions":6685},"NCT04773405","Minimum Effective Volume for Selective Trunk Block",[94],"2021-11-12","2021-11-17","2021-03-10",[158],[6663],{"intervention":6687,"totalTrials":121,"cells":6688},"Perampanel",{"EARLY_PHASE1":6689,"PHASE1":6691,"PHASE2":6693,"PHASE3":6695,"PHASE4":6697,"NA":6699},{"trials":6690,"activeCount":102},[],{"trials":6692,"activeCount":102},[],{"trials":6694,"activeCount":102},[],{"trials":6696,"activeCount":102},[],{"trials":6698,"activeCount":102},[],{"trials":6700,"activeCount":102},[6701],{"nctId":6702,"briefTitle":6703,"status":189,"phases":6704,"primaryCompletion":6705,"completion":6705,"start":6706,"enrollment":11,"conditions":6707,"interventions":6711},"NCT03457961","Post-market Study of AMPA Receptor Antagonists for Epilepsy Patients in Hong Kong",[],"2021-07-01","2016-07-23",[6708,6709,6710],"Focal Epilepsy","Generalized Epilepsy","Partial Seizures, Simple",[6687],{"intervention":6713,"totalTrials":121,"cells":6714},"Rosuvastatin 10mg",{"EARLY_PHASE1":6715,"PHASE1":6717,"PHASE2":6719,"PHASE3":6721,"PHASE4":6723,"NA":6725},{"trials":6716,"activeCount":102},[],{"trials":6718,"activeCount":102},[],{"trials":6720,"activeCount":102},[],{"trials":6722,"activeCount":102},[],{"trials":6724,"activeCount":102},[],{"trials":6726,"activeCount":102},[6727],{"nctId":6728,"briefTitle":6729,"status":203,"phases":6730,"primaryCompletion":6731,"completion":6731,"start":3306,"enrollment":6732,"conditions":6733,"interventions":6734},"NCT04921657","Genome-wide Analysis of Lipid-lowering Efficacy and Drug Level of Simvastatin and Rosuvastatin",[],"2021-08",362,[1381],[6713],{"intervention":6736,"totalTrials":121,"cells":6737},"Aspirin and Pantoloc",{"EARLY_PHASE1":6738,"PHASE1":6740,"PHASE2":6742,"PHASE3":6744,"PHASE4":6746,"NA":6748},{"trials":6739,"activeCount":102},[],{"trials":6741,"activeCount":102},[],{"trials":6743,"activeCount":102},[],{"trials":6745,"activeCount":102},[],{"trials":6747,"activeCount":102},[],{"trials":6749,"activeCount":102},[6750],{"nctId":6751,"briefTitle":6752,"status":203,"phases":6753,"completion":5506,"start":4342,"enrollment":6754,"conditions":6755,"interventions":6757},"NCT00153725","Intravenous Pantoloc In Aspirin-Induced Ulcer Bleeding",[94],156,[6756,3313],"Cardiovascular Disease",[6736],{"intervention":6759,"totalTrials":121,"cells":6760},"NTM drug treatment",{"EARLY_PHASE1":6761,"PHASE1":6763,"PHASE2":6765,"PHASE3":6767,"PHASE4":6769,"NA":6771},{"trials":6762,"activeCount":102},[],{"trials":6764,"activeCount":102},[],{"trials":6766,"activeCount":102},[],{"trials":6768,"activeCount":102},[],{"trials":6770,"activeCount":102},[],{"trials":6772,"activeCount":102},[6773],{"nctId":6774,"briefTitle":6775,"status":189,"phases":6776,"primaryCompletion":4726,"completion":6777,"start":6778,"enrollment":1901,"conditions":6779,"interventions":6781},"NCT04463134","An Observational Study on Patients With NTM Pulmonary Disease",[],"2023-07-31","2020-08-01",[6780],"Clinical Outcomes",[6759],{"intervention":6783,"totalTrials":121,"cells":6784},"Baclofen, Diltiazem",{"EARLY_PHASE1":6785,"PHASE1":6787,"PHASE2":6789,"PHASE3":6791,"PHASE4":6793,"NA":6795},{"trials":6786,"activeCount":102},[],{"trials":6788,"activeCount":102},[],{"trials":6790,"activeCount":102},[],{"trials":6792,"activeCount":102},[],{"trials":6794,"activeCount":102},[],{"trials":6796,"activeCount":102},[6797],{"nctId":6798,"briefTitle":6799,"status":2169,"phases":6800,"completion":2346,"start":3129,"enrollment":548,"conditions":6801,"interventions":6803},"NCT00164801","Effect of GABAB Agonist on Visceral Hyperalgesia in NCCP patientsChinese?",[94],[6802],"Non-Cardiac Chest Pain",[6783],{"intervention":1706,"totalTrials":121,"cells":6805},{"EARLY_PHASE1":6806,"PHASE1":6808,"PHASE2":6810,"PHASE3":6812,"PHASE4":6814,"NA":6816},{"trials":6807,"activeCount":102},[],{"trials":6809,"activeCount":102},[],{"trials":6811,"activeCount":102},[],{"trials":6813,"activeCount":102},[],{"trials":6815,"activeCount":102},[],{"trials":6817,"activeCount":102},[6818],{"nctId":1696,"briefTitle":1697,"status":203,"phases":6819,"primaryCompletion":1699,"completion":1700,"start":1701,"enrollment":1702,"conditions":6820,"interventions":6821},[94],[1704],[1706,1675],{"intervention":6823,"totalTrials":121,"cells":6824},"Shaoyao Gancao Decoction Jiawei",{"EARLY_PHASE1":6825,"PHASE1":6827,"PHASE2":6829,"PHASE3":6831,"PHASE4":6833,"NA":6835},{"trials":6826,"activeCount":102},[],{"trials":6828,"activeCount":102},[],{"trials":6830,"activeCount":102},[],{"trials":6832,"activeCount":102},[],{"trials":6834,"activeCount":102},[],{"trials":6836,"activeCount":102},[6837],{"nctId":6838,"briefTitle":6839,"status":203,"phases":6840,"primaryCompletion":2856,"completion":2856,"start":6841,"enrollment":497,"conditions":6842,"interventions":6843},"NCT04500730","Evaluate the Efficacy of Herbal Medicine (Shaoyao Gancao Decoction Jiawei) in Sleep-related Leg Cramps",[94],"2019-08-01",[4127],[6823]]